DLL3-binding molecule, composition, and method of use
DLL3-binding molecules with specific CDR sequences and Fc regions address the limitations of current DLL3 modulators, offering enhanced binding and therapeutic efficacy in cancer treatment.
Patent Information
- Application Number
- PCT/US2026/028033
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Current therapeutic molecules for modulating DLL3 activity are inadequate for effective cancer immunotherapy, necessitating improved DLL3-binding molecules with enhanced specificity and versatility.
Development of DLL3-binding molecules, including multivalent and multispecific molecules comprising heavy chain only variable domains (DLL3 VHH) with specific CDR sequences, which can bind DLL3 and optionally additional targets, linked by Fc regions for enhanced therapeutic efficacy.
The DLL3-binding molecules demonstrate improved binding affinity and therapeutic potential, particularly in cancer treatment, enhancing treatment efficacy when used alone or in combination with other therapeutic agents.
Smart Images

Figure US2026028033_19112026_PF_FP_ABST
Abstract
Description
WSGRRefNo. 65457-709.601DLL3-BINDING MOLECULE, COMPOSITION, AND METHOD OF USECROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 805,805, filed May 14, 2025, which is hereby incorporated by reference in its entirety herein.BACKGROUND
[0002] DLL3 (also known as Delta-like ligand 3) is involved in various cell signaling cascades. DLL3 is of interest as a therapeutic for treating diseases or conditions such as cancer. DLL3 modulation, including in combination with other therapeutics (e.g., co-stimulatory immune checkpoint molecules), can be useful for cancer immunotherapy. As such, improved therapeutic molecules and agents for modulating DLL3 activity are needed. Provided herein are embodiments that meet such needs.SUMMARY
[0003] The disclosure provides DLL3-binding molecules, comprising at least one heavy chain only variable domain (referred to herein as a “DLL3 VHH domain”, or simply a “DLL3 VHH”) that specifically bind at least DLL3. This disclosure further provides DLL3-binding molecules which are multivalent and / or multispecific molecules, that bind at least DLL3. The disclosure also provides nucleic acid molecules encoding the molecules and vectors and cells thereof, and methods of use and uses of the provided DLL3 -binding molecules for treating diseases and conditions, such as cancer. In some embodiments, the DLL3-binding molecule is a multivalent molecule. In some embodiments, the DLL3-binding molecule is a multispecific molecule. In some embodiments, the DLL3-binding molecule is a multivalent and multispecific molecule. Some additional embodiments are provided below.
[0004] In one aspect provided herein is a DLL3 -binding molecule, comprising at least one heavy chain only variable domain that binds DLL3 (DLL3 VHH), wherein the at least one DLL-3 VHH comprises: a complementarity determining region 1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 27, 47, 67, 87, 107, 127, 147, 167, 187, 207, 227, or 247; a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 28, 48, 68, 88, 108, 128, 148, 168, 188, 208, 228, or 248; and a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 29, 49, 69, 89, 109, 129, 149, 169, 189, 209, 229, or 249.
[0005] In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 27, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 28, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 29; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 47, the CDR-H2 comprisingWSGRRefNo. 65457-709.601the amino acid sequence of SEQ ID NO: 248, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 49; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 67, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 68, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 69; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 87, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 88, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 89; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 107, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 108, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 109; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 127, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 147, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 148, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 149; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 167, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 168, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 169; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 187, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 188, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 189; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 207, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 208, and the CORED comprising the amino acid sequence of SEQ ID NO: 209; the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 227, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 228, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 229; or the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 247, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 248, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 249.
[0006] In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 27-29. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 47-49. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 67-69. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 87-89. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQWSGRRefNo. 65457-709.601ID NOs: 107-109. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 127-129. In some embodiments, the at least one DLL-3 VHH comprises the CDR-Hl, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 147-149. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 167-169. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 187-189. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 207-209. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 227-229. In some embodiments, the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 247-249.
[0007] In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-12.
[0008] In some embodiments, the DLL3 to which the DLL3 binding molecule binds is a human DLL3.
[0009] In some embodiments, the DDL binding molecule comprises two DLL3 VHHs. In some embodiments, the DDL binding molecule comprises three DLL3 VHHs.
[0010] In some embodiments, the DLL3-binding molecule comprises one or more additional binding domains that bind to a target other than DLL3. In some embodiments, the one or more additional binding domains is a domain that binds to an antigen selected from the group consisting of: 1-92-LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGR2, Anti-Lewis- Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CDlla, CD16, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD 138, CD 166, CD 172 A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL4, DPP-4, DSG1,WSGRRefNo. 65457-709.601EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRD), GAL3ST1, G-CSF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP Ilb / IIIa receptors, Gpl30, GPIIB / IIIA, GPNMB, GRP78, HER2 / neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27 / IL27R (wsxl), IL29, IL-31R, IL31 / IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISS1-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin-16 (MUC16, CA-125), Na / K ATPase, NGF, NKp46, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, 0X40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidylserine, Pl GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFR2, NFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3. In some embodiments, at least one of the additional binding domains comprises an antibody or antigen-binding fragment thereof. In some embodiments, each of the additional binding domains comprises an antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), scFv, a Fab, a single domain antibody (sdAb).
[0011] In some embodiments, the molecule comprises an Fc region. In some embodiments, the molecule comprises an immunoglobulin Fc region that links the at least one DLL3 VHH and the one or more additional binding domain. In some embodiments, the molecule comprises at least two polypeptide chains each comprising an Fc region polypeptide. In some embodiments, the Fc region is a homodimeric Fc region. In some embodiments, the Fc region comprises the sequence of any of SEQ ID NO: 301-304, 312-317, or 330-332, or an amino acid that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 301-304, 312-317, or 330-332. In some embodiments, the Fc region is a heterodimeric Fc region. In some embodiments, the heterodimeric Fc region comprises paired or complementary amino acid modifications. In some embodiments, the heterodimeric Fc region comprises “knob” and “hole” modifications. In some embodiments, the heterodimeric Fc region comprises a first Fc polypeptide and a second Fc polypeptide, wherein the first Fc polypeptide comprises any of SEQ ID NOs: 318-323, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,WSGRRefNo. 65457-709.60197%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 318-323, and the second Fc polypeptide comprises any one of SEQ ID NOs: 324-329 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 324-329.
[0012] In some embodiments, the at least one DLL3 VHH comprises the sequence of SEQ ID NO: 1. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 2. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 3. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 4. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 5. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 6. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 7. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 8. In some embodiments, at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 9. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 10. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 11. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 12.
[0013] In another aspect provided herein is a polynucleotide encoding a DLL3 -binding molecule described herein. Also provided herein are vectors comprising such polynucleotides. Further provided herein are cells or host cells comprising such polynucleotides or vectors.
[0014] In another aspect described herein is a method of producing a DLL3 -binding molecule, the method comprising introducing into a cell a polynucleotide or vector described herein, and culturing the cell under conditions to produce the DLL3 -binding molecule.
[0015] In some embodiments, the method further comprises isolating or purifying the DLL3-binding molecule from the cell. Also provided herein are DLL-3 binding molecules produced by such methods.
[0016] In another aspect herein is a pharmaceutical composition comprising a DLL3-binding molecule described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
[0017] In another aspect herein is a method of treating a disease or condition comprising administering to a subject a pharmaceutically effective amount of a DLL3 -binding molecule described herein or a pharmaceutical composition described herein.
[0018] In some embodiments, the disease or condition is a tumor or a cancer, an immune disorder, or an inflammatory disorder. In some embodiments, the disease or condition is a cancerWSGRRefNo. 65457-709.601selected from basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intraepithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia. In some embodiments, the method comprises administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an anticancer agent. In some embodiments, the anti -cancer agent is selected from a chemotherapeutic agent, an anti-cancer biologic, radiation therapy, CAR-T therapy, and an oncolytic virus. In some embodiments, the additional therapeutic agent is an anti-cancer biologic. In some embodiments, the anti-cancer biologic is an antibody. In some embodiments, the anti -cancer biologic is a cytokine. In some embodiments, the anti-cancer biologic is a CAR-T therapy. In some embodiments, the anti-cancer biologic is an oncolytic virus. In some embodiments, the method further comprises tumor resection and / or radiation therapy. In some embodiments, the subject is a human.
[0019] Provided herein are DLL3-binding molecules, comprising at least one heavy chain only variable domain, or antigen binding fragment thereof, that binds DLL3 (DLL3 VHH), wherein the DLL3 VHH comprises a complementarity determining region 1 (CDR-H1), a complementarity determining region 2 (CDR-H2), and a complementarity determining region 3 (CDR-H3) of any one of clonotypes A to Y, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype A, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3WSGRRefNo. 65457-709.601of clonotype B, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype C, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype D, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype E, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype F, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype G, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype H, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype I, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype J, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype K, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype L, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype M, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype N, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype O, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype P, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype Q, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype R, as set forth in Table 2. In some embodiments, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype S, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype T, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype U, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype V, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype W, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype X, as set forth in Table 2. In some embodiments, the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype Y, as set forth in Table 2.
[0020] In some embodiments, the CDRs are determined by IMGT, Kabat, AbM, Chotia, or Contact numbering systems. In some embodiments, the CDRs are determined by the IMGT numbering systems. In some embodiments, the CDRs are determined by the Kabat numberingWSGRRefNo. 65457-709.601systems. In some embodiments, the CDRs are determined by the AbM numbering systems. In some embodiments, the CDRs are determined by the Chothia numbering systems. In certain embodiments, the CDRs are determined by the Contact numbering systems.
[0021] In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 351-373. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-12. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 351-373.
[0022] In certain embodiments, the DLL3 is a human DLL3. In some embodiments, the DLL3-binding molecule comprises two DLL3 VHHs. In some embodiments, the DLL3-binding molecule comprises three DLL3 VHHs. In some embodiments, the DLL3-binding molecule comprises one or more additional binding domains that bind to a target other than DLL3. In some embodiments, the one or more additional binding domains is a domain that binds to an antigen selected from the group consisting of: 1-92-LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGR2, Anti-Lewis-Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CDlla, CD16, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD138, CD166, CD172A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRa), GAL3ST1, G-CSF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP Ilb / IIIa receptors, Gpl30, GPIIB / IIIA, GPNMB, GRP78, HER2 / neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL IB, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27 / IL27R (wsxl), IL29, IL-31R, IL31 / IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISSl-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin- 16 (MUC16, CA-125),WSGRRefNo. 65457-709.601Na / K ATPase, NGF, NKp46, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, 0X40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, P1GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFR2, NFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3. In some embodiments, the additional binding domains comprise an antibody or antigen-binding fragment thereof. In some embodiments, each of the additional binding domains comprises an antibody or antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), scFv, a Fab, a single domain antibody (sdAb).
[0023] In some embodiments, the DLL3-binding molecule comprises an Fc region. In some embodiments, the DLL3-binding molecule comprises an immunoglobulin Fc region that links the at least one DLL3 VHH and the one or more additional binding domain. In some embodiments, the DLL3-binding molecule comprises at least two polypeptide chains each comprising an Fc region polypeptide. In some embodiments, the Fc region is a homodimeric Fc region. In some embodiments, the Fc region comprises the sequence of any of SEQ ID NO: 301-304, 312-317, or 330-332, or an amino acid that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 301-304, 312-317, or 330-332. In some embodiments, the Fc region is a heterodimeric Fc region. In some embodiments, the heterodimeric Fc region comprises paired or complementary amino acid modifications. In some embodiments, the heterodimeric Fc region comprises “knob” and “hole” modifications. In some embodiments, the heterodimeric Fc region comprises a first Fc polypeptide and a second Fc polypeptide, wherein the first Fc polypeptide comprises any of SEQ ID NOs: 318-323, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 318-323, and the second Fc polypeptide comprises any one of SEQ ID NOs: 324-329 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 324-329.
[0024] In some embodiments, the at least one DLL3 VHH comprises the sequence of SEQ ID NO: 1. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 2. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 3. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 4. In some embodiments, the at least one DLL3 VHHWSGRRefNo. 65457-709.601comprises an amino acid sequence of SEQ ID NO: 5. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 6. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 7. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 8. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 9. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 10. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 11. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 12. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 351. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 352. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 353. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 354. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 355. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 356. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 357. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 358. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 359. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 360. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 361. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 362. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 363. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 364. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 365. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 366. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 367. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 368. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 369. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 370. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 371. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 372. In some embodiments, the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 373.WSGRRefNo. 65457-709.601
[0025] In another aspect provided herein is a polynucleotide encoding a DLL3 -binding molecule described herein. Also provided herein are vectors comprising such polynucleotides. Further provided herein are cells or host cells comprising such polynucleotides or vectors.
[0026] In another aspect described herein is a method of producing a DLL3 -binding molecule, the method comprising introducing into a cell a polynucleotide or vector described herein, and culturing the cell under conditions to produce the DLL3 -binding molecule. In some embodiments, the method further comprises isolating or purifying the DLL3 -binding molecule from the cell. Also provided herein are DLL-3 binding molecules produced by such methods.
[0027] In another aspect provided herein is a pharmaceutical composition comprising a DLL3-binding molecule described herein. In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
[0028] In another aspect provided herein is a method of treating a disease or condition comprising administering to a subject a pharmaceutically effective amount of a DLL3-binding molecule described herein or a pharmaceutical composition described herein. In some embodiments, the disease or condition is a tumor or a cancer, an immune disorder, or an inflammatory disorder. In some embodiments, the disease or condition is a cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the disease or condition is a cancer selected from basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom'sWSGRRefNo. 65457-709.601Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia.
[0029] In some embodiments, the method further comprises administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an anti-cancer agent. In some embodiments, the anti-cancer agent is selected from a chemotherapeutic agent, an anticancer biologic, radiation therapy, CAR-T therapy, and an oncolytic virus. In some embodiments, the additional therapeutic agent is an anti -cancer biologic. In some embodiments, the anti-cancer biologic is an antibody. In some embodiments, the anti-cancer biologic is a cytokine. In some embodiments, the anti-cancer biologic is a CAR-T therapy. In some embodiments, the anti-cancer biologic is an oncolytic virus. In some embodiments, the method further comprises tumor resection and / or radiation therapy. In some embodiments, the subject is a human.BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The novel features described herein are set forth with particularity in the appended claims. A better understanding of the features and advantages of the features described herein will be obtained by reference to the following detailed description that sets forth illustrative examples, in which the principles of the features described herein are utilized, and the accompanying drawings of which:
[0031] Fig. 1 illustrates monovalent DLL3 sdAb affinity screening. DLL3 sdAbs were screened for monovalent binding to DLL3 expressing SHP-77 cells.
[0032] Fig. 2 illustrates monovalent DLL3 sdAb binding to mouse DLL3. DLL3 sdAbs were screened for monovalent binding to CHO cells transiently expressing mouse DLL3.
[0033] Fig. 3 illustrates binding of humanized DLL3 sdAbs to DLL3 expressing SHP-77 cells. DLL3 sdAbs with high monovalent affinity were selected for humanization. Binders to multiple epitopes were included.
[0034] Fig. 4 illustrates that DLL3 sdAbs did not bind other DLL family members. DLL3 sdAbs were tested for binding to DLL1, DLL3, DLL4. Only binding to DLL3 was observed.
[0035] Fig. 5A-5G illustrates binding of monovalent DLL3 sdADbs to DLL3 expressing SHP-77 cells.
[0036] Fig. 6A-6F illustrates binding of monovalent DLL3 sdADbs to DLL3 expressing NCI-H524 cells.
[0037] Fig. 7A-7J illustrates binding of monovalent DLL3 sdADbs to DLL3 expressing SHP-77 cells.WSGRRefNo. 65457-709.601DETAILED DESCRIPTION
[0038] Provided herein are molecules that specifically bind to DLL3, hereinafter also called DLL3 -binding molecules, and their use in modulating DLL3 signaling in a cell or in a subject. A variety of DLL3 -binding molecule formats are provided. Provided herein are DLL3 -binding molecules that comprise at least one VHH that specifically binds to DLL3. In some embodiments, the VHH binds human DLL3. In some of the provided embodiments, the VHH that binds DLL3 has the sequence set forth in any one of SEQ ID NOs: 1-12 or SEQ ID NOs: 351-373
[0039] In some embodiments, the provided binding molecules comprise at least one VHH that binds DLL3. In some embodiments, the at least one VHH comprises an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of any one of the amino acid sequences shown in Table 1 (e.g., any one of SEQ ID NOs: 1-12 or SEQ ID NOs: 351-373). In some embodiments, a DLL3-binding molecule provided herein comprises one, two, three, four, five, six, seven, or eight VHHs that each individually binds DLL3. In some embodiments, a DLL3-binding molecule provided herein comprises one, two, three, or four VHHs that bind DLL3. In some embodiments, the DLL3-binding molecules are monospecific. In such embodiments, the DLL3 -binding molecule may incorporate multiple copies of the same VHH. In some embodiments, the DLL3 -binding molecules may incorporate multiple copies of a VHH that are different but that recognize the same epitope on DLL3.
[0040] In some embodiments, a DLL3 -binding molecule described herein binds only to DLL3 and not to other DLL family members (e.g., DLL1, DLL4, etc.). For example, Fig. 4 illustrates that the DLL3-binding molecules provided therein did not bind DLL1 or DLL4.Table 1. Non-limiting example of DLL3 VH or CDR amino acid sequencesIdentifier Amino acid sequence CDR1 CDR2 CDR3lmlOA9 QVQLVQSGGGLVQAGGSLRLSCVASR RSIFSF VITSG GVDKG SIFSFDAMGWYRQAPGKQREMVAVITS DAMG GSAH SYFSYD GGSAHSADSVKGRFTISRDNAKNTVY (SEQ ID (SEQ Y (SEQ MQMNNLKPEDTADYYCAAGVDKGSY NO: 27) ID NO: ID NO FSYDYWGQGTQVTVSS (SEQ ID NO: 1) 28) 29) hzlOA9v!3 QVQLLESGGGEVQPGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKQREMVAVITS DAMG GSAH SYFSYD GGSAHSAESVKGRFTISRDNAKNTVYL (SEQ ID Y QMNSLRAEDTAVYYCAAGVDKGSYFS NO: 47) YDYWGQGTLVTVEP (SEQ ID NO: 2)WSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR3(SEQ (SEQ ID ID NO: NO: 49) 48)ImlOGll QVQLVQSGGSLVQPGGSLRLSCAASGT GTIFSI GFTGD DVFIDQ IFSINAMGWYRQAPGKQRELVAGFTG NAMG GATT AAVEW DGATTYADSVKGRFTISRDHAKNTVYL Y QMNSLKPEDTAVYYCAADVFIDQAAV (SEQ ID (SEQ EWYWGQGTQVTVSS (SEQ ID NO: 3) NO: 67) ID NO: (SEQ ID 68) NO: 69) hzl0Gllv30 QVQLVESGGGEVQPGRSLRLSCAASGT GTIFSI GFTGD DVFIDQ IFSINAMGWYRQAPGKQRELVAGFTG NAMG AATT AAVEW DAATTYAESVKGRFTISRDHAKNTVYL Y QMNSLRAEDTAVYYCAADVFIDQAAV (SEQ ID (SEQ EWYWGQGTLVTVRP (SEQ ID NO: 4) NO: 87) ID NO: (SEQ ID 87) NO: 89) ImlOBl EVQLVQSGGGLVQAGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKQREMVAVITS DAMG GSAH SYFSYD GGSAHSADSVKGRFTISRDNAKNTVY Y MQMNNLKPEDTADYYCAAGVDKGSY (SEQ ID (SEQ F S YD YWGQGTQ VT VS S NO: ID NO: (SEQ ID 107) 108) NO: 109) (SEQ ID NO: 5)hzlOBlv31 QVQLLESGGGEVQPGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKQREMVAVITS DAMG GSAH SYFSYD GGSAHYAESVKGRFTISRDNAKNTVYL Y QMNSLRAEDTAVYYCAAGVDKGSYFS (SEQ ID (SEQ YDYWGQGTLVTVEP (SEQ ID NO: 6) NO: ID NO: (SEQ ID 127) 128) NO: 129) lm5A8 QVQLVQSGGGLVQAGESLRLSCAASG GSIFSI VVSSD REWYS SIFSINAMGWYRQVLGKQRELVAVVSS NAMG GRTT DSDWR DGRTTVAPSVKGRFTISRDNAKNTVSL DY QMNSLKPEDTGVYYCGVREWYSDSD (SEQ ID (SEQ WRDYEGQGTQVTVSS(SEQ ID NO: 7) NO: ID NO: (SEQ ID 147) 148) NO: 149) hz5A8.1v4 EVQLLESGGGEVQPGGSLRLSCAASGSI GSIFSI VVSSD REWYS F SINAMGWYRQ APGKQREL VAVVS SD NAMG ARTT DADWR ARTTVAPSVKGRFTISRDNAKNTVYLQ DY MNSLRAEDTAVYYCGVREWYSDADW (SEQ ID (SEQ RDYEGQGTLVTVRP (SEQ ID NO: 8) NO: ID NO: (SEQ ID 167) 168) NO: 169) lm3G5 EVQLQESGGGLVQAGGSLRLSCAASGS GSILSI AITGD DVLSDS IL SINAMGWYRQ APGKQREL VAAITGD NAMG GNTN GYVTP GNTNYADSVKGRFTISRDNTKNTVYLQWSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR3MNSLKPEDTAVYYCLLDVLSD SGYVT (SEQ ID (SEQ (SEQ ID PWGQGTQVTVSS (SEQ ID NO: 9) NO: ID NO: NO: 189)187) 188)hz3G5v6 EVQLVESGGGEVKPGGSLRLSCAASGS GSILSI AITGD DVLSD ILSINAMGWYRQAPGKQRELVAAITGD NAMG ANTN AGYVT ANTNYAESVKGRFTISRDNTKNTVYLQ P MNSLRAEDTAVYYCLLDVLSDAGYVT (SEQ ID (SEQ PWGQGTLVTVRP (SEQ ID NO: 10) NO: ID NO: (SEQ ID 207) 208) NO: 209) lm3F9 QVQLQESGGGLVQAGGSLRLSCAASG GRTFS AISWS DLLMR RTFSSYGMAWFRQTPGKERDFVAAIS SYGM GPSTY QGWGT WSGPSTYYADSVKGRFTISRDNAKNTV A RPNDY YLQMNSLKPEDTAVYYCAADLLMRQ (SEQ DY GWGTRPNDYDYWGQGTQVTVSS (SEQ (SEQ ID ID NO:ID NO: 11) NO: 228) (SEQ ID 227) NO: 229) hz3F9v5 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLMR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYAESVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLMRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 12) NO: 248) (SEQ ID 247) NO: 249) 10D9v7 EVQLVESGGGEVQPGGSLRLSCAASGS GSIFSI GFTGD DVQLFS IFSINAMGWYRQAPGKQRELVAGFTG NAMG TNTI RDYEF DTNTIYAESVKGRFTISRDNAKNTVYL Y QMSSLRAEDTAVYYCAADVQLFSRDY (SEQ ID (SEQ EFYWGQGTLVTVKP (SEQ ID NO: 351) NO: ID NO: (SEQ ID 387) 388) NO: 389) 8E7vl6 EVQLVESGGGEVQPGGSLRLSCGPSEII EIITSD GISNV RDFENE TSDKSMGWVRQAPGKQRNLVAGISNV KSMG GSTN Y GSTNYAQSVKGRFTISRDNAKNTVYLQ MS SLRAEDT AVYYC YARDFENEYWGQ (SEQ ID (SEQ (SEQ ID GTLVTVKP (SEQ ID NO: 352) NO: ID NO: NO: 409)407) 408)5A7v6 EVQLVESGGGEVQPGGSLRLSCAASGS GSDFSI GFTGD DVKIGG DF SINAIGWYRQPPGKQRDMVAGFTG NAIG GVTT DYEWF DGVTTYAESVKGRFTISRDNAKNTVYL QMSSLRAEDTAVYYCAADVKIGGDYE (SEQ ID (SEQ (SEQ ID WFWGQGTLVTVKP NO: ID NO: NO: 429)427) 428)(SEQ ID NO: 353)WSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR33G3vl EVQLVESGGGEVQPGGSLRLSCAASGS GSIFSI GFTGD DVFTD IFSINAMGWYRQAPGKQRELVAGFTG NAMG GMTK RDHVD DGMTKYAESVKGRFTISRDNAKNTVY WY LQMS SLRAEDT AVYYC AAD VFTDRDH (SEQ ID (SEQ VDWYWGQGTLVTVKP (SEQ ID NO: NO: ID NO: (SEQ ID 354) 447) 448) NO: 449) 3C5v7 EVQLVESGGGEVQPGGSLRLSCAASGS GSIFSI GFTGD DVQLL IFSINAMGWYRQAPGKQRELVAGFTG NAMG GSTK QSDYEF DGSTKYAESVKGRFTISRDNAKNTVYL Y QMSSLRAEDTAVYYCAADVQLLQSDY (SEQ ID (SEQ EFYWGQGTLVTVKP (SEQ ID NO: 355) NO: ID NO: (SEQ ID 467) 468) NO: 469) 6C5v3 EVQLVESGGGEVQPGGSLRLSCAASEI EITFSD VISNV RDFENE TFSDKTVGWYRQAPGKQRVLVAVISN KTVG DSTN Y VDSTNYAHSVKGRFTISRDNAKNTVYL QMSSLRAEDTAVYYCHARDFENEYWG (SEQ ID (SEQ (SEQ ID QGTLVTVKP (SEQ ID NO: 356) NO: ID NO: NO: 489)487) 488)6Flv6 EVQLVESGGGEVQPGGSLRLSCAASEII EIIFSD VISNV RDFESE F SDKT VGW YRQ APGKQRVL VAVISNV KTVG ESTN Y ESTNYAESVKGRFTISRDNAKNTVYLQ MS SLRAEDT AVYYC YARDFESEYWGQ (SEQ ID (SEQ (SEQ ID GTLVTVKP (SEQ ID NO: 357) NO: ID NO: NO: 509)507) 508)10E5v2 EVQLVESGGGEVQPGGSLRLSCAASGF GFTLD CISSS YCPVV TLDD YTIGWFRQ APGKEREGVSCIS S SG DYTIG GGSTY VGPELG GSTYYAESVKGRFTISRDNAKNTVWL YDY QMSSLRAEDTAVYYCATYCPVVVGPE (SEQ ID (SEQ LGYDYWGQGTLVTVKP (SEQ ID NO: NO: ID NO: (SEQ ID 358) 527) 528) NO: 529) 3F9vlO QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLMR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYAESVKGRFTISRDNAKNTVY A RPNDY LQMS SLRAEDT AVYYC AADLLMRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 359) NO: 228) (SEQ ID 227) NO: 229) 10Blv45 QVQLLESGGGEVQPGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKQREMVAVITS DAMG GSAH SYFSYD GGSAHYAESVKGRFTISRDNAKNTVYL Y QMSSLRAEDTAVYYCAAGVDKGSYFS (SEQ ID (SEQ YDYWGQGTLVTVEP (SEQ ID NO: 360) NO: 27) ID NO: (SEQ ID 28) NO: 29)WSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR310Blv50 QVQLLESGGGEVQPGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKGREFVAVITSG DAMG GSAH SYFSYD GSAHYAESVKGRFTISRDNAKNTVYLQ Y MS SLRAEDT AVYYC AAGVDKGS YF SY (SEQ ID (SEQ DYWGQGTLVTVEP (SEQ ID NO: 361) NO: 27) ID NO: (SEQ ID 28) NO: 29) 10Blv51 QVQLLESGGGEVQPGGSLRLSCVASRS RSIFSF VITSG GVDKG IFSFDAMGWYRQAPGKGRELVAVITSG DAMG GSAH SYFSYD GSAHYAESVKGRFTISRDNAKNTVYLQ Y MS SLRAEDT AVYYC AAGVDKGS YF SY (SEQ ID (SEQ DYWGQGTLVTVEP (SEQ ID NO: 362) NO: 27) ID NO: (SEQ ID 28) NO: 29) 5A8.1v5 EVQLLESGGGEVQPGGSLRLSCAASGSI GSIFSI VVSSD REWYS F SINAMGWYRQ APGKQREL VAVVS SD NAMG ARTT DADWR ARTTVAPSVKGRFTISRDNAKNTVYLQ DY MS SLRAEDT AVYYCGVREWYSDADW (SEQ ID (SEQ RDYEGQGTLVTVRP (SEQ ID NO: 363) NO: ID NO: (SEQ ID 167) 168) NO: 169) 3F9v2 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLLRQ TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY GWGTR SGPSTYYADSVKGRFTISRDNAKNTVY A PNDYD LQMNSLRAEDTAVYYCAADLLLRQG (SEQ Y WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 364) NO: 548) (SEQ ID 547) NO: 549) 3F9v3 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLIRQ TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY GWGTR SGPSTYYADSVKGRFTISRDNAKNTVY A PNDYD LQMNSLRAEDTAVYYCAADLLIRQGW (SEQ Y GTRPNDYDYWGQGTLVTVEP (SEQ ID (SEQ ID ID NO:NO: 365) NO: 568) (SEQ ID 567) NO: 569)3F9v4 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLVR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYADSVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLVRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 366) NO: 588) (SEQ ID 587) NO: 589)WSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR33F9v9 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLAR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYAESVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLARQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 367) NO: 608) (SEQ ID 607) NO: 609) 3F9vl9 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLTRQ TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY GWGTR SGPSTYYADSVKGRFTISRDNAKNTVY A PNDYD LQMNSLRAEDTAVYYCAADLLTRQG (SEQ Y WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 368) NO: 628) (SEQ ID 627) NO: 629) 3F9v20 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLSRQ TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY GWGTR SGPSTYYADSVKGRFTISRDNAKNTVY A PNDYD LQMNSLRAEDTAVYYCAADLLSRQG (SEQ Y WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 369) NO: 648) (SEQ ID 647) NO: 649) 3F9v21 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLGR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYADSVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLGRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 370) NO: 668) (SEQ ID 667) NO: 669) 3F9v22 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLNR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYADSVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLNRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 371) NO: 688) (SEQ ID 687) NO: 689) 3F9v23 QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLQR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYADSVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLQRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 372) NO: 708) (SEQ ID 707) NO: 709)WSGRRefNo. 65457-709.601Identifier Amino acid sequence CDR1 CDR2 CDR33F9vl QVQLLESGGGEVQPGGSLRLSCAASGR GRTFS AISWS DLLMR TFSSYGMAWFRQAPGKERDFVAAISW SYGM GPSTY QGWGT SGPSTYYADSVKGRFTISRDNAKNTVY A RPNDY LQMNSLRAEDTAVYYCAADLLMRQG (SEQ DY WGTRPNDYDYWGQGTLVTVEP (SEQ (SEQ ID ID NO:ID NO: 373) NO: 228) (SEQ ID 227) NO: 229)
[0041] When the identifiers of Table 1 are referenced in the instant disclosure, it is in reference to the full length DLL3 VH sequence unless context clearly indicates otherwise. Additionally, the identifiers of Table 1 all contain the prefix “Im” or “hz” which can be omitted when referring to the antibody of table 1 (e.g., a reference herein to “10A9” refers to “lmlOA9” as defined in Table 1). In some instances, a suffix indicating a fusion partner of the referenced VH sequence will be referred to herein (e.g., a reference to “10A9-NNT” indicates antibody lmlOA9 defined herein fused to a hinge-deleted human Fc containing S364N, Y407N, and K409T mutations).
[0042] In some embodiments, the DLL3-binding molecules are multispecific. For example, provided DLL3-binding molecules include molecules that may comprise at least one VHH that binds DLL3 and one or more additional binding domains, that bind one or more antigens other than DLL3. In some embodiments, such multispecific DLL3-binding molecules exhibit multispecific binding. In some embodiments, the binding to the additional antigen is capable of providing the additional crosslinking function and DLL3 activation can be achieved with only one or two DLL3-binding domains. In some embodiments, DLL3 signaling is enhanced and focused by the presence of the additional antigen. In some embodiments, such multispecific molecules exhibit greatly enhanced DLL3 -dependent signaling when the multispecific molecule is bound to a cell expressing the additional antigen.
[0043] In some embodiments, a DLL3-binding molecule comprises a) at least one VHH that binds DLL3 and b) an Fc region. In some embodiments, a DLL3 -binding molecule provided herein comprises a) one, two, three, or four VHHs that bind DLL3 and b) an Fc region. In some embodiments, an Fc region mediates dimerization of the DLL3 -binding molecule at physiological conditions such that a dimer is formed that doubles the number of DLL3 -binding sites. For example, a DLL3-binding molecule comprising three VHH that bind DLL3 and an Fc region is trivalent as a monomer, but at physiological conditions, the Fc region may mediate dimerization, such that the DLL3-binding molecule exists as a hexavalent dimer under such conditions. The DLL3-binding molecules can be formatted in a number of formats described herein. In some embodiments, the provided DLL3-binding molecules can be used to modulateWSGRRefNo. 65457-709.601an immune response in a subject, which, in some embodiments, treats a disease or disorder, such as a cancer, or an immune and / or inflammatory disease or disorder, in the subject.VHH DOMAINS BINDING DLL3
[0044] Provided herein are optimized DLL3 VHH domains (generally referred to herein simply as “DLL3 VHH” (singular) or “DLL3 VHHs” (plural)) that may be incorporated in DLL3-binding molecules including those provided herein. The DLL3 VHHs can be formatted in a variety of formats, including any as described herein.
[0045] In some embodiments, an optimized VHH that binds DLL3 (a “DLL3 VHH”) comprises a CDR1, CDR2, and CDR3. In some embodiments, the DLL3-binding molecules herein comprise at least one DLL3 VHH that comprises the CDR-H1, CDR-H2, and CDR-H3 sequences, under any CDR definition (e.g., AbM, Kabat, IMGT, Chothia, Contact, etc.) as provided in Table 4. In some embodiments, the DLL3-binding molecule comprises at least one heavy chain only variable domain that binds DLL3 (DLL3 VHH), wherein the at least one DLL-3 VHH comprises: a CDR-H1, CDR-H2 and CDR-H3 from Table 2. In some embodiments, the DLL3-binding molecule comprises at least one DLL3 VHH, wherein the at least one DLL-3 VHH comprises: a set of CDRs (CDR-H1, CDR-H2 and CDR-H3) as defined by any of the clonotypes in Table 2.Table 2. DLL3 VHH Clonotypes and CDR sequencesClonotypes CDRs IMGT KABAT AbM Chothia Contact VHH Clones Clonotype A CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10A9CDR2 NO: 21 NO: 24 ID NO: 30 NO: 33 10A9vl3 CDR3 SEQ ID SEQ ID NO: SEQ ID SEQ ID 10B1 NO: 22 NO: 25 27 NO: 31 NO: 34 10Blv31 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10Blv45 NO: 23 NO: 26 ID NO: 32 NO: 35 10Blv50 NO: 10Blv51 28SEQ ID NO:29Clonotype B CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10G11CDR2 NO: 61 NO: 64 ID NO: 70 NO: 73 CDR3 SEQ ID SEQ ID NO: SEQ ID SEQ IDNO: 62 NO: 65 67 NO: 71 NO: 74SEQ ID SEQ ID SEQ SEQ ID SEQ ID NO: 63 NO: 66 ID NO: 72 NO: 75NO:68SEQIDWSGR RefNo. 65457-709.601NO:69Clonotype C CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10Gl lv30CDR2 NO: 81 NO: 84 ID NO: 90 NO: 93 CDR3 SEQ ID SEQ ID NO: SEQ ID SEQ IDNO: 82 NO: 85 87 NO: 91 NO: 94SEQ ID SEQ ID SEQ SEQ ID SEQ ID NO: 83 NO: 86 ID NO: 92 NO: 95NO:88SEQ ID NO:89Clonotype D CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 5A8CDR2 NO: NO: 144 ID NO: 150 NO: 153CDR3 141 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 145 147 NO: 151 NO: 154NO: SEQ ID SEQ SEQ ID SEQ ID142 NO: 146 ID NO: 152 NO: 155SEQ ID NO:NO: 148143 SEQID NO:149Clonotype E CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 5A8.1v4CDR2 NO: NO: 164 ID NO: 170 NO: 173 5A8.1v5 CDR3 161 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 165 167 NO: 171 NO: 174NO: SEQ ID SEQ SEQ ID SEQ ID162 NO: 166 ID NO: 172 NO: 175SEQ ID NO:NO: 168163 SEQID NO:169Clonotype F CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3G5CDR2 NO: NO: 184 ID NO: 190 NO: 193CDR3 181 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 185 187 NO: 191 NO: 194NO: SEQ ID SEQ SEQ ID SEQ ID182 NO: 186 ID NO: 192 NO: 195SEQ ID NO:NO: 188183 SEQID NO:189WSGR RefNo. 65457-709.601Clonotype G CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3G5v6CDR2 NO: NO: 204 ID NO: 210 NO: 213 CDR3 201 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 205 207 NO: 211 NO: 214 NO: SEQ ID SEQ SEQ ID SEQ ID202 NO: 206 ID NO: 212 NO: 215 SEQ ID NO:NO: 208203 SEQID NO:209Clonotype H CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9 CDR2 NO: NO: 224 ID NO: 230 NO: 233 3F9v5 CDR3 221 SEQ ID NO: SEQ ID SEQ ID 3F9vlO SEQ ID NO: 225 227 NO: 231 NO: 234 3F9vl NO: SEQ ID SEQ SEQ ID SEQ ID222 NO: 226 ID NO: 232 NO: 235 SEQ ID NO:NO: 228223 SEQID NO:229Clonotype I CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10D9v7CDR2 NO: NO: 384 ID NO: 390 NO: 393 CDR3 381 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 385 387 NO: 391 NO: 394 NO: SEQ ID SEQ SEQ ID SEQ ID382 NO: 386 ID NO: 392 NO: 395 SEQ ID NO:NO: 388383 SEQID NO:389Clonotype J CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 8E7vl6CDR2 NO: NO: 404 ID NO: 410 NO: 413 CDR3 401 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 405 407 NO: 411 NO: 414 NO: SEQ ID SEQ SEQ ID SEQ ID402 NO: 406 ID NO: 412 NO: 415 SEQ ID NO:NO: 408403 SEQID NO:409Clonotype K CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 5A7v6CDR2 NO: NO: 424 ID NO: 430 NO: 433 CDR3 421 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 425 427 NO: 431 NO: 434WSGR RefNo. 65457-709.601NO: SEQ ID SEQ SEQ ID SEQ ID422 NO: 426 ID NO: 432 NO: 435 SEQ ID NO:NO: 428423 SEQID NO:429Clonotype L CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3G3vl CDR2 NO: NO: 444 ID NO: 450 NO: 453 CDR3 441 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 445 447 NO: 451 NO: 454 NO: SEQ ID SEQ SEQ ID SEQ ID442 NO: 446 ID NO: 452 NO: 455 SEQ ID NO:NO: 448443 SEQID NO:449Clonotype M CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3C5v7CDR2 NO: NO: 464 ID NO: 470 NO: 473 CDR3 461 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 465 467 NO: 471 NO: 474 NO: SEQ ID SEQ SEQ ID SEQ ID462 NO: 466 ID NO: 472 NO: 475 SEQ ID NO:NO: 468463 SEQID NO:469Clonotype N CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 6C5v3CDR2 NO: NO: 484 ID NO: 490 NO: 493 CDR3 481 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 485 487 NO: 491 NO: 494 NO: SEQ ID SEQ SEQ ID SEQ ID482 NO: 486 ID NO: 492 NO: 495 SEQ ID NO:NO: 488483 SEQID NO:489Clonotype 0 CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 6Flv6CDR2 NO: NO: 504 ID NO: 510 NO: 513 CDR3 501 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 505 507 NO: 511 NO: 514 NO: SEQ ID SEQ SEQ ID SEQ ID502 NO: 506 ID NO: 512 NO: 515 SEQ ID NO:508WSGR RefNo. 65457-709.601NO: SEQ503 IDNO:509Clonotype P CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 10E5v2CDR2 NO: NO: 524 ID NO: 530 NO: 533 CDR3 521 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 525 527 NO: 531 NO: 534 NO: SEQ ID SEQ SEQ ID SEQ ID522 NO: 526 ID NO: 532 NO: 535 SEQ ID NO:NO: 528523 SEQID NO:529Clonotype Q CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v2CDR2 NO: NO: 544 ID NO: 550 NO: 553 CDR3 541 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 545 547 NO: 551 NO: 554 NO: SEQ ID SEQ SEQ ID SEQ ID542 NO: 546 ID NO: 552 NO: 555 SEQ ID NO:NO: 548543 SEQID NO:549Clonotype R CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v3CDR2 NO: NO: 564 ID NO: 570 NO: 573 CDR3 561 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 565 567 NO: 571 NO: 574 NO: SEQ ID SEQ SEQ ID SEQ ID562 NO: 566 ID NO: 572 NO: 575 SEQ ID NO:NO: 568563 SEQID NO:569Clonotype S CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v4CDR2 NO: NO: 584 ID NO: 590 NO: 593 CDR3 581 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 585 587 NO: 591 NO: 594 NO: SEQ ID SEQ SEQ ID SEQ ID582 NO: 586 ID NO: 592 NO: 595 SEQ ID NO:NO: 588583 SEQID NO:589WSGR RefNo. 65457-709.601Clonotype T CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v9CDR2 NO: NO: 604 ID NO: 610 NO: 613 CDR3 601 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 605 607 NO: 611 NO: 614 NO: SEQ ID SEQ SEQ ID SEQ ID602 NO: 606 ID NO: 612 NO: 615 SEQ ID NO:NO: 608603 SEQID NO:609Clonotype U CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9vl9CDR2 NO: NO: 624 ID NO: 630 NO: 633 CDR3 621 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 625 627 NO: 631 NO: 634 NO: SEQ ID SEQ SEQ ID SEQ ID622 NO: 626 ID NO: 632 NO: 635 SEQ ID NO:NO: 628623 SEQID NO:629Clonotype V CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v20CDR2 NO: NO: 644 ID NO: 650 NO: 653 CDR3 641 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 645 647 NO: 651 NO: 654 NO: SEQ ID SEQ SEQ ID SEQ ID642 NO: 646 ID NO: 652 NO: 655 SEQ ID NO:NO: 648643 SEQID NO:649Clonotype W CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v21CDR2 NO: NO: 664 ID NO: 670 NO: 673 CDR3 661 SEQ ID NO: SEQ ID SEQ ID SEQ ID NO: 665 667 NO: 671 NO: 674 NO: SEQ ID SEQ SEQ ID SEQ ID662 NO: 666 ID NO: 672 NO: 675 SEQ ID NO:NO: 668663 SEQID NO:669Clonotype X CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v22CDR2 NO: NO: 684 ID NO: 690 NO: 693 CDR3 681 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 685 687 NO: 691 NO: 694WSGRRefNo. 65457-709.601NO: SEQ ID SEQ SEQ ID SEQ ID682 NO: 686 ID NO: 692 NO: 695SEQ ID NO:NO: 688683 SEQID NO:689Clonotype Y CDR1 SEQ ID SEQ ID SEQ SEQ ID SEQ ID 3F9v23CDR2 NO: NO: 704 ID NO: 710 NO: 713 CDR3 701 SEQ ID NO: SEQ ID SEQ IDSEQ ID NO: 705 707 NO: 711 NO: 714NO: SEQ ID SEQ SEQ ID SEQ ID702 NO: 706 ID NO: 712 NO: 715SEQ ID NO:NO: 708703 SEQID NO:709
[0046] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-Hl, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 1, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 1.
[0047] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3WSGRRefNo. 65457-709.601VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-Hl, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 2, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 2.
[0048] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype B in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype B in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 61-63. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 64-66. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences ofSEQ ID NOs: 67-69 In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 70-72. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 73-75. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 3, wherein the CDRs as defined by clonotype B in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 3.
[0049] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype C in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype C in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 81-83. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 84-86. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acidWSGRRefNo. 65457-709.601sequences ofSEQ ID NOs: 87-89 In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 90-92. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 93-95. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 4, wherein the CDRs as defined by clonotype C in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 4.
[0050] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 5, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 5.
[0051] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-WSGRRefNo. 65457-709.601H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 6, wherein the CDRs as defined by clonotype A in Table 2 below are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 6.
[0052] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype D in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype D in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 141-143. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 144-146. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 147-149. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 150-152. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 153-155. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 7, wherein the CDRs as defined by clonotype D in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 7
[0053] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype E in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype E in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 161-163. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 164-166. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 167-169. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 170-172. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 173-175. In some embodiments, the DLL3 VHH comprises an amino acid sequenceWSGRRefNo. 65457-709.601having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 8, wherein the CDRs as defined by clonotype E in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 8
[0054] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype F in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype F in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 181-183. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 184-186. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 187-189. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 190-192. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 193-195. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 9, wherein the CDRs as defined by clonotype F in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 9
[0055] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype G in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype G in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 201-203. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 204-206. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 207-209. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 210-212. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 213-215. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to theWSGRRefNo. 65457-709.601sequence set forth in SEQ ID NO: 10, wherein the CDRs as defined by clonotype G in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 10
[0056] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype H in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype H in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 221-223. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 224-226. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 227-229. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 230-232. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 233-235. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 11, wherein the CDRs as defined by clonotype H in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 11
[0057] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype H in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype H in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 221-243. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 224-226. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 227-229. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 230-232. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 233-235. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 12, wherein the CDRs as defined by clonotype H in Table 2WSGRRefNo. 65457-709.601are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 12
[0058] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype I in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype I in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 381-383. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 384-386. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 387-389. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 390-392. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 393-395. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 351, wherein the CDRs as defined by clonotype I in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 351
[0059] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype J in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype J in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 401-403. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 404-406. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 407-409. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 410-412. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 413-415. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 352, wherein the CDRs as defined by clonotype J in Table 2WSGRRefNo. 65457-709.601are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 352
[0060] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype K in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype K in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 421-423. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 424-426. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 427-429. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 430-432. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 433-435. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 353, wherein the CDRs as defined by clonotype K in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 353
[0061] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype L in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype L in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 441-443. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 444-446. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 447-449. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 450-452. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 453-455. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 354, wherein the CDRs as defined by clonotype L in Table 2WSGRRefNo. 65457-709.601are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 354
[0062] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype M in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype M in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 461-463. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 464-466. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 466-469. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 470-472. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 473-475. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 355, wherein the CDRs as defined by clonotype M in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 355
[0063] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype N in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype N in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 481-483. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 484-486. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 487-489. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 490-492. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 493-495. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 356, wherein the CDRs as defined by clonotype N in Table 2WSGRRefNo. 65457-709.601are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 356
[0064] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype O in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype O in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 501-503. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 504-506. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 507-509. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 510-512. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 513-515. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 357, wherein the CDRs as defined by clonotype O in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 357
[0065] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype P in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype P in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 521-523. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 524-526. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 527-529. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 530-532. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 533-535. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 358, wherein the CDRs as defined by clonotype P in Table 2WSGRRefNo. 65457-709.601are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 358
[0066] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype H in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype H in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 221-223. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 224-226. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 227-229. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 230-232. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 233-235. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 359, wherein the CDRs as defined by clonotype H in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 359
[0067] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-Hl, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 360, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 360.WSGRRefNo. 65457-709.601
[0068] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-Hl, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 361, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 361.
[0069] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype A in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 21-23. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 24-26. In some embodiments, the DLL3 VHH comprises a CDR-Hl, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 27-29. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 30-32. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 33-35. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 362, wherein the CDRs as defined by clonotype A in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 362.
[0070] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype E in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype E in Table 2. In someWSGRRefNo. 65457-709.601embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 161-163. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 164-166. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 167-169. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 170-172. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 173-175. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 363, wherein the CDRs as defined by clonotype E in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 363
[0071] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype Q in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype Q in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 541-543. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 544-546. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 547-549. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 550-552. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 553-555. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 364, wherein the CDRs as defined by clonotype Q in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 364
[0072] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype R in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype R in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3WSGRRefNo. 65457-709.601comprising, respectively, amino acid sequences of SEQ ID NOs: 561-563. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 564-566. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 567-569. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 570-572. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 573-575. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 365, wherein the CDRs as defined by clonotype R in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 365
[0073] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype S in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype S in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 581-583. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 584-586. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 587-589. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 590-592. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 593-595. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 366, wherein the CDRs as defined by clonotype S in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 366
[0074] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype T in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype T in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 601-603. In someWSGRRefNo. 65457-709.601embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 604-606. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 607-609. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 610-612. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 613-615. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 367, wherein the CDRs as defined by clonotype T in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 367
[0075] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype U in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype U in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 621-623. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 624-626. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 627-629. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 630-632. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 633-635. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 368, wherein the CDRs as defined by clonotype U in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 368
[0076] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype V in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype V in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 641-643. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3WSGRRefNo. 65457-709.601comprising, respectively, amino acid sequences of SEQ ID NOs: 644-646. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 647-649. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 650-652. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 653-655. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 369, wherein the CDRs as defined by clonotype V in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 369
[0077] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype W in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype W in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 661-663. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 664-666. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 667-669. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 670-672. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 673-675. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 370, wherein the CDRs as defined by clonotype W in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 370
[0078] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype X in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype X in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 681-683. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 684-686. In someWSGRRefNo. 65457-709.601embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 687-689. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 670-672. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 673-675. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 371, wherein the CDRs as defined by clonotype X in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 371
[0079] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype Y in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype Y in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 701-703. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 704-706. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 707-709. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 710-712. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 713-715. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 372, wherein the CDRs as defined by clonotype Y in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 372
[0080] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 of any one of the amino acid sequences of clonotype H in Table 2. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 of clonotype H in Table 2. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 221-223. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 224-226. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising,WSGRRefNo. 65457-709.601respectively, amino acid sequences of SEQ ID NOs: 227-229. In some embodiments, the DLL3 VHH molecule comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 230-232. In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, amino acid sequences of SEQ ID NOs: 233-235. In some embodiments, the DLL3 VHH comprises an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence set forth in SEQ ID NO: 373, wherein the CDRs as defined by clonotype H in Table 2 are retained. In some embodiments, the DLL3 VHH comprises the sequence set forth in SEQ ID NO: 373
[0081] In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a VHH of any one of SEQ ID NOs: 1-12 or SEQ ID NOs: 351-373. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 1. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 2. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 3. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 4. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 5. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 6. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 7. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 8. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 9. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 10. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 11. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, orWSGRRefNo. 65457-709.60199% sequence identity with SEQ ID NO: 12. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 351. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 352. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 353. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 354. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 355. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 356. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 357. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 358. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 359. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 360. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 361. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 362. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 363. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 364. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 365. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 366. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 367. In some embodiments, the DLL3 VHH has anWSGRRefNo. 65457-709.601amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 368. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 369. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 370. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 371. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 372. In some embodiments, the DLL3 VHH has an amino acid sequence that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 373.
[0082] In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 4. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 5. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 6. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 9. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 10. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 351. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 352. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 353. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 354. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 355. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 356. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 357. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 358. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 359. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 360. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ IDWSGRRefNo. 65457-709.601NO: 361. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 362. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 363. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 364. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 365. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 366. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 367. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 368. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 369. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 370. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 371. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 372. In some embodiments, the DLL3 VHH comprises the amino acid sequence of SEQ ID NO: 373
[0083] In some embodiments, the DLL3 VHH comprises a CDR-H1, CDR-H2, or CDR-H3 sequences, under any CDR definition provided in Table 2, where the VHH sequence has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a VHH of any one of SEQ ID NOs: 1-12 or SEQ ID NOs: 351-373. In some embodiments, the DLL3 VHH has the amino acid sequence of any one of SEQ ID NOs: 1-12 or SEQ ID NOs: 351-373. FUSION PROTEINS AND CONJUGATES CONTAINING DLL3-BINDING VHH DOMAINS
[0084] Provided herein are DLL3 -binding molecules containing at least one VHH domain that specifically binds DLL3 (“DLL3 VHH”) linked, directly or indirectly, to one or more additional domains or moieties. In some embodiments, the DLL3-binding molecules of the present disclosure are composed of a single polypeptide. In other embodiments, the DLL3-binding molecules of the present disclosure are composed of more than one polypeptide. In some embodiments, the DLL3-binding molecules of the present disclosure incorporate at least one DLL3 VHH. In some embodiments, the DLL3 -binding molecules are multivalent. In some embodiments, the DLL3 -binding molecules include two or more copies of a DLL3 VHH, for example, three or more, four or more, five or more, or six or more copies of a DLL3 VHH. In certain embodiments, the DLL3-binding molecules are multispecific. For example, in some cases, the one or more additional domain may be one or more additional binding domain that binds to one or more further antigen.A. Linkers
[0085] In some embodiments, the DLL3-binding molecules of the present disclosure include two or more polypeptide sequences that are operably linked via amino acid linkers. VariousWSGRRefNo. 65457-709.601polypeptide linkers for use in fusion proteins are known (see e.g. Chen et al. (2013) Adv. Drug. Deliv. 65:1357-1369; and International PCT publication No. WO 2014099997, W0200024884; U.S. Pat. No. 5,258,498; U.S. Pat. No. 5,525,491; U.S. Pat. No. 5,525,491, U.S. Pat. No.6,132,992).
[0086] The polypeptide linker can be a flexible linker or a rigid linker or a combination of both. In some embodiments, the linker is a short, medium or long linker. In some embodiments, the linker is up to 40 amino acids in length. In some embodiments, the linker is up to 25 amino acids in length. In some embodiments, the linker is at least or is at least about 2 amino acids in length. In some embodiments, a suitable length is, e.g., a length of at least one and typically fewer than about 40 amino acid residues, such as 2-25 amino acid residues, 5-20 amino acid residues, 5-15 amino acid residues, 8-12 amino acid. In some embodiments, the linker is from or from about 2 to 24 amino acids, 2 to 20 amino acids, 2 to 18 amino acids, 2 to 14 amino acids, 2 to 12 amino acids, 2 to 10 amino acids, 2 to 8 amino acids, 2 to 6 amino acids, 6 to 24 amino acids, 6 to 20 amino acids, 6 to 18 amino acids, 6 to 14 amino acids, 6 to 12 amino acids, 6 to 10 amino acids, 6 to 8 amino acids, 8 to 24 amino acids, 8 to 20 amino acids, 8 to 18 amino acids, 8 to 14 amino acids, 8 to 12 amino acids, 8 to 10 amino acids, 10 to 24 amino acids, 10 to 20 amino acids, 10 to 18 amino acids, 10 to 14 amino acids, 10 to 12 amino acids, 12 to 24 amino acids, 12 to 20 amino acids, 12 to 18 amino acids, 12 to 14 amino acids, 14 to 24 amino acids, 14 to 20 amino acids, 14 to 18 amino acids, 18 to 24 amino acids, 18 to 20 amino acids or 20 to 24 amino acids. In some embodiments, the linker is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length.
[0087] The linkers can be naturally-occurring, synthetic or a combination of both. Particularly suitable linker polypeptides predominantly include amino acid residues selected from Glycine (Gly), Serine (Ser), Alanine (Ala), and Threonine (Thr). For example, the linker may contain at least 75% (calculated on the basis of the total number of residues present in the peptide linker), such as at least 80%, at least 85%, or at least 90% of amino acid residues selected from Gly, Ser, Ala, and Thr. The linker may also consist of Gly, Ser, Ala and / or Thr residues only. In some embodiments, the linker contains 1-25 glycine residues, 5-20 glycine residues, 5-15 glycine residues, or 8-12 glycine residues. In some embodiments, suitable peptide linkers typically contain at least 50% glycine residues, such as at least 75% glycine residues. In some embodiments, a peptide linker comprises glycine residues only. In some embodiments, a peptide linker comprises glycine and serine residues only.
[0088] In some embodiments, the linker is a flexible linker comprising predominately, or solely Glycine residues, such as, by way of non-limiting example, GG, GGG, GGGG (SEQ ID NO: 333), etc. The glycine linkers of the fusion proteins of the present disclosure can be ofWSGRRefNo. 65457-709.601various lengths, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length. In some embodiments, the glycine linker comprises 1-6 amino acids, 1-12 amino acids, 6-12 amino acids, 6-18 amino acids, 12-18 amino acids, 12 to 20 amino acids, or 18-20 amino acids. In some embodiments, these linkers are composed predominately of the amino acids Glycine and Serine, denoted as GS-linkers herein. The GS-linkers of the fusion proteins of the present disclosure can be of various lengths, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acids in length. In some embodiments, the GS-linker comprises 1-6 amino acids, 1-12 amino acids, 6-12 amino acids, 6-18 amino acids, 12-18 amino acids, 12 to 20 amino acids, or 18-20 amino acids. In some embodiments, the linker contains (GGS)n, wherein n is 1 to 10, or n is 1 to 5, or n is 1 to 3. In some embodiments, the linker contains the sequence (GGGGS)n (SEQ ID NO: 341), wherein n is 1 to 10 or n is 1 to 5, or n is 1 to 3.
[0089] In some embodiments, the GS-linker comprises an amino acid sequence selected from the group consisting of GSGGGS (SEQ ID NO: 334), GGSGGS, i.e., (GGS)2(SEQ ID NO: 335); GGSGGSGGS, i.e., (GGS)3(SEQ ID NO: 336); GGSGGSGGSGGS, i.e., (GGS)4(SEQ ID NO: 337); and GGSGGS GGSGGSGGS, i.e., (GGS)5(SEQ ID NO: 338). In some embodiments, the linker is (GGGGS)n, wherein n is 1 to 5 (SEQ ID NO: 341); (GGGGGS)n, wherein n is 1 to 4 (SEQ ID NO: 342). In some embodiments, the DLL3 -binding molecule includes a combination of a GS-linker and a Glycine linker.
[0090] In some cases, it may be desirable to provide some rigidity into the peptide linker. This may be accomplished by including proline residues in the amino acid sequence of the peptide linker. Thus, in some embodiments, a linker comprises at least one proline residue in the amino acid sequence of the peptide linker. For example, a peptide linker can have an amino acid sequence wherein at least 25% (e.g., at least 50% or at least 75%) of the amino acid residues are proline residues. In one particular embodiment, the peptide linker comprises proline residues only. In some embodiments, the linker comprises PGGGG (SEQ ID NO: 343).B. Fc Fusions
[0091] Provided herein is a DLL3-binding molecule that is a fusion protein containing at least one DLL3 VHH provided herein and an Fc region. In some embodiments, a DLL3-binding molecule provided herein comprises one, two, three, or four DLL3 VHHs and an Fc region.
[0092] In some embodiments, incorporation of an immunoglobulin Fc region into the fusion protein can, in some embodiments, be composed of two polypeptides that together form a dimer. In some embodiments, an Fc region mediates dimerization of the DLL3-binding molecule at physiological conditions, such as when expressed from a cell, such that a dimer is formed that doubles the number of DLL3 -binding sites. For example, a DLL3-binding molecule comprising three DLL3 VHHs and an Fc region is trivalent as a monomer, but the Fc region may mediateWSGRRefNo. 65457-709.601dimerization, such that the DLL3-binding molecule exists as a hexavalent dimer under such conditions. In some embodiments, a DLL3 VHH is fused to an IgG Fc region and in these embodiments, the fusion protein is bivalent having two DLL3 VHHs per molecule. In some embodiments, two DLL3VHHs (2x) are fused to an IgG Fc region and in these embodiments, the fusion protein is tetravalent having four DLL3 VHHs per molecule. In some embodiments, three DLL3 VHHs (3x) are fused to an IgG Fc region and in these embodiments, the fusion protein is hexavalent having six DLL3 VHHs per molecule.
[0093] In some embodiments, the multivalent DLL3-binding molecule is bivalent. In some embodiments, the bivalent DLL3-binding molecule of the disclosure includes two copies of a polypeptide having the following structure: ( DLL3 VHH)-Linker-Fc. In some embodiments, the multivalent DLL3-binding molecule is tetravalent. In some embodiments, the tetraval ent DLL3-binding molecule of the disclosure includes two copies of a polypeptide having the following structure: ( DLL3 VHH)-Linker-( DLL3 VHH)-Linker- Fc or ( DLL3 VHH)-Linker-Fc-Linker-( DLL3 VHH). In some embodiments, the multivalent DLL3-binding molecule is hexavalent. In some embodiments, the hexavalent DLL3-binding molecule of the disclosure includes two copies of a polypeptide having the following structure: ( DLL3 VHH)-Linker-( DLL3 VHH)-Linker-( DLL3 VHH)-Linker- Fc.
[0094] In some cases, the CH3 domain of the Fc region can be used as homodimerization domain, such that the resulting fusion protein is formed from two identical polypeptides. In other cases, the CH3 dimer interface region of the Fc region can be mutated so as to enable heterodimerization. For example, a heterodimerization domain can be incorporated into the fusion protein such that the construct is an asymmetric fusion protein.
[0095] In some embodiments, an Fc region included in a DLL3-binding molecule is a human Fc region, or is derived from a human Fc region. In some embodiments, the DLL3-binding molecule contains an immunoglobulin Fc region. In some embodiments, the immunoglobulin Fc region is an IgG isotype selected from the group consisting of IgGl isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype. In some embodiments, the Fc region is derived from a human Fc region and lacks the C-terminal lysine residue. In some embodiments, the Fc region is derived from a human Fc region and comprises the C-terminal lysine residue. In some embodiments, the C-terminal amino acid of the Fc region is an amino acid other than lysine. In some embodiments, the Fc region is derived from a human Fc region and lacks the C-terminal glycine and lysine residues.
[0096] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof comprises a human IgGl, IgG2, IgG3 or IgG4 polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acidWSGRRefNo. 65457-709.601sequence of any one of SEQ ID NOs: 301-304. In some embodiments, the Fc region or a variant thereof such as any described below can be from any IgG allotype, e.g., a G1 ml or G1 m3 allotype. In some embodiments, the Fc region can contain amino acids of the human G1 ml allotype, such as residues containing Asp (D) and Leu (L) at positions 356 and 358 by EU numbering. In other embodiments, the Fc region can contain amino acids of the human G1 m3 allotype, such as residues Glu (E) and Met (M) at positions 356 and 358 by EU numbering.
[0097] In some embodiments where the DLL3-binding molecule of the disclosure includes an Fc region, the Fc region is mutated or modified at one or more position. In some cases, the mutations include one or more amino acid substitutions to reduce an effector function of the Fc region. Various examples of mutations to Fc regions to alter, such as reduce, effector function are known, including any as described below. Unless described with reference to a position within a specific SEQ ID NO. reference to an amino acid position in an Fc region is according to the EU index
[0098] In some embodiments, an Fc region that exhibits reduced effector functions may be a desirable candidate for applications in which DLL3 binding is desired yet certain effector functions (such as CDC and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays can be conducted to confirm the reduction / depletion of CDC and / or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the fusion proteinsand / or cleaved components thereof lack FcyR binding (hence likely lacking ADCC activity), but retain FcRn binding ability.
[0099] In some embodiments, the Fc is an Fc that exhibits immune effector activity, such as one or more effector functions such as antibody-dependent cellular cytotoxicity (ADCC), antibodydependent cellular phagocytosis (ADCP) and / or complement-dependent cytotoxicity (CDC).
[0100] In some embodiments, the human IgG Fc region is modified to alter antibody-dependent cellular cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC), e.g., the amino acid modifications described inNatsume et al., 2008 Cancer Res, 68(10): 3863-72; Idusogie et al., 2001 J Immunol, 166(4): 2571-5; Moore et al., 2010 mAbs, 2(2): 181-189; Lazar et al., 2006 PNAS, 103(11): 4005-4010, Shields et al., 2001 JBC, 276(9): 6591-6604; Stavenhagen et al., 2007 Cancer Res, 67(18): 8882-8890; Stavenhagen et al., 2008 Advan. Enzyme Regul., 48: 152-164; Alegre et al, 1992 J Immunol, 148: 3461-3468; Reviewed in Kaneko and Niwa, 2011 Biodrugs, 25(1): 1-11.
[0101] Examples of mutations that enhance ADCC include modification at Ser239 and Ile332, for example Ser239Asp and Ile332Glu (S239D, I332E). Examples of mutations that enhance CDC include modifications at Lys326 and Glu333. In some embodiments, the Fc region isWSGRRefNo. 65457-709.601modified at one or both of these positions, for example Lys326Ala and / or Glu333 Ala (K326A and E333A) using the EU numbering system.
[0102] In some embodiments, the Fc region of the fusion protein is altered at one or more of the following positions to reduce Fc receptor binding: 234, 235, 265, 270, 298, 297, 325, 327 or 329. For example, Leu234Ala (L234A), Leu235Ala (L235A), Leu235Glu (L235E), Asp265Asn (D265N), Asp265Ala (D265A), Asp270Asn (D270N), Ser298Asn (S298N), Asn297Ala (N297A), Pro329Ala (P329A) or Pro239Gly (P329G), Asn325Glu (N325E), or Ala327Ser (A327S) (EU numbering). In preferred embodiments, modifications within the Fc region reduce binding to Fc-receptor-gamma receptors while have minimal impact on binding to the neonatal Fc receptor (FcRn).
[0103] In some embodiments, the human IgGl Fc region is modified at amino acid Asn297 (EU Numbering) to prevent glycosylation of the fusion protein, e.g., Asn297Ala (N297A) or Asn297Asp (N297D). In some embodiments, the Fc region of the fusion protein is modified at position 235 (EU Numbering) to alter Fc receptor interactions, e.g., Leu235Glu (L235E) or Leu235Ala (L235A). In some embodiments, the Fc region of the fusion protein is modified at position 234 (EU Numbering) to alter Fc receptor interactions, e.g., Leu234Ala (L234A). In some embodiments, the Fc region of the fusion protein is modified at position 235 (EU Numbering) to alter Fc receptor interactions, e.g., Leu235Glu (L235E). In some embodiments, the Fc region of the fusion protein is altered at both positions 234 and 235, e.g., Leu234Ala and Leu235Ala (L234A / L235A) or Leu234Val and Leu235Ala (L234V / L235A). In some embodiments, the Fc region of the fusion protein is altered at positions at 234, 235, and 297, e.g., Leu234Ala, Leu235Ala, Asn297Ala (L234A / L235A / N297A). In some embodiments, the Fc region of the fusion protein is altered at positions at 234, 235, and 329, e.g., Leu234Ala, Leu235Ala, Pro239Ala (L234A / L235A / P329A). In some embodiments, the Fc region of the fusion protein is modified at position 265 (EU Numbering) to alter Fc receptor interactions, e.g., Asp265Ala (D265A). In some embodiments, the Fc region of the fusion protein is modified at position 329 (EU Numbering) to alter Fc receptor interactions, e.g Pro329Ala (P329A) or Pro329Gly (P329G). In some embodiments, the Fc region of the fusion protein is altered at both positions 265 and 329, e.g., Asp265Ala and Pro329Ala (D265A / P329A) or Asp265Ala and Pro329Gly (D265A / P329G). In some embodiments, the Fc region of the fusion protein is altered at positions at 234, 235, and 265, e.g., Leu234Ala, Leu235Ala, Asp265Ala (L234A / L235A / D265A). In some embodiments, the Fc region of the fusion protein is altered at positions at 234, 235, and 329, e.g., Leu234Ala, Leu235Ala, Pro329Gly (L234A / L235A / P329G). In some embodiments, the Fc region of the fusion protein is altered at positions at 234, 235, 265 and 329, e.g., Leu234Ala, Leu235Ala, Asp265Ala, Pro329GlyWSGRRefNo. 65457-709.601(L234A / L235A / D265A / P329G). In some embodiments, the human IgGl Fc region is modified at amino acid Gly236 to enhance the interaction with CD32A, e.g., Gly236Ala (G236A).
[0104] In some embodiments, the Fc region of the fusion protein is lacking an amino acid at one or more of the following positions to reduce Fc receptor binding: 233, 234, and 235 (EU Numbering). In some embodiments, the Fc region of the fusion protein is lacking an amino acid at one or more of the following positions 233, 234, and 235 and is modified at one or more of the positions 265, 297, or 329 (EU numbering) to reduce Fc receptor binding. For example, an Fc region included in a DLL3-binding molecule is derived from a human Fc region, and comprises a three amino acid deletion in the lower hinge corresponding to IgGl E233, L234, and L235, IgG2 P233, V234, V235, IgG3 E233, E234, L235, or IgG4 E233, F234, L235. In some embodiments, such Fc regions do not engage FcyRs and thus are referred to as “effector silent” or “effector null.” For example, Fc deletion of these three amino acids reduces the complement protein Clq binding. In some embodiments, a polypeptide with an Fc region with Fc deletion of these three amino acids retains binding to FcRn and therefore has extended halflife and transcytosis associated with FcRn mediated recycling. Such a modified Fc region is referred to as “Fc xELL” (see, e.g., SEQ ID NOs: 312-329). In some embodiments, the human IgG Fc region is modified to enhance FcRn binding. Examples of Fc mutations that enhance binding to FcRn are Met252Tyr, Ser254Thr, Thr256Glu (M252Y, S254T, T256E, respectively) (EU Numbering, Dall’Acqua et al 2006, J. Biol Chem Vol. 281(33) 23514-23524), Met428Leu and Asn434Ser (M428L, N434S) (Zalevsky et al 2010 Nature Biotech, Vol. 28(2) 157-159), or Met252Ile, Thr256Asp, Met428Leu (M252I, T256D, M428L, respectively), (EU Numbering).
[0105] In some embodiments, the Fc region included in a DLL3 -binding molecule is derived from a human Fc region and comprises mutations M252Y and M428V (EU Numbering), herein referred to as “YV” (see, e.g., SEQ ID NOs: 314, 317, 320, 323, 326, 329, or 332). In some embodiments, the mutated or modified Fc region includes the following mutations: M252Y and M428L (EU Numbering), herein referred to as “YL” (see e.g., SEQ ID NOs: 315, 316, 321, 322, 326, or 328). In some embodiments, such mutations enhance binding to FcRn at the acidic pH of the endosome (near 6.5), while losing detectable binding at neutral pH (about 7.2), allowing for enhanced FcRn mediated recycling and extended half-life.
[0106] In some embodiments, the Fc region included in a DLL3 -binding molecule is derived from a human Fc region and comprises mutations to induce heterodimerization. Various methods are known for promoting heterodimerization of complementary Fc polypeptides, see e.g. Ridgway et al, Protein Eng. 9:617-621 (1996); Merchant et al, Nat. Biotechnol. 16(7): 677-81 (1998); Moore et al. (2011) MAbs, 3:546-57; Von Kreudenstein et al. MAbs, (2013) 5:646-54; Gunasekaran et al. (2010) J. Biol. Chem., 285:19637-46; Leaver-Fay et al. (2016) Structure,WSGRRefNo. 65457-709.60124:641-51; Ha et al. (2016) Frontiers in Immunology, 7:1; Davis et al. (2010) Protein Eng Des Sei, 23:195-202; published international PCT Appl. No. WO 1998 / 050431, WO 2009 / 089004, WO2011143545 WO 2014 / 067011, WO 2012 / 058768, WO2018027025; published U.S. patent Appl. No. US20140363426, US20150307628, US20180016354, US20150239991; and U.S. patent Nos. US5731168, US7183076, US9701759, US9605084, and US9650446. Methods to promote heterodimerization of Fc chains include mutagenesis of the Fc region, such as by including a set of “knob-into-hole” mutations or including mutations to effect electrostatic steering of the Fc to favor attractive interactions among different polypeptide chains. For example, in some embodiments, the Fc polypeptides of a heterodimer includes a mutation to alter charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive interactions thereby promoting desired Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress unwanted Fc homodimer formation (Guneskaran et al. (2010) JBC, 285: 19637-19646). When co-expressed in a cell, association between the chains is possible but the chains do not substantially selfassociate due to charge repulsion. Other strategies for generating a heterodimeric Fc include mixing human IgG and IgA CH3 domain segments to create a complementary CH3 heterodimer, which is referred to as a SEED Fc.
[0107] Methods and variants for heterodimerization also include those described in published international PCT App. WO2014145806, including “knobs and holes” mutations (also called “skew” variants), mutations that relate to “electrostatic steering” or “charge pairs,” and pl variants. Heterodimeric variants also include any as described in U.S. published Appl. No.US2012 / 0149876 or US2018 / 011883.
[0108] In some embodiments, to promote heterodimerization both polypeptides of the heterodimeric Fc region contain paired or complementary amino acid modifications. Exemplary paired amino acid modifications of polypeptides of an Fc fusion are set forth in Table 3.Table 3. Paired amino acids of Heterodimeric FcFirst Fc polypeptide Second Fc PolypeptideT366W (Knob) T366S / L368W / Y407V (Hole) T366W / S354C (Knob-Cys) T366S / L368A / Y407V / Y349C (Hole-Cys) S364H / F405A Y349T / Y349FT350 V / L351 Y / F405 A / Y407 V T350 V / T366L / K392L / T394W K360D / D399M / Y407A E345R / Q347R / T366V / K409V K409D / K392D D399K / E356KK360E / K409W Q347R / D399V / F405TWSGRRefNo. 65457-709.601L360E / K409W7Y349C Q347R / 399V / F405T / S354C K370E / K409W E357N / D399V / F405T
[0109] Additional examples of variants that can facilitate the promotion of heterodimers are any combination or pair of steric variants (e.g. skew variants) of a first Fc polypeptide and a second Fc polypeptide from among: S364K / E357Q and L368D / K370S; L368D / K370S and S364K; L368E / K370S and S364K; T411T / E360E / Q362E and D401K; L368D / K370S and S364K / E357L, K370S and S364K / E357Q and T366S / L368A / Y407V and T366W or 366S / L368A / Y407V / Y349C and T366W / S354C), where each pair represents mutations in the first Fc polypeptide and second Fc polypeptide. In particular embodiments, a provided molecule contains a first and second Fc polypeptide containing the pair of mutations L368D / K370S and S364K and E357Q.
[0110] An additional mechanism that can be used in the generation of heterodimers is sometimes referred to as “electrostatic steering” as described in Gunasekaran et al., J. Biol. Chem. 285(25): 19637 (2010). This is sometimes referred to herein as “charge pairs”. In this embodiment, electrostatics are used to skew the formation towards heterodimerization. As those in the art will appreciate, these may also have an effect on pl, and thus on purification, and thus could in some cases also be considered pl variants. However, as these were generated to force heterodimerization and were not used as purification tools, they are classified as “steric variants”. In some embodiments, a first Fc polypeptide can contain mutations D221E / P228E / L368E and a second Fc polypeptide can contain mutations D221R / P228R / K409R. In another embodiments, a first Fc polypeptide can contain mutations C220E / P228E / 368E and a second Fc polypeptide can contain mutations C220R / E224R / P228R / K409R.[OHl] In some embodiments, heterodimerization can be facilitated by pl variants. In some embodiments, a pl variant can include those that increase the pl of the protein (basic changes). In other embodiments, the pl variant can include those that decrease the pl of the protein (acidic changes). In some cases, all combinations of these variants can be done, including combinations in which one Fc polypeptide may be wild type, or a variant that does not display a significantly different pl from wild-type, and the other Fc polypeptide can be either more basic or more acidic. Alternatively, each Fc polypeptide can be changed, one to more basic and one to more acidic. In some embodiments, at least one Fc polypeptide is a negative pl variant Fc containing mutations Q295E / N384D / Q418E / N421D.
[0112] In some embodiments, one member of a heterodimeric Fc pair comprises the “knob” mutation (see, e.g., SEQ ID NOs: 318-323) and the other member of a heterodimeric Fc pairWSGRRefNo. 65457-709.601comprises the “hole” mutations (see, e.g., SEQ ID NOs: 324-329). In some embodiments, one member of a heterodimeric Fc pair comprises the modification H435R or H435K to prevent protein A binding while maintaining FcRn binding (see, e.g., SEQ ID NOs: 22, 23, 28, or 29).In some embodiments, one member of a heterodimeric Fc pair comprises the modification H435R or H435K, while the second member of the heterodimeric Fc pair is not modified at H435. In various embodiments, the hole Fc region comprises the modification H435R or H435K (referred to as “hole-R” in some instances when the modification is H435R), while the knob Fc region does not. In some instances, the hole-R mutation improves purification of the heterodimer over homodimeric hole Fc regions that may be present.
[0113] In some embodiments, the Fc region comprises a first Fc polypeptide and a second Fc polypeptide. In some embodiments, the first Fc polypeptide comprises any of SEQ ID NOs: 318-323, or comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 318-323. In some embodiments, the second Fc polypeptide comprises any of SEQ ID NOs: 324-329, or comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 324-329.
[0114] In some embodiments, the human IgG Fc region included in a DLL3-binding molecule is modified to prevent dimerization. In these embodiments, the fusion proteins of the present disclosure are monomeric. For example modification at residue Thr366 to a charged residue, e.g. Thr366Lys, Thr366Arg, Thr366Asp, or Thr366Glu (T366K, T366R, T366D, or T366E, respectively), prevents CH3-CH3 dimerization.
[0115] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof included in a DLL3-binding molecule comprises a human IgGl polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 301. In some embodiments, the human IgGl Fc region lacks Lys447 (EU Numbering).
[0116] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof included in a DLL3-binding molecule comprises a human IgG2 polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 302. In some embodiments, the human IgG2 Fc region lacks Lys447 (EU Numbering).
[0117] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof included in a DLL3-binding molecule comprises a human IgG3 polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 303. In some embodiments, the human IgG3 Fc regionWSGRRefNo. 65457-709.601is modified at amino acid 435 to extend the half-life, e.g., Arg435His (R435H). In some embodiments, the human IgG3 Fc region lacks Lys447 (EU Numbering). In some embodiments, the human IgG3 Fc region lacks Lys447 (EU Numbering).
[0118] In some embodiments, the immunoglobulin Fc region or immunologically active fragment thereof included in a DLL3-binding molecule comprises a human IgG4 polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 304. In some embodiments, the human IgG4 Fc region is modified at amino acid 235 to alter Fc receptor interactions, e.g., Leu235Glu (L235E). In some embodiments, the human IgG4 Fc region lacks Lys447 (EU numbering).
[0119] In some embodiments, the Fc region included in a DLL3-binding molecule comprises a polypeptide derived from an immunoglobulin hinge region. The hinge region can be derived from any of the human IgG subclasses (see, e.g., SEQ ID NOs: 305-311). For example, the Fc region may contain a modified IgGl hinge having the sequence of EPKSSDKTHTCPPC (SEQ ID NO: 306), where in the Cys220 that forms a disulfide with the C-terminal cysteine of the light chain is mutated to serine, e.g., Cys220Ser (C220S). In other embodiments, the fusion protein contains a truncated hinge having a sequence DKTHTCPPC (SEQ ID NO: 307). Unless noted the Fc regions provided in the Table of Certain Sequences comprise a truncated hinge having the sequence SEQ ID NO: 307.
[0120] In some embodiments, the Fc region included in a DLL3 -binding molecule has a modified hinge from IgG4, which is modified to prevent or reduce strand exchange, e.g., Ser228Pro (S228P), having the sequence ESKYGPPCPPC (SEQ ID NO: 311). In some embodiments, the Fc region included in a DLL3-binding molecule contains linker polypeptides. In other embodiments, the Fc region included in a DLL3 -binding molecule contains linker and hinge polypeptides.
[0121] In some embodiments, the Fc region included in a DLL3-binding molecule comprises any of SEQ ID NOs: 311-332, or a polypeptide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 311-332
[0122] In some embodiments, the Fc region included in a DLL3-binding molecule lacks or has reduced Fucose attached to the N-linked glycan-chain at N297. There are numerous ways to prevent fucosylation, including but not limited to production in a FUT8 deficient cell line; additional inhibitors to the mammalian cell culture media, for example castanospermine; and metabolic engineering of the production cell line.
[0123] In some embodiments, the Fc regions included in a DLL3-binding molecule are operably linked to the other domains (e.g., VHH) via amino acid linkers, such as any described above.WSGRRefNo. 65457-709.601C. Conjugates
[0124] Provided herein are DLL3-binding molecules containing at least one DLL3 VHH provided herein conjugated to one or more further moiety referred to herein as “DLL3 -binding conjugates”. The further moiety can be a therapeutic agent, or can be a detection agent. In some embodiments, the moiety can be a DLL3ing moiety, a small molecule drug (non-polypeptide drug of less than 500 Daltons molar mass), a toxin, a cytostatic agent, a cytotoxic agent, an immunosuppressive agent, a radioactive agent suitable for diagnostic purposes, a radioactive metal ion for therapeutic purposes, a prodrug-activating enzyme, an agent that increases biological half-life, or a diagnostic or detectable agent.
[0125] In some embodiments, the DLL3-binding conjugate is an antibody drug conjugate (ADC, also called immunoconjugates) containing one or more DLL3-binding molecules provided herein conjugated to a therapeutic agent, which is either cytotoxic, cytostatic or otherwise provides some therapeutic benefit. In some embodiments, the cytotoxic agent is a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate). In some embodiments, provided antibody drug conjugates of the present disclosure allow DLL3-delivery of the drug moiety to tumors. In some cases, this can result in DLL3 killing of the tumor cell.
[0126] In some embodiments, there is provided a DLL3-binding molecule conjugated with a therapeutic agent. In some embodiments, the therapeutic agent includes, for example, daunomycin, doxorubicin, methotrexate, and vindesine (Rowland et al., Cancer Immunol.Immunother. 21:183-187, 1986). In some embodiments, the therapeutic agent has an intracellular activity. In some embodiments, the DLL3-binding conjugate is internalized and the therapeutic agent is a cytotoxin that blocks the protein synthesis of the cell, therein leading to cell death. In some embodiments, the therapeutic agent is a cytotoxin comprising a polypeptide having ribosome-inactivating activity including, for example, gelonin, bouganin, saporin, ricin, ricin A chain, bryodin, diphtheria toxin, restrictocin, Pseudomonas exotoxin A and variants thereof. In some embodiments, where the therapeutic agent is a cytotoxin comprising a polypeptide having a ribosome-inactivating activity, the DLL3-binding conjugate must be internalized upon binding to the DLL3 cell in order for the protein to be cytotoxic to the cells.
[0127] In some embodiments, there is provided a DLL3-binding molecule conjugated with a toxin. In some embodiments, the toxin includes, for example, bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin (Mandi er et al., J. Nat. Cancer Inst. 92(19): 1573-1581 (2000); Mandler et al., Bioorganic & Med. Chem. Letters 10:1025- 1028 (2000); Mandler et al., Bioconjugate Chem. 13:786-791 (2002)), maytansinoidsWSGRRefNo. 65457-709.601(EP 1391213; Liu et al., Proc. Natl. Acad. Sci. USA 93:8618-8623 (1996)), and calicheamicin (Lode et al., Cancer Res. 58:2928 (1998); Hinman et al., Cancer Res. 53:3336-3342 (1993)). The toxins may exert their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition.
[0128] In some embodiments, there is provided a DLL3-binding molecule conjugated to a topoisomerase inhibitor which may be an inhibitor of topoisomerase I (Topi) or topoisomerase II (TopII). In some such embodiments the Topi inhibitor is deruxtecan, irinotecan, topotecan, or camptothecin. In some embodiments, the TopII inhibitor is etoposide, doxorubicin, or epirubicin.
[0129] In some embodiments, the DLL3-binding conjugate is radionucleotide antibody conjugate (RAC, also called radioconjugates) containing one or more DLL3-binding molecule provided herein conjugated radioactive metal ion for therapeutic purposes. In some embodiments, the radioactive metal ion is an alpha particle emitter such as actinium-225 or radium-223, or a beta particle emitter such as lutetium-177. In some embodiments, DLL3-binding molecule is conjugated to a chelating agent capable of chelating a radioactive metal ion, such as DOTA (also known as tetraxetan, see, e.g., CAS No: 60239-18-1), DTPA (see e.g., CAS No: 67-43-6), CHX-A”-DTPA (see, e.g., CAS No: 142434-84-2), PEPA, see e.g., CAS No: ), Oxo-D03A (see, e.g., CAS No: 112193-74-5), and derivatives of the same.
[0130] In some embodiments, there is provided a DLL3-binding molecule conjugated with a label, which can generate a detectable signal, indirectly or directly. These DLL3-binding conjugates can be used for research or diagnostic applications, such as for the in vivo detection of cancer. The label is preferably capable of producing, either directly or indirectly, a detectable signal. For example, the label may be radio-opaque or a radioisotope, such as 3H, 14C, 32P, 35S, 1231, 1251, 1311; a fluorescent (fluorophore) or chemiluminescent (chromophore) compound, such as fluorescein isothiocyanate, rhodamine or luciferin; an enzyme, such as alkaline phosphatase, P-galactosidase or horseradish peroxidase; an imaging agent; or a metal ion. In some embodiments, the label is a radioactive atom for scintigraphic studies, for example 99Tc or 1231, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as zirconium-89, iodine-123, iodine-131, indium-ill, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron. Zirconium-89 may be complexed to various metal chelating agents and conjugated to antibodies, e.g., for PET imaging (WO 2011 / 056983).
[0131] The DLL3-binding conjugates may be prepared using any methods known in the art. See, e.g., WO 2009 / 067800, WO 2011 / 133886, and U.S. Patent Application Publication No.2014322129, incorporated by reference herein in their entirety.WSGRRefNo. 65457-709.601
[0132] In some embodiments, the attachment can be covalent or non-covalent, e.g., via a biotinstreptavidin, or chelator non-covalent interaction. In some embodiments, 1, 2, 3, 4, 5 or more moieties, which can be the same or different, are conjugated, linked or fused to a DLL3-binding molecule to form a DLL3-binding conjugate. In some embodiments, such moieties can be attached to the DLL3 -binding molecule using various molecular biological or chemical conjugation and linkage methods known in the art and described below. In some embodiments, linkers such as peptide linkers, cleavable linkers, non-cleavable linkers or linkers that aid in the conjugation reaction, can be used to link or conjugate the effector moieties the DLL3-binding molecule.
[0133] In some embodiments, a DLL3-binding molecule is conjugated to one or more moieties, e.g. about 1 to about 20 moieties per molecule, through a linker (L). In some embodiments, the DLL3-binding conjugate comprises the following components: (VHH domain), (L)qand (moiety )m, wherein the VHH domain is any of the described VHH domains capable of specifically binding DLL3 as described; L is a linker for linking the protein or polypeptide to the moiety; m is at least 1; q is 0 or more; and the resulting DLL3-binding conjugate binds to DLL3. In particular embodiments, m is 1 to 4 and q is 0 to 8.
[0134] The linker may be composed of one or more linker components. For covalent attachment of the antibody and the drug moiety the linker typically has two reactive functional groups, i.e. bivalency in a reactive sense. Bivalent linker reagents which are useful to attach two or more functional or biologically active moieties, such as peptides, nucleic acids, drugs, toxins, antibodies, haptens, and reporter groups are known, and methods have been described their resulting conjugates (Hermanson, G. T. (1996) Bioconjugate Techniques; Academic Press: New York, p 234-242).
[0135] Non-limiting examples of linker components include 6-maleimidocaproyl (“MC”), maleimidopropanoyl (“MP”), valine-citrulline (“val-cif ’), a alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (“PAB”), N-Succinimidyl 4-(2-pyridylthio)pentanoate (“SPP”), N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-I carboxylate (“SMCC”), andN-Succinimidyl (4-iodo-acetyl)aminobenzoate (“SLAB”).
[0136] In some embodiments, the linker may comprise amino acid residues. Exemplary amino acid linker components include a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide.Exemplary dipeptides include: valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe). Exemplary tripeptides include: glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). Amino acid residues which comprise an amino acid linker component include those occurring naturally, as well as minor amino acids and non-naturally occurring amino acid analogs, such as citrulline. Amino acid linker components can be designed andWSGRRefNo. 65457-709.601optimized in their selectivity for enzymatic cleavage by particular enzymes, for example, a tumor-associated protease, cathepsin B, C and D, at a plasmin protease.
[0137] Conjugates of a DLL3-binding molecule and cytotoxic agent can be made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2 -pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HC1), active esters (such as disuccinimidyl substrate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene).
[0138] The DLL3-binding conjugates can be prepared by a variety of methods, such as organic chemistry reactions, conditions, and reagents known to those skilled in the art. In one embodiments, methods include: (1) reaction of a nucleophilic group of a DLL3-binding molecule with a bivalent linker reagent, to form VHH-L, via a covalent bond, followed by reaction with a drug moiety D; and (2) reaction of a nucleophilic group of a drug moiety with a bivalent linker reagent, to form D-L, via a covalent bond, followed by reaction with the nucleophilic group of a DLL3 -binding molecule.
[0139] Nucleophilic groups on antibodies, including DLL3-binding molecules, include, but are not limited to: (i) N-terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated. Amine, thiol, and hydroxyl groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Trauf s reagent) resulting in conversion of an amine into a thiol. Reactive thiol groups may be introduced into the antibody (or fragment thereof) by introducing one, two, three, four, or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues).
[0140] Conjugates, such as antibody drug conjugates, may also be produced by modification of an antibody, such as a DLL3 -binding molecule, to introduce electrophilic moieties, which can react with nucleophilic substituents on the linker reagent or drug. The sugars of glycosylated antibodies may be oxidized, e.g., with periodate oxidizing reagents, to form aldehyde or ketone groups which may lead with the amine group of linker reagentsor drug moieties. The resulting imine Schiff base groups may form a stable linkage, or may beWSGRRefNo. 65457-709.601reduced, e.g., by borohydride reagents to form stable amine linkages. In one embodiment, reaction of the carbohydrate portion of a glycosylated antibody with either galactose oxidase or sodium meta-periodate may yield carbonyl (aldehyde and ketone) groups in the protein that can react with appropriate groups on the drug (Hermanson, Bioconjugate Techniques). In another embodiment, proteins containing N-terminal serine or threonine residues can react with sodium meta-periodate, resulting in production of an aldehyde in place of the first amino acid. Such aldehyde can be reacted with a drug moiety or linker nucleophile.
[0141] Likewise, nucleophilic groups on a drug moiety include, but are not limited to: amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups capable of reacting to form covalent bonds with electrophilic groups on linker moieties and linker reagents including: (i) active esters such as NHS esters, HOBi esters, haloformates, and acid halides; (ii) alkyl and benzyl halides such as haloacetamides; (iii) aldehydes, ketones, carboxyl, and maleimide groups.
[0142] Alternatively, a fusion protein containing a VHH domain and cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis. The length of DNA may comprise respective regions encoding the two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.D. Multispecific Formats
[0143] Provided herein are DLL3-binding molecules that are multispecific comprises at least one DLL3 VHH and one or more additional binding domains that bind one or more additional antigens. In some embodiments, such multispecific DLL3-binding molecules exhibit multispecific binding. Typically, the one or more additional binding domains bind to one or more additional antigen other than DLL3. In some embodiments, an additional binding domain is an antibody or antigen-binding fragment specific for the one or more additional antigens. In some embodiments, an additional binding domain is an antigen-binding fragment such as, a Fab fragment, a F(ab')2 fragment, an Fv fragment, a scFv, disulfide stabilized Fv fragment (dsFv), a scAb, a dAb, a single domain heavy chain antibody (VHH), or a single domain light chain antibody. In some embodiments, an additional binding domain is an scFv. In some embodiments, an addition binding domain is a Fab fragment, or a F(ab’)2 fragment. In some embodiments, an additional binding domain is a VHH. In some embodiments, DLL3-binding molecules that are multispecific comprises at least one DLL3 VHH and at least two additional binding domains that bind an antigen other than DLL3. In some embodiments, some or all of additional binding domains bind the same antigen. In some embodiments, some or all of the additional binding domains bind different antigens.WSGRRefNo. 65457-709.601
[0144] In some embodiments, an additional binding domain binds an antigen selected from the group consisting of: 1-92-LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGR2, Anti-Lewis- Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CDlla, CD16, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD 138, CD 166, CD 172 A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRoc), GAL3ST1, G-CSF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP Ilb / IIIa receptors, Gpl30, GPIIB / IIIA, GPNMB, GRP78, HER2 / neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27 / IL27R (wsxl), IL29, IL-31R, IL31 / IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISS1-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin-16 (MUC16, CA-125), Na / K ATPase, NGF, NKp46, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, 0X40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidylserine, P1GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFR2, NFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3.
[0145] In some embodiments, a DLL3-binding molecule comprises at least one DLL3 VHH and at least one additional binding domain that binds an additional antigen. In some embodiments, the binding to the additional antigen is capable of providing the additional crosslinking function and DLL3 activation can be achieved with only one or two DLL3-binding domains. In some embodiments, DLL3 signaling is enhanced and focused by the presence of the additional antigen. In some embodiments, such multispecific molecules exhibit greatly enhanced DLL3-WSGRRefNo. 65457-709.601dependent signaling when the multispecific molecule is bound to a cell expressing the additional antigen.
[0146] In some embodiments, an additional antigen is a tumor associated antigen (TAA) or tumor microenvironment associated antigen (TMEAA) (e.g., Folate Receptor Alpha, FRa). In some embodiments, the binding to the TAA or TMEAA antigen is capable of providing the additional crosslinking function and DLL3 activation can be achieved with only one or two DLL3 -binding domains.
[0147] In some embodiments, an additional antigen is an immunomodulatory antigen. In some embodiments, the immunomodulatory antigen is involved with enhancing or dampening a signaling pathway in an immune cell. In some embodiments, the immunomodulatory antigen is an immune checkpoint antigen (e.g., PD-L1, CTLA-4). In some embodiments, binding to the immune checkpoint antigen inhibits the immune checkpoint antigen leading to enhanced immune cell activation. In some embodiments, such DLL3 -binding molecule modulates immune cells leading to enhanced tumor destruction. In some embodiments, the binding to the immunomodulatory antigen is capable of providing the additional crosslinking function and DLL3 activation can be achieved with only one or two DLL3-binding domains.
[0148] In some embodiments, a DLL3 -binding molecule can further contain an Fc region, such as any described above. In some embodiments, a multispecific DLL3-binding molecule provided herein at least one VHH that bind DLL3, at least one additional binding domain that binds a second antigen, and an Fc region. In some embodiments, an Fc region mediates dimerization of the multispecific DLL3-binding molecule at physiological conditions such that a dimer is formed that doubles the number of binding sites for DLL3 and for the additional antigen.
[0149] Non-limiting exemplary multispecific DLL3-binding molecules are described herein.
[0150] In one embodiment, the DLL3-binding molecule is a multispecific single-domain antibody-linked Fab (S-Fab) containing at least one DLL3 VHH linked, directly or indirectly to at least one Fab specific for an additional antigen. In some embodiments, the DLL3 VHH is linked to the C-terminus of the VH or VL of the Fab specific for the additional antigen. In some embodiments, the S-Fab can be further modified, such as by conjugation with polyethylene glycol (PEG), N-(2 -hydroxypropyl) methacrylamide (HPMA) copolymers, proteins (such as albumin), polyglutamic acid or PASylation (Pan et al. (2018) International Journal of Nanomedicine, 2018:3189-3201).
[0151] In another embodiment, the multispecific molecule is a scFv-single domain antibody in which the molecule comprises at least one DLL3 VHH as described linked, directly or indirectly, to at least one scFv containing a VH and a VL of an antigen binding domain specific for an additional antigen. In some embodiments, the VHH domain and the scFv are connectedWSGRRefNo. 65457-709.601by a linker, such as a peptide linker. In some embodiments, the peptide linker can be a peptide linker as described herein. In some embodiments, the VHH domain and the scFv are each connected, optionally through a hinge region or a linker (e.g. peptide linker), to an Fc region, such as the N-terminus and / or C-terminus of an Fc region. In some embodiments, the Fc region can be an Fc region as described herein. In particular examples, the Fc region is formed by variant Fc regions, e.g. variant human IgGl domains, that are mutated or modified to promote heterodimerization in which different Fc polypeptides can be dimerized to yield a heterodimer.
[0152] In another embodiment, the multispecific molecule is a single domain antibody molecule comprising at least one DLL3 VHH as described linked, directly or indirectly, to at least one VHH specific for the additional antigen. For formatting the molecules, in some cases, each VHH domain is connected, optionally through a hinge region or linker (e.g. peptide linker), to an Fc region, such as the N-terminus and / or C-terminus of an Fc region. The Fc region can be any described herein, such as a human Fc region or a variant thereof, e.g. a human IgGl Fc region or a variant thereof. In particular examples, the Fc region is formed by variant Fc regions, e.g. variant human IgGl domains, that are mutated or modified to promote heterodimerization in which different Fc polypeptides can be dimerized to yield a heterodimer.
[0153] In some embodiments, a DLL3 -binding molecule further comprises at least one binding domain for an antigen expressed on the surface of a target cell (also referred to herein as a target cell surface antigen or a “TCSA”) and at least one binding domain for an antigen present on the surface of an immune effector cell (e.g., a T cell or an NK cell). In some embodiments, such DLL3-binding molecules are capable of engaging or activating immune effectors cells at the site of a tumor upon binding of the TCSA. In some embodiments, such DLL3-binding molecules bind DLL3, a TCSA, and a T cell antigen such as CD3. In some embodiments, DLL3-binding molecules bind a TCSA and CD3 and exhibit constrained CD3 binding. In some embodiments, such DLL3-binding molecules are capable of engaging or activating T cells at the site of a tumor upon binding of the TCSA. In some embodiments, the DLL3-binding molecule mediates enhanced T cell-mediated cell killing of TCSA expressing cells by co-simulating DLL3. In some embodiments, the DLL3 -binding molecules bind DLL3, a TCSA, and an NK cell antigen such as NKp46 or CD 16. In some embodiments, such multispecific molecules are capable of engaging or activating NK cells at the site of a tumor upon binding of the TCSA. In some embodiments, the DLL3 -binding molecule mediates enhanced NK cell-mediated cell killing of TCSA expressing cells by co-simulating DLL3.POLYPEPTIDE EXPRESSION AND PRODUCTION
[0154] Nucleic acid molecules comprising polynucleotides that encode any of the provided sdAb and DLL3 -binding molecules are provided. In some embodiments, the provided nucleicWSGRRefNo. 65457-709.601acid sequences and particularly DNA sequences encode fusion proteins as provided herein. In any of the foregoing embodiments, the nucleic acid molecule may also encode a leader sequence that directs secretion of the DLL3-binding molecule, which leader sequence is typically cleaved such that it is not present in the secreted polypeptide. The leader sequence may be a native heavy chain (or VHH) leader sequence, or may be another heterologous leader sequence.
[0155] Nucleic acid molecules can be constructed using recombinant DNA techniques conventional in the art. In some embodiments, a nucleic acid molecule is an expression vector that is suitable for expression in a selected host cell.
[0156] Vectors comprising nucleic acids that encode the DLL3-binding molecules described herein are provided. Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc. In some embodiments, a vector is selected that is optimized for expression of polypeptides in a desired cell type, such as CHO or CHO-derived cells, or in NSO cells. Exemplary such vectors are described, for example, in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004).
[0157] In particular, a DNA vector that encodes a desired DLL3 -binding molecules, such as a fusion protein, can be used to facilitate the methods of preparing the DLL3 -binding molecules described herein and to obtain significant quantities. The DNA sequence can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA or cosmid DNA. Depending on the hostvector system utilized, any one of a number of suitable transcription and translation elements may be used.
[0158] The disclosure also provides methods of producing a DLL3-binding molecules by culturing a cell under conditions that lead to expression of the molecules, wherein the cell comprises an isolated nucleic acid molecule encoding a DLL3-binding molecule described herein, and / or vectors that include these isolated nucleic acid sequences.
[0159] In some embodiments, a DLL3-binding molecule may be expressed in prokaryotic cells, such as bacterial cells; or in eukaryotic cells, such as fungal cells (such as yeast), plant cells, insect cells, and mammalian cells. Such expression may be carried out, for example, according to procedures known in the art. Exemplary eukaryotic cells that may be used to express polypeptides include, but are not limited to, COS cells, including COS 7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S, DG44. Lecl3 CHO cells, and FUT8 CHOWSGRRefNo. 65457-709.601cells; PER.C6® cells (Crucell); and NSO cells. In some embodiments, the DLL3-binding molecules may be expressed in yeast. See, e.g., U.S. Publication No. US 2006 / 0270045. In some embodiments, a particular eukaryotic host cell is selected based on its ability to make desired post-translational modifications to the polypeptide. For example, in some embodiments, CHO cells produce polypeptides that have a higher level of sialylation than the same polypeptide produced in 293 cells.
[0160] Introduction of one or more nucleic acids (such as vectors) into a desired host cell may be accomplished by any method, including but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Nonlimiting exemplary methods are described, for example, in Sambrook etal., Molecular Cloning, A Laboratory Manual, 3rded. Cold Spring Harbor Laboratory Press (2001). Nucleic acids may be transiently or stably transfected in the desired host cells, according to any suitable method.
[0161] Host cells comprising any of the nucleic acids or vectors described herein are also provided. In some embodiments, a host cell that expresses a DLL3 -binding molecule described herein is provided. The DLL3-binding molecules expressed in host cells can be purified by any suitable method. Such methods include, but are not limited to, the use of affinity matrices or hydrophobic interaction chromatography. Suitable affinity ligands include the R0R1 ECD and agents that bind Fc regions. For example, a Protein A, Protein G, Protein A / G, or an antibody affinity column may be used to bind the Fc region and to purify a DLL3 -binding molecule that comprises an Fc region. Hydrophobic interactive chromatography, for example, a butyl or phenyl column, may also suitable for purifying some polypeptides such as antibodies. Ion exchange chromatography (for example anion exchange chromatography and / or cation exchange chromatography) may also suitable for purifying some polypeptides such as antibodies. Mixedmode chromatography (for example reversed phase / anion exchange, reversed phase / cation exchange, hydrophilic interaction / anion exchange, hydrophilic interaction / cation exchange, efc.) may also suitable for purifying some polypeptides such as antibodies. Many methods of purifying polypeptides are known in the art.
[0162] In some embodiments, the DLL3-binding molecule is produced in a cell-free system. Nonlimiting exemplary cell-free systems are described, for example, in Sitaraman etal., Methods Mol. Biol. 498: 229-44 (2009); Spirin, Trends Biotechnol. 22: 538-45 (2004); Endo et al., Biotechnol. Adv. 21: 695-713 (2003).
[0163] In some embodiments, DLL3 -binding molecules prepared by the methods described above are provided. In some embodiments, the DLL3-binding molecule is prepared in a host cell. In some embodiments, the DLL3-binding molecule is prepared in a cell-free system. InWSGRRefNo. 65457-709.601some embodiments, the DLL3-binding molecule is purified. In some embodiments, a cell culture media comprising a DLL3-binding molecule is provided.
[0164] In some embodiments, compositions comprising antibodies prepared by the methods described above are provided. In some embodiments, the composition comprises a DLL3-binding molecule prepared in a host cell. In some embodiments, the composition comprises a DLL3-binding molecule prepared in a cell-free system. In some embodiments, the composition comprises a purified DLL3-binding molecule.PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS
[0165] Provided herein are pharmaceutical compositions containing any of the DLL3-binding molecules provided herein or engineered cells expressing the same. In some embodiments, DLL3-binding molecules, such as fusion proteins of the disclosure (also referred to herein as “active compounds”), and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. In some embodiments, engineered cells expressing a chimeric receptor, such as a chimeric antigen receptor, containing a DLL3 -binding molecule provided herein can be incorporated into pharmaceutical compositions suitable for administration.
[0166] In some embodiments, compositions comprising DLL3-binding molecules are provided in formulations with a wide variety of pharmaceutically acceptable carriers (see, for example, Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7thed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rded., Pharmaceutical Press (2000)). Various pharmaceutically acceptable carriers, which include vehicles, adjuvants, and diluents, are available. Moreover, various pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are also available.
[0167] The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration. These pharmaceutical compositions can be included in diagnostic kits with instructions for use.METHODS OF TREATMENT AND USES
[0168] The DLL3 -binding molecules described herein are useful in a variety of therapeutic, diagnostic and prophylactic indications. For example, the DLL3-binding molecules or engineered cells are useful in treating a variety of diseases and disorders in a subject. Such methods and uses include therapeutic methods and uses, for example, involving administration of the molecules, or compositions containing the same, to a subject having a disease, condition, or disorder, such as a tumor or cancer, an inflammatory or autoimmunity disorder. In someWSGRRefNo. 65457-709.601embodiments, the molecule ore engineered cell is administered in an effective amount to effect treatment of the disease or disorder. Uses include uses of molecules containing the DLL3-binding molecules or engineered cells in such methods and treatments, and in the preparation of a medicament in order to carry out such therapeutic methods. In some embodiments, the methods are carried out by administering the DLL3-binding molecules or engineered cells, or compositions comprising the same, to the subject having or suspected of having the disease or condition. In some embodiments, the methods thereby treat the disease or condition or disorder in the subject.
[0169] In some embodiments, administration of a DLL3-binding molecule, such as an DLL3-Fc fusion protein or a multispecific DLL3-binding molecule containing an Fc region, may activate innate immune cells via engagement of FcyRs through the Fc-region of the DLL3-binding molecule. Administration of such DLL3-binding molecules may agonize, stimulate, activate, and / or augment innate immune cell effector functions, including ADCC, cytokine release, degranulation and / or ADCP.
[0170] In some embodiments, the provided methods are for treating a disease or condition in a subject by administering a therapeutically effective amount of any of the provided DLL3-binding molecules or engineered cells or pharmaceutical compositions thereof. In some embodiments, the disease or condition is a tumor or a cancer. In other embodiments, the disease or condition is an inflammatory condition. In other embodiments, the disease or condition is an inflammatory condition. Generally, alleviation or treatment of a disease or disorder involves the lessening of one or more symptoms or medical problems associated with the disease or disorder. For example, in the case of cancer, the therapeutically effective amount of the drug can accomplish one or a combination of the following: reduce the number of cancer cells; reduce the tumor size; inhibit ( / .< ., to decrease to some extent and / or stop) cancer cell infiltration into peripheral organs; inhibit tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve to some extent one or more of the symptoms associated with the cancer. In some embodiments, a composition of this disclosure can be used to prevent the onset or reoccurrence of the disease or disorder in a subject, e.g., a human or other mammal, such as a non-human primate, companion animal (e.g., cat, dog, horse), farm animal, work animal, or zoo animal. The terms subject and patient are used interchangeably herein.
[0171] In some embodiments, the DLL3-binding molecules or engineered cells, or pharmaceutical compositions thereof, can be used to inhibit growth of mammalian cancer cells (such as human cancer cells). A method of treating cancer can include administering an effective amount of any of the pharmaceutical compositions described herein to a subject with cancer. The effective amount of the pharmaceutical composition can be administered to inhibit, halt, orWSGRRefNo. 65457-709.601reverse progression of cancers. Human cancer cells can be treated in vivo, or ex vivo. In ex vivo treatment of a human patient, tissue or fluids containing cancer cells are treated outside the body and then the tissue or fluids are reintroduced back into the patient. In some embodiments, the cancer is treated in a human patient in vivo by administration of the therapeutic composition into the patient.
[0172] Non-liming examples of disease include: all types of cancers (breast, lung, colorectal, prostate, melanomas, head and neck, pancreatic, etc.), rheumatoid arthritis, Crohn’s disuse, SLE, cardiovascular damage, ischemia, etc. For example, indications would include leukemias, including T-cell acute lymphoblastic leukemia (T-ALL), lymphoblastic diseases including multiple myeloma, and solid tumors, including lung, colorectal, prostate, pancreatic, and breast, including triple negative breast cancer. For example, indications include bone disease or metastasis in cancer, regardless of primary tumor origin; breast cancer, including by way of nonlimiting example, ER / PR+ breast cancer, Her2+ breast cancer, triple-negative breast cancer; colorectal cancer; endometrial cancer; gastric cancer; glioblastoma; head and neck cancer, such as esophageal cancer; lung cancer, such as by way of non-limiting example, non-small cell lung cancer; multiple myeloma ovarian cancer; pancreatic cancer; prostate cancer; sarcoma, such as osteosarcoma; renal cancer, such as by way of nonlimiting example, renal cell carcinoma; and / or skin cancer, such as by way of nonlimiting example, squamous cell cancer, basal cell carcinoma, or melanoma. In some embodiments, the cancer is a squamous cell cancer. In some embodiments, the cancer is a skin squamous cell carcinoma. In some embodiments, the cancer is an esophageal squamous cell carcinoma. In some embodiments, the cancer is a head and neck squamous cell carcinoma. In some embodiments, the cancer is a lung squamous cell carcinoma.
[0173] In certain embodiments, the cancer is a metastatic cancer, refractory cancer, or recurrent cancer.
[0174] In some embodiments, a therapeutically effective amount of a DLL3 -binding molecule of the disclosure relates generally to the amount needed to achieve a therapeutic objective.Typically, precise amount of the compositions of the present disclosure to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, type, extent and symptoms of disease, e.g., inflammation, infection or metastasis, and condition of the patient (subject).
[0175] In some embodiments, administration of the provided DLL3-binding molecules modulates immunological activity. In some embodiments, the DLL3 -binding molecules modulate immunological activity by eliminating, sequestering, or inactivating immune cells mediating or capable of mediating an undesired immune response; inducing, generating, or turning on immune cells that mediate or are capable of mediating a protective immune response;WSGRRefNo. 65457-709.601changing the physical or functional properties of immune cells; or a combination of these effects.Combination Therapy
[0176] DLL3-binding molecules or engineered cells of the present disclosure can be administered alone or in combination with other modes of treatment, such as other anti-cancer agents, anti-inflammatory agents, agents that modulate autoimmunity. They can be provided before, substantially contemporaneous with, or after other modes of treatment (i.e., concurrently or sequentially). In some embodiments, the method of treatment described herein can further include administering: radiation therapy, chemotherapy, vaccination, DLL3ed tumor therapy, CAR-T therapy, oncolytic virus therapy, cancer immunotherapy, cytokine therapy, surgical resection, chromatin modification, ablation, cryotherapy, an antisense agent against, a siRNA agent, a microRNA agent, or a biologic, such as an antibody, cytokine, or receptor extracellular domain-Fc fusion.
[0177] All publications, including patent documents, scientific articles and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication were individually incorporated by reference. If a definition set forth herein is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth herein prevails over the definition that is incorporated herein by reference.
[0178] The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd. edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, et al. eds., (2003)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc ): PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J. E. Cellis, ed, 1998) Academic Press; Animal Cell Culture (R. I. Freshney), ed., 1987);Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Cell and Tissue Culture Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds. , Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P. Calos,WSGRRefNo. 65457-709.601eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis etal., eds., 1994); Current Protocols in Immunology (J. E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed, IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (V. T. DeVita etal., eds., J.B. Lippincott Company, 1993); and updated versions thereof.
[0179] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0180] Unless otherwise defined, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context or expressly indicated, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization described herein are those well-known and commonly used in the art. For any conflict in definitions between various sources or references, the definition provided herein will control.
[0181] It is understood that embodiments of the invention described herein include “consisting” and / or “consisting essentially of’ embodiments. As used herein, the singular form “a”, “an”, and “the” includes plural references unless indicated otherwise. Use of the term “or” herein is not meant to imply that alternatives are mutually exclusive.
[0182] In this application, the use of “or” means “and / or” unless expressly stated or understood by one skilled in the art. In the context of a multiple dependent claim, the use of “or” refers back to more than one preceding independent or dependent claim.
[0183] The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
[0184] In this disclosure, “comprises,” “comprising,” “containing,” “having,” and the like can have the meaning ascribed to them in U.S. Patent law and can mean “includes,” “including,” and the like; the terms “consisting essentially of’ or “consists essentially” likewise have the meaning ascribed in U.S. Patent law and these terms are open-ended, allowing for the presence of moreWSGRRefNo. 65457-709.601than that which is recited so long as basic or novel characteristics of that which is recited are not changed by the presence of more than that which is recited, but excludes prior art embodiments.
[0185] The terms “nucleic acid molecule”, “nucleic acid” “and “polynucleotide” may be used interchangeably, and refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and / or non-natural nucleotides, and include, but are not limited to, DNA, RNA, and PNA. “Nucleic acid sequence” refers to the linear sequence of nucleotides comprised in the nucleic acid molecule or polynucleotide.
[0186] The term “isolated polynucleotide” as used herein shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin (1) is not associated with all or a portion of a polynucleotide found in nature, (2) is operably linked to a polynucleotide that it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.
[0187] The terms “polypeptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length and macromolecules comprising one or more polymers of amino acid residues, a multimer (e.g., dimer, trimer, or tetramer) formed by a plurality of the same or different polymers of amino acids. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins, and fragments thereof are encompassed by the definition. The terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for purposes of the present disclosure, a “polypeptide” refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
[0188] “DLL3” as used herein refers to any native, mature albumin that results from processing of an DLL3 precursor in a cell. The use of the term “DLL3” is intended to cover any variation thereof and all variations are used herein interchangeably. The term includes DLL3 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally-occurring variants of DLL3, such as splice variants or allelic variants.
[0189] As used herein a “DLL3-binding molecule” comprising at least one heavy chain only variable domain that specifically binds DLL3. DLL3-binding molecules may also be referred to herein as “DLL3 -binding polypeptides” or “DLL3 -binding fusions” or “DLL3 -binding proteins”WSGRRefNo. 65457-709.601or “DLL3-binding fusion polypeptides” or “DLL3-binding fusion proteins.” As used herein, the term “fusion protein” or “fusion polypeptide” or “DLL3 -binding fusion protein” or “DLL3-binding fusion polypeptide,” unless otherwise specifically denoted, refers to any fusion protein embodiment of the disclosure, including, but not limited to, multivalent fusion proteins, multispecific fusion proteins, or multivalent and multispecific fusion proteins.
[0190] The term “isolated” as used herein refers to a molecule that has been separated from at least some of the components with which it is typically found in nature or produced. For example, a molecule is referred to as “isolated” when it is separated from at least some of the components of the cell in which it was produced. Where a molecule is secreted by a cell after expression, physically separating the supernatant containing the molecule from the cell that produced it is considered to be “isolating” the molecule. Similarly, a polynucleotide is referred to as “isolated” when it is not part of the larger polynucleotide (such as, for example, genomic DNA or mitochondrial DNA, in the case of a DNA polynucleotide) in which it is typically found in nature, or is separated from at least some of the components of the cell in which it was produced, for example, in the case of an RNA polynucleotide. Thus, a DNA polynucleotide that is contained in a vector inside a host cell may be referred to as “isolated”.
[0191] As used herein, “substantially pure” means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, for example, in some embodiments, more than about 85%, 90%, 95%, and 99%. In some embodiments, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.
[0192] The term “operably linked” as used herein refers to positions of components so described are in a relationship permitting them to function in their intended manner. A control sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
[0193] The term “specifically binds” to an antigen or epitope is a term that is well understood in the art, and methods to determine such specific binding are also well known in the art. A molecule is said to exhibit “specific binding” or “preferential binding” if it reacts or associates more frequently, more rapidly, with greater duration and / or with greater affinity with a particular cell or substance than it does with alternative cells or substances. A single-domain antibodyWSGRRefNo. 65457-709.601(sdAb) or VHH-containing molecule “specifically binds” or “preferentially binds” to a DLL3 if it binds with greater affinity, avidity, more readily, and / or with greater duration than it binds to other substances. For example, a sdAb or VHH-containing molecule that specifically or preferentially binds to a DLL3 epitope is a sdAb or VHH-containing molecule that binds this epitope with greater affinity, avidity, more readily, and / or with greater duration than it binds to other DLL3 epitopes or non- DLL3 epitopes. It is also understood by reading this definition that; for example, a sdAb or VHH-containing molecule that specifically or preferentially binds to a first DLL3 may or may not specifically or preferentially bind to a second DLL3. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding. “Specificity” refers to the ability of a binding protein to selectively bind an antigen.
[0194] As used herein, the term “epitope” refers to a site on a DLL3 molecule (for example, an antigen, such as a protein, nucleic acid, carbohydrate or lipid) to which an antigen-binding molecule (e.g., an IgG based antibody), or an antigen-binding fragment there of (for example, a sdAb or VHH-containing molecule) binds. Epitopes often include a chemically active surface grouping of molecules such as amino acids, polypeptides or sugar side chains and have specific three-dimensional structural characteristics as well as specific charge characteristics. Epitopes can be formed both from contiguous and / or juxtaposed noncontiguous residues (for example, amino acids, nucleotides, sugars, lipid moiety) of the DLL3 molecule. Epitopes formed from contiguous residues (for example, amino acids, nucleotides, sugars, lipid moiety) typically are retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding typically are lost on treatment with denaturing solvents. An epitope may include but is not limited to at least 3, at least 5 or 8-10 residues (for example, amino acids or nucleotides). In some embodiments, an epitope is less than 20 residues (for example, amino acids or nucleotides) in length, less than 15 residues or less than 12 residues. Two antibodies may bind the same epitope within an antigen if they exhibit competitive binding for the antigen. In some embodiments, an epitope can be identified by a certain minimal distance to a CDR residue on the antigen-binding molecule. In some embodiments, an epitope can be identified by the above distance, and further limited to those residues involved in a bond (for example, a hydrogen bond) between a residue of the antigen-binding molecule and an antigen residue. An epitope can be identified by various scans as well, for example an alanine or arginine scan can indicate one or more residues that the antigen-binding molecule can interact with. Unless explicitly denoted, a set of residues as an epitope does not exclude other residues from being part of the epitope for a particular antigen-binding molecule. Rather, the presence of such a set designates a minimalWSGRRefNo. 65457-709.601series (or set of species) of epitopes. Thus, in some embodiments, a set of residues identified as an epitope designates a minimal epitope of relevance for the antigen, rather than an exclusive list of residues for an epitope on an antigen.
[0195] A “nonlinear epitope” or “conformational epitope” comprises noncontiguous polypeptides, amino acids and / or sugars within the antigenic protein to which an antigen-binding molecule specific to the epitope binds. In some embodiments, at least one of the residues will be noncontiguous with the other noted residues of the epitope; however, one or more of the residues can also be contiguous with the other residues.
[0196] A “linear epitope” comprises contiguous polypeptides, amino acids and / or sugars within the antigenic protein to which an antigen-binding molecule specific to the epitope binds. It is noted that, in some embodiments, not every one of the residues within the linear epitope need be directly bound (or involved in a bond) by the antigen-binding molecule. In some embodiments, linear epitopes can be from immunizations with a peptide that effectively consisted of the sequence of the linear epitope, or from structural sections of a protein that are relatively isolated from the remainder of the protein (such that the antigen-binding molecule can interact, at least primarily), just with that sequence section.
[0197] The terms “antibody” and “antigen-binding molecule” are used interchangeably in the broadest sense and encompass various polypeptides that comprise antibody -like antigen-binding domains, including but not limited to conventional antibodies (typically comprising at least one heavy chain and at least one light chain), single-domain antibodies (sdAbs, comprising just one chain, which is typically similar to a heavy chain), VHH-containing molecules (molecules comprising at least one heavy chain only antibody variable domain, or VHH), and fragments of any of the foregoing so long as they exhibit the desired antigen-binding activity. In some embodiments, an antibody comprises a dimerization domain. Such dimerization domains include, but are not limited to, heavy chain constant domains (comprising CHI, hinge, CH2, and CH3, where CHI typically pairs with a light chain constant domain, CL, while the hinge mediates dimerization) and Fc regions (comprising hinge, CH2, and CH3, where the hinge mediates dimerization).
[0198] The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as camelid (including llama), shark, mouse, human, cynomolgus monkey, etc.
[0199] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable regions of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) andWSGRRefNo. 65457-709.601three CDRs. (See, e.g., Kindt etal. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity, e.g. a single domain antibody, such as a VHH. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J.Immunol. 150:880-887 (1993); Clarkson etal., Nature 352:624-628 (1991).
[0200] An “antibody fragment” or “antigen-binding fragment” or “antigen-binding domain” refers to a portion of a conventional or intact antibody containing at least a variable region that binds an antigen. Examples of antibody fragments include but are not limited to Fv, single chain Fvs (sdFvs), Fab, Fab’, Fab’-SH, F(ab’)2; diabodies; linear antibodies; and single-domain antibodies comprising only the VH region (VHH).
[0201] As used herein, “monovalent” with reference to a binding molecule refers to binding molecules that have a single antigen recognition site that is specific for an epitope on a DLL3 antigen. Examples of monovalent binding molecules include, for example, a monovalent antibody fragment, a proteinaceous binding molecule with antibody-like binding properties or an MHC molecule. Examples of monovalent antibody fragments include, but are not limited to, a VHH, a Fab fragment, an Fv fragment, and a single- chain Fv fragment (scFv).
[0202] As used herein, “multivalent” with reference to a binding molecule refers to binding molecules comprising multiple antigen recognition sites. Each antigen recognition sites may recognize the same epitope (“monospecific”) or different epitopes (“multispecific”). Examples of multivalent binding molecules include, for example, a bispecific antibody, or a proteinaceous binding molecule comprising multiple antigen-binding fragments (e.g., multiple VHHs).
[0203] The terms “single domain antibody”, “sdAb,” “VHH” are used interchangeably herein to refer to an antibody having a single monomeric domain antigen binding / recognition domain. Examples include, but are not limited to, heavy chain antibodies, antibodies naturally devoid of light chains, single domain antibodies derived from conventional 4-chain antibodies, engineered antibodies and single domain scaffolds other than those derived from antibodies. Single domain antibodies may be derived from any species including, but not limited to mouse, human, camel, llama, alpaca, vicuna, guanaco, shark, goat, rabbit, and / or bovine. In some embodiments, a single domain antibody as used herein is a naturally occurring single domain antibody known as heavy chain antibody devoid of light chains. For clarity reasons, this variable domain derived from a heavy chain antibody naturally devoid of light chain is known herein as a VHH to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from antibodies raised in Camelidae species, for example in camel, llama, dromedary, alpaca, vicuna and guanaco. Other species besides Camelidae may produce heavyWSGRRefNo. 65457-709.601chain antibodies naturally devoid of light chain; such VHHs are within the scope of the disclosure. A VHH domain is an antibody fragment that is a single monomeric variable antibody domain that is able to bind selectively to a specific antigen. With a molecular weight of only 12-15 kDa, VHH domains (also called single-domain antibodies) are much smaller than common antibodies (150-160 kDa) which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single-chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain).
[0204] In some embodiments, a VHH comprises three CDRs and four framework regions, designated FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiments, a VHH may be truncated at the N-terminus or C-terminus such that it comprises only a partial FR1 and / or FR4, or lacks one or both of those framework regions, so long as the VHH substantially maintains antigen binding and specificity.
[0205] The term “VHH-containing molecule” refers to a molecule that comprises at least one VHH domain. In some embodiments, a VHH molecule comprises two, three, or four or more VHH domains, wherein each VHH domain may be the same or different. In some embodiments, a VHH-containing molecule comprises an Fc region. In some such embodiments, the VHH molecule may form a dimer. Nonlimiting structures of VHH-containing molecules include VHHi-Fc, VHHI-VHH2-FC, and VHH1-VHH2-VHH3-FC, wherein VHHi, VHH2, and VHH3 may be the same or different. In some embodiments of such structures, one VHH may be connected to another VHH by a linker, or one VHH may be connected to the Fc by a linker. In some such embodiments, the linker comprises 1-20 amino acids, preferably 1-20 amino acids predominantly composed of glycine and, optionally, serine. In some embodiments, when a VHH-containing molecule comprises an Fc, it forms a dimer. Thus, the structure VHHi-VHH2-Fc, if it forms a dimer, is considered to be tetravalent (i.e., the dimer has four VHH domains). Similarly, the structure VHHi-VHH2-VHH3-Fc, if it forms a dimer, is considered to be hexavalent (i.e., the dimer has six VHH domains).
[0206] As used herein, a DLL3-binding molecule is a molecule that specifically binds DLL3. Typically, a DLL3-binding molecule herein is a VHH-containing molecule containing at least one VHH domain that binds DLL3. A DLL3-binding molecule includes conjugates, including fusion proteins. A DLL3-binding molecule includes fusion proteins, including those containing an Fc region. In some embodiments, a DLL3-binding molecule comprises a single polypeptide chain. In some embodiments, a DLL3 -binding molecule includes at least two polypeptide chains. In some embodiments, a DLL3 -binding molecule contains two, three, or four or more VHH domains that each specifically bind to DLL3, wherein each VHH domain may be the sameWSGRRefNo. 65457-709.601or different. In some embodiments, a DLL3 -binding molecule is multivalent. In some embodiments, a DLL3-binding molecule is multi specific. In some cases, a DLL3-binding molecule may contain one or more additional domains that bind to one or more further or additional antigens other than DLL3.
[0207] The term “monoclonal antibody” refers to an antibody (including an sdAb or VHH-containing polypeptide) of a substantially homogeneous population of antibodies, that is, the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Thus, a sample of monoclonal antibodies can bind to the same epitope on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies may be made by the hybridoma method first described by Kohler and Milstein, 1975, Nature 256:495, or may be made by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated from phage libraries generated using the techniques described in McCafferty etal., 1990, Nature 348:552-554, for example.
[0208] The term “CDR” denotes a complementarity determining region as defined by at least one manner of identification to one of skill in the art. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme); Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(l):55-77 (“IMGT” numbering scheme); Honegger A and Pliickthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme); and Martin etal., “Modeling antibody hypervariable loops: a combined algorithm,” PNAS, 1989, 86(23):9268-9272, (“AbM” numbering scheme).WSGRRefNo. 65457-709.601
[0209] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. The AbM scheme is a compromise between Kabat and Chothia definitions based on that used by Oxford Molecular’s AbM antibody modeling software.
[0210] In some embodiments, CDRs can be defined in accordance with any of the Chothia numbering schemes, the Kabat numbering scheme, a combination of Kabat and Chothia, the AbM definition, and / or the contact definition. A VHH comprises three CDRs, designated CDR1, CDR2, and CDR3. Table 4, below, lists exemplary position boundaries of CDR-H1, CDR-H2, CDR-H3 as identified by Kabat, Chothia, AbM, and Contact schemes, respectively. For CDR-Hl, residue numbering is listed using both the Kabat and Chothia numbering schemes. FRs are located between CDRs, for example, with FR-H1 located before CDR-H1, FR-H2 located between CDR-H1 and CDR-H2, FR-H3 located between CDR-H2 and CDR-H3 and so forth. It is noted that because the shown Kabat numbering scheme places insertions at H35A and H35B, the end of the Chothia CDR-H1 loop when numbered using the shown Kabat numbering convention varies between H32 and H34, depending on the length of the loop.Table 4. CDR boundaries according to various numbering schemesIMGT Kabat AbM Chothia ContactCDR-H1 (HCDR1 or VHCDR1) 27-38 31-35 26-35 26-32 30-35CDR-H2 (HCDR2 or VHCDR2) 56-65 50-65 50-58 52-56 47-58CDR-H3 (HCDR3 or VHCDR3) 105-117 95-102 95-102 96-101 93-101
[0211] Thus, unless otherwise specified, a “CDR” or “complementary determining region,” or individual specified CDRs (e.g., CDR-H1, CDR-H2, CDR-H3), of a given antibody or region thereof, such as a variable region thereof, should be understood to encompass a (or the specific) complementary determining region as defined by any of the aforementioned schemes. For example, where it is stated that a particular CDR e.g., a CDR-H3) contains the amino acidWSGRRefNo. 65457-709.601sequence of a corresponding CDR in a given VHH amino acid sequence, it is understood that such a CDR has a sequence of the corresponding CDR (e.g., CDR-H3) within the VHH, as defined by any of the aforementioned schemes. In some embodiments, specific CDR sequences are specified. Exemplary CDR sequences of provided antibodies are described using various numbering schemes (see e.g. Table 1), although it is understood that a provided antibody can include CDRs as described according to any of the other aforementioned numbering schemes or other numbering schemes known to a skilled artisan.
[0212] As used herein “clonotype” refers to a set of CDRs derived from a single clone according to the AbM CDR definition described herein, as further elucidated in Table 2.
[0213] As used herein, “conjugate,” “conjugation” or grammatical variations thereof refers the joining or linking together of two or more compounds resulting in the formation of another compound, by any joining or linking methods known in the art. It can also refer to a compound which is generated by the joining or linking together two or more compounds. For example, a VHH domain linked directly or indirectly to one or more agent, or polypeptide is an exemplary conjugate. Such conjugates include fusion proteins, those produced by chemical conjugates and those produced by any other methods.
[0214] The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, and / or an extract made from biological materials. The term “pharmaceutical agent or drug” as used herein refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.
[0215] The term “antineoplastic agent” is used herein to refer to agents that have the functional property of inhibiting a development or progression of a neoplasm in a human, particularly a malignant (cancerous) lesion, such as a carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is frequently a property of antineoplastic agents. Exemplary classes of such agents in include, but are not limited to, chemotherapeutic agents, anti-cancer biologies (such as cytokines, receptor extracellular domain-Fc fusions, and antibodies), radiation therapy, CAR-T therapy, therapeutic oligonucleotides (such as antisense oligonucleotides and siRNAs) and oncolytic viruses.
[0216] The term “heavy chain constant region” as used herein refers to a region comprising at least three heavy chain constant domains, CHI, hinge, CH2, and CH3. Of course, non-function-altering deletions and alterations within the domains are encompassed within the scope of the term “heavy chain constant region,” unless designated otherwise. Nonlimiting exemplary heavy chain constant regions include y, 8, and a. Nonlimiting exemplary heavy chain constant regions also include a and p. Each heavy constant region corresponds to an antibody isotype. ForWSGRRefNo. 65457-709.601example, an antibody comprising a y constant region is an IgG antibody, an antibody comprising a 6 constant region is an IgD antibody, and an antibody comprising an a constant region is an IgA antibody. Further, an antibody comprising a p constant region is an IgM antibody, and an antibody comprising an 8 constant region is an IgE antibody. Certain isotypes can be further subdivided into subclasses. For example, IgG antibodies include, but are not limited to, IgGl (comprising a yi constant region), IgG2 (comprising a 72 constant region), IgG3 (comprising a 73 constant region), and IgG4 (comprising a 74 constant region) antibodies; IgA antibodies include, but are not limited to, IgAl (comprising an ai constant region) and IgA2 (comprising an 012 constant region) antibodies; and IgM antibodies include, but are not limited to, IgMl and IgM2.
[0217] A “Fc region” as used herein refers to a portion of a heavy chain constant region comprising CH2 and CH3. In some embodiments, an Fc region comprises a hinge (or portion thereof), CH2, and CH3. In some embodiments, when an Fc region comprises a hinge (or portion thereof), the hinge and / or CH3 mediates dimerization between two Fc-containing polypeptides. An Fc region may be of any antibody heavy chain constant region isotype discussed herein. In some embodiments, an Fc region is an IgGl, IgG2, IgG3, or IgG4.
[0218] A “functional Fc region” possesses an “effector function” of a native sequence Fc region. Exemplary “effector functions” include Fc receptor binding; Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (for example B-cell receptor); and B-cell activation, etc. Such effector functions generally require the Fc region to be combined with a binding domain (for example, an antibody variable domain) and can be assessed using various assays. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nat' I Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96™ non-radioactive cytotoxicity assay (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes etal. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). Clq binding assays may also be carried out to confirm that the multispecific polypeptide construct or cleaved components thereof is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, a CDCWSGRRefNo. 65457-709.601assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, M. S. et al., Blood 101:1045-1052 (2003); and Cragg, M. S. andM. J. Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance / half-life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., Int'L Immunol. 18(12): 1759-1769 (2006))
[0219] A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include a native sequence human IgGl Fc region (e.g., non-A and A allotypes); native sequence human IgG2 Fc region; native sequence human IgG3 Fc region; and native sequence human IgG4 Fc region as well as naturally occurring variants thereof. Nonlimiting representative human IgGl, IgG2, IgG3 and IgG4 amino acid sequences are set forth in SEQ ID NOs: 301-304.
[0220] A “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification. In some embodiments, a “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification, yet retains at least one effector function of the native sequence Fc region. In some embodiments, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent Fc region, for example, from about one to about ten amino acid substitutions, and preferably, from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent Fc region. In some embodiments, the variant Fc region herein will possess at least about 80% sequence identity with a native sequence Fc region and / or with an Fc region of a parent Fc region, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity therewith.
[0221] In general, the numbering of the residues in an immunoglobulin heavy chain or portion thereof, such as an Fc region, is by EU numbering system. “EU Numbering” refers to the residue numbering of the human IgGl EU antibody according to the most recently updated IMGT Scientific Chart (IMGT®, the international ImMunoGeneTics information system®, http: / / www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html (created: 17 May 2001, last updated: 10 Jan 2013) and the EU index as reported in Kabat, E.A. et al. Sequences of Proteins of Immunological interest. 5th ed. US Department of Health and Human Services, NIH publication No. 91-3242 (1991).
[0222] An immunoglobulin Fc fusion (“Fc-fusion”), such as VHH-Fc, is a molecule comprising one or more VHH domains operably linked to an Fc region of an immunoglobulin. An immunoglobulin Fc region may be linked indirectly or directly to one or more VHH domains.WSGRRefNo. 65457-709.601Various linkers are known in the art and can optionally be used to link an Fc to a fusion partner to generate an Fc-fusion. In some such embodiments, the linker comprises 1-20 amino acids, preferably 1-20 amino acids predominantly composed of glycine and, optionally, serine. Fc-fusions of identical species can be dimerized to form Fc-fusion homodimers, or using nonidentical species to form Fc-fusion heterodimers. In some embodiments, the Fc is a mammalian Fc such as human Fc.
[0223] “Fc receptor” or “FcR” describes a receptor that binds to the Fc region of an antibody. In some embodiments, an FcyR is a native human FcR. In some embodiments, an FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and alternatively spliced forms of those receptors. FcyRII receptors include FcyRIIA (an “activating receptor”) and FcyRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcyRIIA contains an immunoreceptor tyrosine-based activation motif (IT AM) in its cytoplasmic domain Inhibiting receptor FcyRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITEM) in its cytoplasmic domain. (See, for example, Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed, for example, in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel etal., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term “FcR” herein. For example, the term “Fc receptor” or “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and regulation of homeostasis of immunoglobulins. Methods of measuring binding to FcRn are known (see, for example, Ghetie and Ward, Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton et al., J. Biol. Chem. 279(8): 6213 -6216 (2004); WO 2004 / 92219 (Hinton et al.).
[0224] An “acceptor human framework” as used herein is a framework comprising the amino acid sequence of a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as discussed herein. An acceptor human framework derived from a human immunoglobulin framework or a human consensus framework can comprise the same amino acid sequence thereof, or it can contain amino acid sequence changes. In some embodiments, the number of amino acid changes are fewer than 10, or fewer than 9, or fewer than 8, or fewer than 7, or fewer than 6, or fewer than 5, or fewer than 4, or fewer than 3, across all of the human frameworks in a single antigen binding domain, such as a VHH.WSGRRefNo. 65457-709.601
[0225] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (for example, an antibody or VHH-containing molecule) and its binding partner (for example, an antigen). The affinity or the apparent affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD) or the Ko-apparent, respectively, wherein a smaller KD represents a greater affinity. The affinity may be determined by measuring the rates of antigen-binding site / antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Thus, both the “on rate constant” (kon) and the “off rate constant” (koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. (See Nature 361:186-87 (1993)). The ratio of koff / konenables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant Kd. See, generally, Davies et al. (1990) Annual Rev Biochem 59:439-473). Affinity can be measured by common methods known in the art (such as, for example, ELISA KD, KinExA, flow cytometry, and / or surface plasmon resonance devices), including those described herein. Such methods include, but are not limited to, methods involving BIAcore®, Octet®, or flow cytometry.
[0226] The term “KD”, as used herein, refers to the equilibrium dissociation constant of an antigen-binding molecule / antigen interaction. When the term “KD” is used herein, it includes KD and KD -apparent-
[0227] In some embodiments, the KD of the antigen-binding molecule is measured by flow cytometry using an antigen-expressing cell line and fitting the mean fluorescence measured at each antibody concentration to a non-linear one-site binding equation (Prism Software graphpad). In some such embodiments, the KD is KD -apparent- 10228] The term “biological activity” refers to any one or more biological properties of a molecule (whether present naturally as found in vivo, or provided or enabled by recombinant means). Biological properties include, but are not limited to, binding a ligand, inducing or increasing cell proliferation (such as T cell proliferation), and inducing or increasing expression of cytokines.
[0229] An “affinity matured” VHH-containing molecule refers to a VHH-containing molecule with one or more alterations in one or more CDRs compared to a parent VHH-containing molecule that does not possess such alterations, such alterations resulting in an improvement in the affinity of the VHH-containing molecule for antigen.
[0230] A “humanized VHH” as used herein refers to a VHH in which one or more framework regions have been substantially replaced with human framework regions. In some instances, certain framework region (FR) residues of the human immunoglobulin are replaced byWSGRRefNo. 65457-709.601corresponding non-human residues. Furthermore, the humanized VHH can comprise residues that are found neither in the original VHH nor in the human framework sequences, but are included to further refine and optimize VHH or VHH-containing molecule performance. In some embodiments, a humanized VHH-containing molecule comprises a human Fc region. As will be appreciated, a humanized sequence can be identified by its primary sequence and does not necessarily denote the process by which the antibody was created. Humanized antibodies and methods of making them are reviewed, for example, in Almagro and Fransson, (2008) Front. Biosci. 13: 1619-1633, and are further described, for example, in Riechmann etal., (1988) Nature 332:323-329; Queen etal., (1989) Proc. Natl Acad. Set. USA 86: 10029-10033; US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri etal., (2005) Methods 36:25-34; Padlan, (1991) Mol. Immunol. 28:489-498 (describing “resurfacing”);Dall'Acqua et al., (2005) Methods 36:43-60 (describing “FR shuffling”); and Osbourn et al., (2005) Methods 36:61-68 and Klimka et al., (2000) Br. J. Cancer, 83 :252-260 (describing the “guided selection” approach to FR shuffling). Human framework regions that can be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, for example, Sims et al. (1993) J. Immunol. 151 :2296); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of heavy chain variable regions (see, for example, Carter et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285; and Presta etal. (1993) J. Immunol, 151:2623); human mature (somatically mutated) framework regions or human germline framework regions (see, for example, Almagro and Fransson, (2008) Front. Biosci. 13:1619-1633); and framework regions derived from screening FR libraries (see, for example, Baca et al., (1997) J. Biol. Chem. 272: 10678-10684 and Rosok et al., (1996) J. Biol. Chem. 271 :22611-22618). Typically, the FR regions of a VHH are replaced with human FR regions to make a humanized VHH. In some embodiments, certain FR residues of the human FR are replaced in order to improve one or more properties of the humanized VHH. VHH domains with such replaced residues are still referred to herein as “humanized.”
[0231] The term “substantially similar” or “substantially the same,” as used herein, denotes a sufficiently high degree of similarity between two or more numeric values such that one of skill in the art would consider the difference between the two or more values to be of little or no biological and / or statistical significance within the context of the biological characteristic measured by said value. In some embodiments the two or more substantially similar values differ by no more than about any one of 5%, 10%, 15%, 20%, 25%, or 50%.
[0232] A polypeptide “variant” means a biologically active polypeptide having at least about 80% amino acid sequence identity with the native or parental sequence polypeptide after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percentWSGRRefNo. 65457-709.601sequence identity, and not considering any conservative substitutions as part of the sequence identity. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the polypeptide. In some embodiments, a variant will have at least about 80% amino acid sequence identity. In some embodiments, a variant will have at least about 90% amino acid sequence identity. In some embodiments, a variant will have at least about 95% amino acid sequence identity with the native or parental sequence polypeptide.
[0233] As used herein, “percent (%) amino acid sequence identity” and “homology” with respect to a peptide, polypeptide or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNTM (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
[0234] An amino acid substitution may include but are not limited to the replacement of one amino acid in a polypeptide with another amino acid. Exemplary substitutions are shown in Table 5. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, for example, retained / improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.Table 5. Exemplary Amino Acid SubstitutionsOriginal Residue Exemplary SubstitutionsAla (A) Vai; Leu; HeArg (R) Lys; Gin; AsnAsn (N) Gin; His; Asp, Lys; ArgAsp (D) Glu; AsnCys (C) Ser; AlaGln (Q) Asn; GluGlu (E) Asp; GinGly (G) AlaHis (H) Asn; Gin; Lys; ArgWSGRRefNo. 65457-709.601He (I) Leu; Vai; Met; Ala; Phe; NorleucineLeu (L) Norleucine; He; Vai; Met; Ala; PheLys (K) Arg; Gin; AsnMet (M) Leu; Phe; liePhe (F) Trp; Leu; Vai; lie; Ala; TyrPro (P) AlaSer (S) ThrThr (T) Vai; SerTrp (W) Tyr; PheTyr (Y) Trp; Phe; Thr; SerVai (V) lie; Leu; Met; Phe; Ala; Norleucine
[0235] Amino acids may be grouped according to common side-chain properties:(1) hydrophobic: Norleucine, Met, Ala, Vai, Leu, He;(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin;(3) acidic: Asp, Glu;(4) basic: His, Lys, Arg;(5) residues that influence chain orientation: Gly, Pro;(6) aromatic: Trp, Tyr, Phe.
[0236] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0237] The term “vector” is used to describe a polynucleotide that can be engineered to contain a cloned polynucleotide or polynucleotides that can be propagated in a host cell. A vector can include one or more of the following elements: an origin of replication, one or more regulatory sequences (such as, for example, promoters and / or enhancers) that regulate the expression of the polypeptide of interest, and / or one or more selectable marker genes (such as, for example, antibiotic resistance genes and genes that can be used in colorimetric assays, for example, P-galactosidase). The term “expression vector” refers to a vector that is used to express a polypeptide of interest in a host cell.
[0238] A “host cell” refers to a cell that may be or has been a recipient of a vector or isolated polynucleotide. Host cells may be prokaryotic cells or eukaryotic cells. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate animal cells; fungal cells, such as yeast; plant cells; and insect cells. Nonlimiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6® cells (Crucell), and 293 and CHO cells, and their derivatives, such as 293-6E, CHO-DG44, CHO-K1, CHO-S, and CHO-DS cells. Host cells include progenyWSGRRefNo. 65457-709.601of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) a provided herein.
[0239] The terms “individual” and “subject” are used interchangeably herein to refer to an animal; for example a mammal. The term patient includes human and veterinary subjects. In some embodiments, methods of treating mammals, including, but not limited to, humans, rodents, simians, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets, are provided. The subject can be male or female and can be any suitable age, including infant, juvenile, adolescent, adult, and geriatric subjects. In some examples, an “individual” or “subject” refers to an individual or subject in need of treatment for a disease or disorder. In some embodiments, the subject to receive the treatment can be a patient, designating the fact that the subject has been identified as having a disorder of relevance to the treatment, or being at adequate risk of contracting the disorder. In particular embodiments, the subject is a human, such as a human patient.
[0240] A “disease” or “disorder” as used herein refers to a condition where treatment is needed and / or desired.
[0241] The term “tumor cell”, “cancer cell”, “cancer”, “tumor”, and / or “neoplasm”, unless otherwise designated, are used herein interchangeably and refer to a cell (or cells) exhibiting an uncontrolled growth and / or abnormal increased cell survival and / or inhibition of apoptosis which interferes with the normal functioning of bodily organs and systems. Included in this definition are benign and malignant cancers, polyps, hyperplasia, as well as dormant tumors or micrometastases.
[0242] The terms “cancer” and “tumor” encompass solid and hematological / lymphatic cancers and also encompass malignant, pre-malignant, and benign growth, such as dysplasia. Also, included in this definition are cells having abnormal proliferation that is not impeded (e.g. immune evasion and immune escape mechanisms) by the immune system (e.g. virus infected cells). Exemplary cancers include, but are not limited to: basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cellWSGRRefNo. 65457-709.601lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small noncleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs' syndrome.
[0243] The term “non-tumor cell” as used herein refers to a normal cells or tissue. Exemplary non-tumor cells include, but are not limited to: T-cells, B-cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, macrophages, epithelial cells, fibroblasts, hepatocytes, interstitial kidney cells, fibroblast-like synoviocytes, osteoblasts, and cells located in the breast, skeletal muscle, pancreas, stomach, ovary, small intestines, placenta, uterus, testis, kidney, lung, heart, brain, liver, prostate, colon, lymphoid organs, bone, and bone-derived mesenchymal stem cells. The term “a cell or tissue located in the periphery” as used herein refers to non-tumor cells not located near tumor cells and / or within the tumor microenvironment.
[0244] The term “cells or tissue within the tumor microenvironment” as used herein refers to the cells, molecules, extracellular matrix and / or blood vessels that surround and / or feed a tumor cell. Exemplary cells or tissue within the tumor microenvironment include, but are not limited to: tumor vasculature; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPC); cancer-associated fibroblasts; pericytes; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen presenting cells; T-cells; regulatory T-cells (Treg cells); macrophages; neutrophils; myeloid-derived suppressor cells (MDSCs) and other immune cells located proximal to a tumor. Methods for identifying tumor cells, and / or cells / tissues located within the tumor microenvironment are well known in the art, as described herein, below.WSGRRefNo. 65457-709.601
[0245] In some embodiments, an “increase” or “decrease” refers to a statistically significant increase or decrease, respectively. As will be clear to the skilled person, “modulating” can also involve effecting a change (which can either be an increase or a decrease) in affinity, avidity, specificity and / or selectivity of a DLL3 or antigen, for one or more of its ligands, binding partners, partners for association into a homomultimeric or heteromultimeric form, or substrates; effecting a change (which can either be an increase or a decrease) in the sensitivity of the DLL3 or antigen for one or more conditions in the medium or surroundings in which the DLL3 or antigen is present (such as pH, ion strength, the presence of co-factors, efc.); and / or cellular proliferation or cytokine production, compared to the same conditions but without the presence of a test agent. This can be determined in any suitable manner and / or using any suitable assay known per se or described herein, depending on the DLL3 involved.
[0246] As used herein, “an immune response” is meant to encompass cellular and / or humoral immune responses that are sufficient to inhibit or prevent onset or ameliorate the symptoms of disease (for example, cancer or cancer metastasis). “An immune response” can encompass aspects of both the innate and adaptive immune systems.
[0247] As used herein, the terms “treating,” “treatment,” or “therapy” of a disease, disorder or condition is an approach for obtaining beneficial or desired clinical results. “Treatment” as used herein, covers any administration or application of a therapeutic for disease in a mammal, including a human. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, any one or more of: alleviation of one or more symptoms, dimini shm ent of extent of disease, preventing or delaying spread (for example, metastasis, for example metastasis to the lung or to the lymph node) of disease, preventing or delaying recurrence of disease, delay or slowing of disease progression, amelioration of the disease state, inhibiting the disease or progression of the disease, inhibiting or slowing the disease or its progression, arresting its development, and remission (whether partial or total). Also encompassed by “treatment” is a reduction of pathological consequence of a proliferative disease. The methods provided herein contemplate any one or more of these aspects of treatment. In-line with the above, the term treatment does not require one-hundred percent removal of all aspects of the disorder.
[0248] As used herein in the context of cancer, the terms “treatment” or, “inhibit,” “inhibiting” or “inhibition” of cancer refers to at least one of: a statistically significant decrease in the rate of tumor growth, a cessation of tumor growth, or a reduction in the size, mass, metabolic activity, or volume of the tumor, as measured by standard criteria such as, but not limited to, the Response Evaluation Criteria for Solid Tumors (RECIST), or a statistically significant increase in progression free survival (PFS) or overall survival (OS).WSGRRefNo. 65457-709.601
[0249] “Ameliorating” means a lessening or improvement of one or more symptoms as compared to not administering a therapeutic agent. “Ameliorating” also includes shortening or reduction in duration of a symptom.
[0250] “Preventing,” “prophylaxis,” or “prevention” of a disease or disorder refers to administration of a pharmaceutical composition, either alone or in combination with another compound, to prevent the occurrence or onset of a disease or disorder or some or all of the symptoms of a disease or disorder or to lessen the likelihood of the onset of a disease or disorder.
[0251] The terms “inhibition” or “inhibit” refer to a decrease or cessation of any phenotypic characteristic or to the decrease or cessation in the incidence, degree, or likelihood of that characteristic. To “reduce” or “inhibit” is to decrease, reduce or arrest an activity, function, and / or amount as compared to a reference. In some embodiments, by “reduce” or “inhibit” is meant the ability to cause an overall decrease of 10% or greater. In some embodiments, by “reduce” or “inhibit” is meant the ability to cause an overall decrease of 50% or greater. In some embodiments, by “reduce” or “inhibit” is meant the ability to cause an overall decrease of 75%, 85%, 90%, 95%, or greater. In some embodiments, the amount noted above is inhibited or decreased over a period of time, relative to a control over the same period of time.
[0252] As used herein, “delaying development of a disease” means to defer, hinder, slow, retard, stabilize, suppress and / or postpone development of the disease (such as cancer). This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.
[0253] “Preventing,” as used herein, includes providing prophylaxis with respect to the occurrence or recurrence of a disease in a subject that may be predisposed to the disease but has not yet been diagnosed with the disease. Unless otherwise specified, the terms “reduce”, “inhibit”, or “prevent” do not denote or require complete prevention over all time, but just over the time period being measured.
[0254] The term “biological sample” means a quantity of a substance from a living thing or formerly living thing. Such substances include, but are not limited to, blood, (for example, whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes and spleen.
[0255] The term “control” or “reference” refers to a composition known to not contain an analyte (“negative control”) or to contain an analyte (“positive control”). A positive control can comprise a known concentration of analyte.WSGRRefNo. 65457-709.601
[0256] The terms “effective amount” or “therapeutically effective amount” refer to a quantity and / or concentration of a composition containing an active ingredient (e.g. sdAb or VHH-containing molecule) that when administered into a patient either alone (i.e., as a monotherapy) or in combination with additional therapeutic agents, yields a statistically significant decrease in disease progression as, for example, by ameliorating or eliminating symptoms and / or the cause of the disease. An effective amount may be an amount that relieves, lessens, or alleviates at least one symptom or biological response or effect associated with a disease or disorder, prevents progression of the disease or disorder, or improves physical functioning of the patient. A therapeutically effective amount of a composition containing an active agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the active agent to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the active agent are outweighed by the therapeutically beneficial effects. A therapeutically effective amount may be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic and / or prophylactic result.
[0257] As used herein, a composition refers to any mixture of two or more products, substances, or compounds, including cells. It may be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.
[0258] The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to a preparation which is in such form as to permit the biological activity of the active ingredient(s) to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. Hence, it is a composition suitable for pharmaceutical use in a mammalian subject, often a human. A pharmaceutical composition typically comprises an effective amount of an active agent (e.g., sdAb or VHH-containing molecule) and a carrier, excipient, or diluent. The carrier, excipient, or diluent is typically a pharmaceutically acceptable carrier, excipient or diluent, respectively. Such formulations may be sterile.
[0259] A “pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid, or liquid filler, diluent, encapsulating material, formulation auxiliary, or carrier conventional in the art for use with a therapeutic agent that together comprise a “pharmaceutical composition” for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and are compatible with other ingredients of the formulation. The pharmaceutically acceptable carrier is appropriate for the formulation employed.WSGRRefNo. 65457-709.601
[0260] Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and sequential administration in any order.
[0261] The term “concurrently” is used herein to refer to administration of two or more therapeutic agents, where at least part of the administration overlaps in time, or where the administration of one therapeutic agent falls within a short period of time relative to administration of the other therapeutic agent, or wherein the therapeutic effect of both agents overlap for at least a period of time.
[0262] The term “sequentially” is used herein to refer to administration of two or more therapeutic agents that does not overlap in time, or wherein the therapeutic effects of the agents do not overlap.
[0263] As used herein, “in conjunction with” refers to administration of one treatment modality in addition to another treatment modality. As such, “in conjunction with” refers to administration of one treatment modality before, during, or after administration of the other treatment modality to the individual.
[0264] The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contain dications and / or warnings concerning the use of such therapeutic products.
[0265] An “article of manufacture” is any manufacture (for example, a package or container) or kit comprising at least one reagent, for example, a medicament for treatment of a disease or disorder (for example, cancer), or a probe for specifically detecting a biomarker described herein. In some embodiments, the manufacture or kit is promoted, distributed, or sold as a unit for performing the methods described herein.
[0266] The terms “label” and “detectable label” mean a moiety attached, for example, to an antibody or antigen to render a reaction (for example, binding) between the members of the specific binding pair, detectable. The labeled member of the specific binding pair is referred to as “detectably labeled.” Thus, the term “labeled binding protein” refers to a protein with a label incorporated that provides for the identification of the binding protein. In some embodiments, the label is a detectable marker that can produce a signal that is detectable by visual or instrumental means, for example, incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moi eties that can be detected by marked avidin (for example, streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (for example,3H,14C,35S,90Y, "Tc,U1ln,125I,131I,177LU,166HO, or153Sm); chromogens, fluorescent labels (for example, FITC, rhodamine,WSGRRefNo. 65457-709.601lanthanide phosphors), enzymatic labels (for example, horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by a secondary reporter (for example, leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags); and magnetic agents, such as gadolinium chelates. Representative examples of labels commonly employed for immunoassays include moieties that produce light, for example, acridinium compounds, and moieties that produce fluorescence, for example, fluorescein. In this regard, the moiety itself may not be detectably labeled but may become detectable upon reaction with yet another moiety.EXAMPLES
[0267] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention. The examples are not intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (for example, amounts, temperature, etc. but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.Example 1. DLL3-binding molecule examination
[0268] DLL3-binding molecules were produced and screened against cells that expressed DLL3 for determining the binding affinity and specificity of the DLL3 -binding molecules against the expressed DLL3. Binding assays were performed using SHP-77 cells or CHO cells transiently expressing mouse DLL3, with antibodies titrated and detected with a polyclonal anti-human secondary antibody (Jackson ImmunoResearch, 709-605-098). The assay was read on an iQue flow cytometer.
[0269] Fig. 1 illustrates DLL3 single domain antibody (sdAb) binding against SHP-77 cells. Antibodies cloned as monovalent Fc fusions using a hinge-deleted human Fc containing S364N, Y407N, and K409T mutations (“NNT”) were titrated 1:3 from a starting concentration of 50 nM. Antibodies in the panel were generated from camelids immunized with recombinant EGF domain 3 to 4 of DLL3.
[0270] Fig. 2 illustrates monovalent DLL3 sdAb affinity for mouse DLL3 transiently expressed on CHO cells. Antibodies were titrated 1:4 starting at 100 nM. Antibodies tested were the same NNT format as described for Fig. 1.
[0271] Humanized VHHs derived from the panel of VHHs described above with high monovalent affinity were then generated. Binders to multiple epitopes were included. Fig. 3WSGRRefNo. 65457-709.601illustrates binding of selected humanized DLL3 sdAbs in monovalent format to SHP-77 cells. Antibodies tested were the same NNT format as described for Fig. 1
[0272] Selected variants were then screened for their ability to bind to other DLL family members, including DLL1 and DLL4. Fig. 4 illustrates that DLL3 sdAbs did not bind other DLL family members. Only binding to DLL3 was observed. Antibodies were tested as fusions of the sdAbs to effector silenced Fc domains analogously to the NNT fusions of Figs. 1-3.Example 2. Binding affinity of DLL3 clones
[0273] Purified DLL3-sdAb-Fc fusion proteins expressed as monovalent Fc variants were assessed for specificity and relative affinity. To ensure a non-associating, monovalent format, the IgGl Fc region was engineered with the NNT triple mutation (K392N / D399N / K409T, EU numbering). Binding was assessed by flow cytometry using DLL3 -expressing cell lines, including the lung carcinoma lines SHP-77 and NCI-H524. A titration series of the VHH-NNT-Fc fusion proteins was incubated with the target cells (approximately 50k cells / well) for 30 minutes at room temperature in FACS Buffer (PBS 1% BSA, 0.1% NaN3 pH 7.4). Following a wash step, an AF647-conjugated anti-human Fc-specific secondary antibody (Jackson ImmunoResearch) was added for 30 minutes at room temperature. After washing, bound antibody was detected using an IQue flow cytometer (Sartorius).
[0274] Table 6A shows the dissociation constant (Ka) values in the nanomolar (nM) range for binding of DLL3 sdAbs in monovalent format to SHP-77 cells (Figs. 5A-5G); indicates no substantial binding observed. Table 6B shows the dissociation constant (Ka) values in the nanomolar range for binding of DLL3 sdAbs in monovalent format to NCI-H524 cells (Figs. 6A-6F). Table 6C shows the dissociation constant (Ka) values in the nanomolar (nM) range for binding of DLL3 sdAbs in monovalent format to SHP-77 cells binding of DLL3 sdAbs in monovalent format to SHP-77 cells (Figs. 7A-7J); indicates no substantial binding observed.Table 6 A. Monovalent DLL3 sdAb affinities in SHP-77Clone Kd (nM)10D9v7 4.5438E7vl6 5.0495A7v6 - 3G3vl - 3C5v7 1.7736C5v3 - 6Flv6 -WSGRRefNo. 65457-709.601Table 6B. Monovalent DLL3 sdAb affinities in NCI-H524Clone Kd (nM)3F9vlO 0.13110Blv45 1.47910Blv50 0.90210Blv51 0.5385A8.1v4 0.2205A8.1v5 0.741Table 6C. Monovalent DLL3 sdAb affinities in SHP-77Clone Kd (nM)3F9v2 24.253F9v3 - 3F9v4 - 3F9v9 - 3F9vl9 - 3F9v20 79.443F9v21 - 3F9v22 - 3F9v23 - 3F9vl 1.077NUMBERED EMBODIMENTSEmbodiment 1: A DLL3-binding molecule, comprising at least one heavy chain only variable domain that binds DLL3 (DLL3 VHH), wherein the at least one DLL-3 VHH comprises:a complementarity determining region 1 (CDR-H1) comprising the amino acid sequence set forth in SEQ ID NO: 27, 47, 67, 87, 107, 127, 147, 167, 187, 207, 227, or 247;a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 28, 48, 68, 88, 108, 128, 148, 168, 188, 208, 228, or 248; anda CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 29, 49, 69, 89, 109, 129, 149, 169, 189, 209, 229, or 249.Embodiment 2: The DLL3-binding molecule of Embodiment 1, wherein the at least one DLL-3 VHH comprisesthe CDR-H1 comprising the amino acid sequence of SEQ ID NO: 27, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 28, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 29;WSGRRefNo. 65457-709.601the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 47, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 248, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 49;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 67, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 68, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 69;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 87, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 88, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 89;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 107, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 108, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 109;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 127, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 147, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 148, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 149;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 167, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 168, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 169;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 187, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 188, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 189;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 207, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 208, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 209;the CDR-H1 comprising the amino acid sequence of SEQ ID NO: 227, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 228, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 229; orthe CDR-H1 comprising the amino acid sequence of SEQ ID NO: 247, the CDR-H2 comprising the amino acid sequence of SEQ ID NO: 248, and the CDR-H3 comprising the amino acid sequence of SEQ ID NO: 249.WSGRRefNo. 65457-709.601Embodiment 3: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 27-29.Embodiment 4: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 47-49.Embodiment 5: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 67-69.Embodiment 6: The DLL3-binding molecule of Embodiment 2, w wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 87-89.Embodiment 7: The DLL3 -binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 107-109.Embodiment 8: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 127-129.Embodiment 9: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 147-149.Embodiment 10: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 167-169.Embodiment 11: The DLL3 -binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 187-189.Embodiment 12: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 207-209.Embodiment 13: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 227-229.WSGRRefNo. 65457-709.601Embodiment 14: The DLL3-binding molecule of Embodiment 2, wherein the at least one DLL-3 VHH comprises the CDR-H1, the CDR-H2, and the CDR-H3 comprising, respectively, the amino acid sequences set forth in SEQ ID NOs: 247-249.Embodiment 15: The DLL3-binding molecule of any one of Embodiments 1 to 14, wherein the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12.Embodiment 16: The DDL3-binding molecule of any one of Embodiment 1 to 15, wherein the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-12.Embodiment 17: The DLL3-binding molecule of any one of Embodiments 1 to 16, wherein the DLL3 is a human DLL3.Embodiment 18: The DLL3-binding molecule of any one of Embodiments 1 to 17, comprising two DLL3 VHHs.Embodiment 19: The DLL3-binding molecule of any one of Embodiments 1 to 18, comprising three DLL3 VHHs.Embodiment 20: The DLL3-binding molecule of any one of Embodiments 1 to 19, wherein the DLL3-binding molecule comprises one or more additional binding domains that bind to a target other than DLL3.Embodiment 21: The DLL3-binding molecule of Embodiment 20, wherein the one or more additional binding domains is a domain that binds to an antigen selected from the group consisting of: 1-92-LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGR2, Anti-Lewis- Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CDlla, CD16, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD 138, CD 166, CD 172 A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRD), GAL3ST1, G-CSF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP Ilb / IIIa receptors, Gpl30, GPIIB / IIIA, GPNMB, GRP78, HER2 / neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta,WSGRRefNo. 65457-709.601IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17, IL18, IL21, IL23, IL23R, IL27 / IL27R (wsxl), IL29, IL-31R, IL31 / IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISS1-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin-16 (MUC16, CA-125), Na / K ATPase, NGF, NKp46, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, 0X40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidylserine, P1GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNFalpha, TNFR, TNFR2, NFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3.Embodiment 22: The DLL3-binding molecule of Embodiment 20 or 21, wherein at least one of the additional binding domains comprises an antibody or antigen-binding fragment thereof.Embodiment 23: The DLL3-binding molecule of Embodiment 22, wherein each of the additional binding domains comprises an antibody or antigen-binding fragment thereof.Embodiment 24: The DLL3-binding molecule of Embodiment 22 or 23, wherein the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), scFv, a Fab, a single domain antibody (sdAb).Embodiment 25: The DLL3-binding molecule of any one of Embodiments 1 to 24, wherein the molecule comprises an Fc region.Embodiment 26: The DLL3-binding molecule of any one of Embodiments 20 to 25, wherein the molecule comprises an immunoglobulin Fc region that links the at least one DLL3 VHH and the one or more additional binding domain.Embodiment 27: The DLL3 -binding molecule of any one of Embodiments 1 to 26, wherein the molecule comprises at least two polypeptide chains each comprising an Fc region polypeptide.Embodiment 28: The DLL3-binding molecule of any one of Embodiments 25 to 27, wherein the Fc region is a homodimeric Fc region.Embodiment 29: The DLL3-binding molecule of any one of Embodiments 25 to 28, wherein the Fc region comprises the sequence of any of SEQ ID NO: 301-304, 312-317, or 330-332, or an amino acid that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ ID NOs: 301-304, 312-317, or 330-332.WSGRRefNo. 65457-709.601Embodiment 30: The DLL3-binding molecule of any one of Embodiments 25 to 29, wherein the Fc region is a heterodimeric Fc region.Embodiment 31: The DLL3-binding molecule of Embodiment 30, where the heterodimeric Fc region comprises paired or complementary amino acid modifications.Embodiment 32: The DLL3-binding molecule of Embodiment 30 or 31 wherein the heterodimeric Fc region comprises “knob” and “hole” modifications.Embodiment 33: The DLL3-binding molecule of any one of Embodiments 30 to 32, wherein the heterodimeric Fc region comprises a first Fc polypeptide and a second Fc polypeptide, wherein the first Fc polypeptide comprises any of SEQ ID NOs: 318-323, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 318-323, and the second Fc polypeptide comprises any one of SEQ ID NOs: 324-329 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 324-329.Embodiment 34: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises the sequence of SEQ ID NO: 1.Embodiment 35: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 2.Embodiment 36: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 3.Embodiment 37: The DLL3 -binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 4.Embodiment 38: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 5.Embodiment 39: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 6.Embodiment 40: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 7.Embodiment 41: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 8.Embodiment 42: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 9.Embodiment 43: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 10.WSGRRefNo. 65457-709.601Embodiment 44: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 11.Embodiment 45: The DLL3-binding molecule of any one of Embodiments 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 12.Embodiment 46: A polynucleotide encoding the DLL3-binding molecule of any one of Embodiments 1-45.Embodiment 47: A vector comprising the polynucleotide of Embodiment 46.Embodiment 48: A cell or host cell comprising the polynucleotide of Embodiment 46 or the vector of Embodiment 47.Embodiment 49: A method of producing a DLL3-binding molecule, the method comprising introducing into a cell the polynucleotide of Embodiment 46 or the vector of Embodiment 47, and culturing the cell under conditions to produce the DLL3 -binding molecule.Embodiment 50: The method of Embodiment 49, further comprising isolating or purifying the DLL3 -binding molecule from the cell.Embodiment 51: A DLL3-binding molecule produced by the method of Embodiment 49 or 50.Embodiment 52: A pharmaceutical composition comprising the DLL3-binding molecule of any of Embodiments 1 to 45 or 51.Embodiment 53: The pharmaceutical composition of Embodiment 52, comprising a pharmaceutically acceptable carrier.Embodiment 54: A method of treating a disease or condition comprising administering to a subject a pharmaceutically effective amount of the DLL3 -binding molecule of any one of Embodiments 1-45 or 51 or the pharmaceutical composition of Embodiment 52 or 53.Embodiment 55: The method of Embodiment 54, wherein the disease or condition is a tumor or a cancer, an immune disorder, or an inflammatory disorder.Embodiment 56: The method of Embodiment 54 or 55, wherein the disease or condition is a cancer selected from basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostateWSGRRefNo. 65457-709.601cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia.Embodiment 57: The method of any one of Embodiments 54 to 56, further comprising administering an additional therapeutic agent.Embodiment 58: The method of Embodiment 57, wherein the additional therapeutic agent is an anti-cancer agent.Embodiment 59: The method of Embodiment 58, wherein the anti-cancer agent is selected from a chemotherapeutic agent, an anti-cancer biologic, radiation therapy, CAR-T therapy, and an oncolytic virus.Embodiment 60: The method of Embodiment 57, wherein the additional therapeutic agent is an anti-cancer biologic.Embodiment 61: The method of Embodiment 58, wherein the anti-cancer biologic is an antibody.Embodiment 62: The method of Embodiment 58, wherein the anti-cancer biologic is a cytokine.Embodiment 63: The method of Embodiment 58, wherein the anti-cancer biologic is a CAR-T therapy.Embodiment 64: The method of Embodiment 58, wherein the anti-cancer biologic is an oncolytic virus.Embodiment 65: The method of any one of Embodiments 54 to 64, further comprising tumor resection and / or radiation therapy.Embodiment 66: The method of any one of Embodiments 54 to 65, wherein the subject is a human.
[0275] The disclosure may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the disclosure. Scope of the disclosure is thus indicated by the appended claims rather than by the foregoing description, and all changes thatWSGRRefNo. 65457-709.601come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.TABLE OF CERTAIN SEQUENCES SEQ Description SequenceID NO301 human IgGl Fc region PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV (no hinge) DVSHEDPEVI<FNWYVDGVEVHNAI<TI<PREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK302 human IgG2 Fc region PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVD (no hinge) VSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNS TFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAP IEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLT CLVKGFYPSDISVEWESNGQPENNYKTTPPMLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH NHYTQKSLSLSPGK303 human IgG3 Fc region PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV (no hinge) DVSHEDPEVQFKWYVDGVEVHNAKTKPREEQY NSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESSGQPENNYNTTPPML DSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL HNRFTQKSLSLSPGK304 human IgG4 Fc region PAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVV (no hinge) DVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGL PSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVWSGRRefNo. 65457-709.601SEQ Description SequenceID NO LDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE ALHNHYTQKSLSLSLGK305 human IgGl hinge EPKSCDKTHTCPPC306 modified human IgGl EPKSSDKTHTCPPChinge307 lower human IgGl hinge DKTHTCPPC308 human IgG2 hinge ERKCCVECPPC309 human IgG3 hinge KTPLDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCD TPPPCPRCPEPKSCDTPPPCPRC310 human IgG4 hinge ESKYGPPCPSC311 modified human IgG4 ESKYGPPCPPChinge312 human IgGl Fc xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK313 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE H435R VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNRYTQKSLSLSPGK314 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428V VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YV) PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYWSGRRefNo. 65457-709.601SEQ Description SequenceID NO KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVVHEALHNHYTQKSLSLSPGK315 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428L VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YL) PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVLHEALHNHYTQKSLSLSPGK316 IgGl 18 Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y19, M428L, VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK H435R (YLR) PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVLHEALHNRYTQKSLSLSPGK317 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y, M22428V, VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK H435R (YVR) PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVVHEALHNRYTQKSLSLSPGK318 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE S354C T366Wknob VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGKWSGRRefNo. 65457-709.601SEQ Description SequenceID NO319 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE H435R S354C T366W VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK knob PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNRYTQKSLSLSPGK320 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428V VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YV) S354C T366W PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK knob VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVVHEALHNHYTQKSLSLSPGK321 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428L VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YL) S354C T366W PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK knob VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVLHEALHNHYTQKSLSLSPGK322 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y, M428L, H435R VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YLR) S354C T366W PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK knob VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVLHEALHNRYTQKSLSLSPGK323 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y, M428V, H435R VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKWSGRRefNo. 65457-709.601SEQ Description SequenceID NO(YVR) S354C T366W VSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDE knob LTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVVHEALHNRYTQKSLSLSPGK324 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE T366S, L368A, Y407V VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK hole PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK325 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLMISRTPE H435R, T366S, L368A, VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK Y407V hole PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNRYTQKSLSLSPGK326 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428V VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YV) T366S, L368A, PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK Y407V hole VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVVHEALHNHYTQKSLSLSPGK327 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y and M428L VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YL) T366S, L368A, PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK Y407V hole VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNWSGRRefNo. 65457-709.601SEQ Description SequenceID NO YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVLHEALHNHYTQKSLSLSPGK328 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y, M428L, H435R VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YLR) T366S, L368A, PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK Y407V hole VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVLHEALHNRYTQKSLSLSPGK329 IgGl Fc region xELL DKTHTCPPCPAPGGPSVFLFPPKPKDTLYISRTPE M252Y, M428V, H435R VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK (YVR) T366S, L368A, PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCK Y407V hole VSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDE LTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVVHEALHNRYTQKSLSLSPGK330 Human IgG4 Fc region ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN VFSCSVMHEALHNHYTQKSLSLSLGK331 IgG4 Fc region S228P ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMIS (P) RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN VFSCSVMHEALHNHYTQKSLSLSLGKWSGRRefNo. 65457-709.601SEQ Description SequenceID NO332 IgG4 Fc region S228P, ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLYIS M252Y and M428V RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN (PYV) AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGN VFSCSVVHEALHNHYTQKSLSLSLGK333 Linker 1 GGGG334 Linker 2 GSGGGS335 Linker 3 (GGS)2 GGSGGS336 Linker 4 (GGS)3 GGGSGGGSGGGS337 Linker 5 (GGS)4 GGSGGSGGSGGS338 Linker 6 (GGS)5 GGSGGSGGSGGSGGS339 Linker 7 GSGGS340 Linker 8 GGSGGGSGGGS341 Linker 9 (GGGGS)n, wherein n is 1 to 10342 Linker 10 (GGGGGS)n, wherein n is 1 to 10343 Linker 11 PGGGGTABLE OF CDR SEQUENCES SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, RSIFSFDA 481 CDR-H1, EITFSDKT 21IMGT IMGT CDR-H2, ITSGGSA 482 CDR-H2, ISNVDST 22IMGT IMGT CDR-H3, AAGVDKGSYFSY 483 CDR-H3, HARDFENEY 23IMGT DY IMGT CDR-H1, FDAMG 484 CDR-H1, DKTVG 24Kabat KabatWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, VITSGGSAHSADS 485 CDR-H2, VISNVDSTNYAHS 25Kabat VKG Kabat VKGCDR-H3, GVDKGSYFSYDY 486 CDR-H3, RDFENEY 26Kabat KabatCDR-H1, RSIFSFDAMG 487 CDR-H1, EITFSDKTVG 27AbM AbMCDR-H2, VITSGGSAH 488 CDR-H2, VISNVDSTN 28AbM AbMCDR-H3, GVDKGSYFSYDY 489 CDR-H3, RDFENEY 29AbM AbMCDR-H1, RSIFSFD 490 CDR-H1, EITFSDK 30Chothia ChothiaCDR-H2, TSGGS 491 CDR-H2, SNVDS 31Chothia ChothiaCDR-H3, GVDKGSYFSYDY 492 CDR-H3, RDFENEY 32Chothia ChothiaCDR-H1, SFDAMG 493 CDR-H1, SDKTVG 33Contact ContactCDR-H2, MVAVITSGGSAH 494 CDR-H2, LVA VISNVDSTN 34Contact ContactCDR-H3, AAGVDKGSYFSY 495 CDR-H3, HARDFENE 35Contact D ContactCDR-H1, GTIFSINA 501 CDR-H1, EIIFSDKT 61IMGT IMGT CDR-H2, FTGDGAT 502 CDR-H2, ISNVEST 62IMGT IMGT CDR-H3, AADVFIDQAAVE 503 CDR-H3, YARDFESEY 63IMGT WY IMGT CDR-H1, INAMG 504 CDR-H1, DKTVG 64Kabat KabatWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, GFTGDGATTYAD 505 CDR-H2, VISNVESTNYAES 65Kabat SVKG Kabat VKGCDR-H3, DVFIDQAAVEWY 506 CDR-H3, RDFESEY 66Kabat KabatCDR-H1, GTIFSINAMG 507 CDR-H1, EIIFSDKTVG 67AbM AbMCDR-H2, GFTGDGATT 508 CDR-H2, VISNVESTN 68AbM AbMCDR-H3, DVFIDQAAVEWY 509 CDR-H3, RDFESEY 69AbM AbMCDR-H1, GTIFSIN 510 CDR-H1, EIIFSDK 70Chothia ChothiaCDR-H2, TGDGA 511 CDR-H2, SNVES71Chothia ChothiaCDR-H3, DVFIDQAAVEWY 512 CDR-H3, RDFESEY 72Chothia ChothiaCDR-H1, SINAMG 513 CDR-H1, SDKTVG 73Contact ContactCDR-H2, LVAGFTGDGATT 514 CDR-H2, LVA VISNVESTN 74Contact ContactCDR-H3, AADVFIDQAAVE 515 CDR-H3, YARDFESE 75Contact W ContactCDR-H1, GTIFSINA 521 CDR-H1, GFTLDDYT 81IMGT IMGT CDR-H2, FTGDAAT 522 CDR-H2, ISSSGGST 82IMGT IMGT CDR-H3, AADVFIDQAAVE 523 CDR-H3, ATYCPVVVGPELG 83IMGT WY IMGT YDYCDR-H1, INAMG 524 CDR-H1, DYTIG84Kabat KabatWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, GFTGDAATTYAES 525 CDR-H2, CISSSGGSTYYAES 85Kabat VKG Kabat VKGCDR-H3, DVFIDQAAVEWY 526 CDR-H3, YCPVVVGPELGY 86Kabat Kabat DYCDR-H1, GTIFSINAMG 527 CDR-H1, GFTLDDYTIG 87AbM AbMCDR-H2, GFTGDAATT 528 CDR-H2, CISSSGGSTY 88AbM AbMCDR-H3, DVFIDQAAVEWY 529 CDR-H3, YCPVVVGPELGY 89AbM AbM DYCDR-H1, GTIFSIN 530 CDR-H1, GFTLDDY90Chothia ChothiaCDR-H2, TGDAA 531 CDR-H2, SSSGGS91Chothia ChothiaCDR-H3, DVFIDQAAVEWY 532 CDR-H3, YCPVVVGPELGY 92Chothia Chothia DYCDR-H1, SINAMG 533 CDR-H1, DDYTIG93Contact ContactCDR-H2, LVAGFTGDAATT 534 CDR-H2, GVSCISSSGGSTY 94Contact ContactCDR-H3, AADVFIDQAAVE 535 CDR-H3, ATYCPVVVGPELG 95Contact W Contact YDCDR-H1, GSIFSINA 541 CDR-H1, GRTFSSYG 141IMGT IMGT CDR-H2, VSSDGRT 542 CDR-H2, ISWSGPST142IMGT IMGT CDR-H3, GVREWYSDSDWR 543 CDR-H3, AADLLLRQGWGT 143IMGT DY IMGT RPNDYDYWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, INAMG 544 CDR-H1, SYGMA 144Kabat KabatCDR-H2, VVSSDGRTTVAPS 545 CDR-H2, AISWSGPSTYYAD 145Kabat VKG Kabat SVKGCDR-H3, REWYSDSDWRDY 546 CDR-H3, DLLLRQGWGTRP 146Kabat Kabat NDYDYCDR-H1, GSIFSINAMG 547 CDR-H1, GRTFSSYGMA 147AbM AbMCDR-H2, VVSSDGRTT 548 CDR-H2, AISWSGPSTY 148AbM AbMCDR-H3, REWYSDSDWRDY 549 CDR-H3, DLLLRQGWGTRP 149AbM AbM NDYDYCDR-H1, GSIFSIN 550 CDR-H1, GRTFSSY 150Chothia ChothiaCDR-H2, SSDGR 551 CDR-H2, SWSGPS 151Chothia ChothiaCDR-H3, REWYSDSDWRDY 552 CDR-H3, DLLLRQGWGTRP 152Chothia Chothia NDYDYCDR-H1, SINAMG 553 CDR-H1, S SYGMA 153Contact ContactCDR-H2, LVAVVSSDGRTT 554 CDR-H2, FVAAISWSGPSTY 154Contact ContactCDR-H3, GVREWYSDSDWR 555 CDR-H3, AADLLLRQGWGT 155Contact D Contact RPNDYDCDR-H1, GSIFSINA 561 CDR-H1, GRTFSSYG 161IMGT IMGT CDR-H2, VSSDART 562 CDR-H2, ISWSGPST 162IMGT IMGTWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H3, GVREWYSDADW 563 CDR-H3, AADLLIRQGWGT 163IMGT RDY IMGT RPNDYDYCDR-H1, INAMG 564 CDR-H1, SYGMA164Kabat KabatCDR-H2, VVSSDARTTVAPS 565 CDR-H2, AISWSGPSTYYAD 165Kabat VKG Kabat SVKGCDR-H3, REWYSDADWRD 566 CDR-H3, DLLIRQGWGTRPN 166Kabat Y Kabat DYDYCDR-H1, GSIFSINAMG 567 CDR-H1, GRTFSSYGMA 167AbM AbMCDR-H2, VVSSDARTT 568 CDR-H2, AISWSGPSTY 168AbM AbMCDR-H3, REWYSDADWRD 569 CDR-H3, DLLIRQGWGTRPN 169AbM Y AbM DYDYCDR-H1, GSIFSIN 570 CDR-H1, GRTFSSY170Chothia ChothiaCDR-H2, SSDAR 571 CDR-H2, SWSGPS171Chothia ChothiaCDR-H3, REWYSDADWRD 572 CDR-H3, DLLIRQGWGTRPN 172Chothia Y Chothia DYDYCDR-H1, SINAMG 573 CDR-H1, S SYGMA173Contact ContactCDR-H2, LVAVVSSDARTT 574 CDR-H2, FVAAISWSGPSTY 174Contact ContactCDR-H3, GVREWYSDADW 575 CDR-H3, AADLLIRQGWGT 175Contact RD Contact RPNDYDCDR-H1, GSILSINA 581 CDR-H1, GRTFSSYG 181IMGT IMGTWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, ITGDGNT 582 CDR-H2, ISWSGPST182IMGT IMGT CDR-H3, LLDVLSDSGYVTP 583 CDR-H3, AADLLVRQGWGT 183IMGT IMGT RPNDYDYCDR-H1, INAMG 584 CDR-H1, SYGMA184Kabat KabatCDR-H2, AITGDGNTNYADS 585 CDR-H2, AISWSGPSTYYAD 185Kabat VKG Kabat SVKGCDR-H3, DVLSDSGYVTP 586 CDR-H3, DLLVRQGWGTRP 186Kabat Kabat NDYDYCDR-H1, GSILSINAMG 587 CDR-H1, GRTFSSYGMA 187AbM AbMCDR-H2, AITGDGNTN 588 CDR-H2, AISWSGPSTY 188AbM AbMCDR-H3, DVLSDSGYVTP 589 CDR-H3, DLLVRQGWGTRP 189AbM AbM NDYDYCDR-H1, GSILSIN 590 CDR-H1, GRTFSSY190Chothia ChothiaCDR-H2, TGDGN 591 CDR-H2, SWSGPS191Chothia ChothiaCDR-H3, DVLSDSGYVTP 592 CDR-H3, DLLVRQGWGTRP 192Chothia Chothia NDYDYCDR-H1, SINAMG 593 CDR-H1, S SYGMA193Contact ContactCDR-H2, LVAAITGDGNTN 594 CDR-H2, FVAAISWSGPSTY 194Contact ContactCDR-H3, LLDVLSDSGYVT 595 CDR-H3, AADLLVRQGWGT 195Contact Contact RPNDYDWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, GSILSINA 601 CDR-H1, GRTFSSYG 201IMGT IMGT CDR-H2, ITGDANT 602 CDR-H2, ISWSGPST 202IMGT IMGT CDR-H3, LLDVLSDAGYVTP 603 CDR-H3, AADLLARQGWGT 203IMGT IMGT RPNDYDYCDR-H1, INAMG 604 CDR-H1, SYGMA 204Kabat KabatCDR-H2, AITGDANTNYAES 605 CDR-H2, AISWSGPSTYYAD 205Kabat VKG Kabat SVKGCDR-H3, DVLSDAGYVTP 606 CDR-H3, DLLARQGWGTRP 206Kabat Kabat NDYDYCDR-H1, GSILSINAMG 607 CDR-H1, GRTFSSYGMA 207AbM AbMCDR-H2, AITGDANTN 608 CDR-H2, AISWSGPSTY 208AbM AbMCDR-H3, DVLSDAGYVTP 609 CDR-H3, DLLARQGWGTRP 209AbM AbM NDYDYCDR-H1, GSILSIN 610 CDR-H1, GRTFSSY 210Chothia ChothiaCDR-H2, TGDAN 611 CDR-H2, SWSGPS 211Chothia ChothiaCDR-H3, DVLSDAGYVTP 612 CDR-H3, DLLARQGWGTRP 212Chothia Chothia NDYDYCDR-H1, SINAMG 613 CDR-H1, S SYGMA 213Contact ContactCDR-H2, LVAAITGDANTN 614 CDR-H2, FVAAISWSGPSTY 214Contact ContactWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H3, LLDVLSDAGYVT 615 CDR-H3, AADLLARQGWGT 215Contact Contact RPNDYDCDR-H1, GRTFSSYG 621 CDR-H1, GRTFSSYG 221IMGT IMGT CDR-H2, ISWSGPST 622 CDR-H2, ISWSGPST 222IMGT IMGT CDR-H3, AADLLMRQGWGT 623 CDR-H3, AADLLTRQGWGT 223IMGT RPNDYDY IMGT RPNDYDYCDR-H1, SYGMA 624 CDR-H1, SYGMA224Kabat KabatCDR-H2, AISWSGPSTYYAD 625 CDR-H2, AISWSGPSTYYAD 225Kabat SVKG Kabat SVKGCDR-H3, DLLMRQGWGTRP 626 CDR-H3, DLLTRQGWGTRP 226Kabat NDYDY Kabat NDYDYCDR-H1, GRTFSSYGMA 627 CDR-H1, GRTFSSYGMA 227AbM AbMCDR-H2, AISWSGPSTY 628 CDR-H2, AISWSGPSTY 228AbM AbMCDR-H3, DLLMRQGWGTRP 629 CDR-H3, DLLTRQGWGTRP 229AbM NDYDY AbM NDYDYCDR-H1, GRTFSSY 630 CDR-H1, GRTFSSY230Chothia ChothiaCDR-H2, SWSGPS 631 CDR-H2, SWSGPS231Chothia ChothiaCDR-H3, DLLMRQGWGTRP 632 CDR-H3, DLLTRQGWGTRP 232Chothia NDYDY Chothia NDYDYCDR-H1, S SYGMA 633 CDR-H1, S SYGMA233Contact ContactWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, FVAAISWSGPSTY 634 CDR-H2, FVAAISWSGPSTY 234Contact ContactCDR-H3, AADLLMRQGWGT 635 CDR-H3, AADLLTRQGWGT 235Contact RPNDYD Contact RPNDYDCDR-H1, GSIFSINA 641 CDR-H1, GRTFSSYG 381IMGT IMGT CDR-H2, FTGDTNT 642 CDR-H2, ISWSGPST 382IMGT IMGT CDR-H3, AADVQLFSRDYEF 643 CDR-H3, AADLLSRQGWGT 383IMGT Y IMGT RPNDYDYCDR-H1, INAMG 644 CDR-H1, SYGMA384Kabat KabatCDR-H2, GFTGDTNTIYAES 645 CDR-H2, AISWSGPSTYYAD 385Kabat VKG Kabat SVKGCDR-H3, DVQLFSRDYEFY 646 CDR-H3, DLLSRQGWGTRP 386Kabat Kabat NDYDYCDR-H1, GSIFSINAMG 647 CDR-H1, GRTFSSYGMA 387AbM AbMCDR-H2, GFTGDTNTI 648 CDR-H2, AISWSGPSTY 388AbM AbMCDR-H3, DVQLFSRDYEFY 649 CDR-H3, DLLSRQGWGTRP 389AbM AbM NDYDYCDR-H1, GSIFSIN 650 CDR-H1, GRTFSSY390Chothia ChothiaCDR-H2, TGDTN 651 CDR-H2, SWSGPS391Chothia ChothiaCDR-H3, DVQLFSRDYEFY 652 CDR-H3, DLLSRQGWGTRP 392Chothia Chothia NDYDYWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, SINAMG 653 CDR-H1, S SYGMA 393Contact ContactCDR-H2, LVAGFTGDTNTI 654 CDR-H2, FVAAISWSGPSTY 394Contact ContactCDR-H3, AADVQLFSRDYEF 655 CDR-H3, AADLLSRQGWGT 395Contact Contact RPNDYDCDR-H1, EIITSDKS 661 CDR-H1, GRTFSSYG 401IMGT IMGT CDR-H2, ISNVGST 662 CDR-H2, ISWSGPST 402IMGT IMGT CDR-H3, YARDFENEY 663 CDR-H3, AADLLGRQGWGT 403IMGT IMGT RPNDYDYCDR-H1, DKSMG 664 CDR-H1, SYGMA 404Kabat KabatCDR-H2, GISNVGSTNYAQS 665 CDR-H2, AISWSGPSTYYAD 405Kabat VKG Kabat SVKGCDR-H3, RDFENEY 666 CDR-H3, DLLGRQGWGTRP 406Kabat Kabat NDYDYCDR-H1, EIITSDKSMG 667 CDR-H1, GRTFSSYGMA 407AbM AbMCDR-H2, GISNVGSTN 668 CDR-H2, AISWSGPSTY 408AbM AbMCDR-H3, RDFENEY 669 CDR-H3, DLLGRQGWGTRP 409AbM AbM NDYDYCDR-H1, EIITSDK 670 CDR-H1, GRTFSSY 410Chothia ChothiaCDR-H2, SNVGS 671 CDR-H2, SWSGPS 411Chothia ChothiaWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H3, RDFENEY 672 CDR-H3, DLLGRQGWGTRP 412Chothia Chothia NDYDYCDR-H1, SDKSMG 673 CDR-H1, S SYGMA413Contact ContactCDR-H2, LVAGISNVGSTN 674 CDR-H2, FVAAISWSGPSTY 414Contact ContactCDR-H3, YARDFENE 675 CDR-H3, AADLLGRQGWGT 415Contact Contact RPNDYDCDR-H1, GSDFSINA 681 CDR-H1, GRTFSSYG 421IMGT IMGT CDR-H2, FTGDGVT 682 CDR-H2, ISWSGPST 422IMGT IMGT CDR-H3, AADVKIGGDYEW 683 CDR-H3, AADLLNRQGWGT 423IMGT F IMGT RPNDYDYCDR-H1, INAIG 684 CDR-H1, SYGMA424Kabat KabatCDR-H2, GFTGDGVTTYAES 685 CDR-H2, AISWSGPSTYYAD 425Kabat VKG Kabat SVKGCDR-H3, DVKIGGDYEWF 686 CDR-H3, DLLNRQGWGTRP 426Kabat Kabat NDYDYCDR-H1, GSDFSINAIG 687 CDR-H1, GRTFSSYGMA 427AbM AbMCDR-H2, GFTGDGVTT 688 CDR-H2, AISWSGPSTY 428AbM AbMCDR-H3, DVKIGGDYEWF 689 CDR-H3, DLLNRQGWGTRP 429AbM AbM NDYDYCDR-H1, GSDFSIN 690 CDR-H1, GRTFSSY430Chothia ChothiaWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H2, TGDGV 691 CDR-H2, SWSGPS431Chothia ChothiaCDR-H3, DVKIGGDYEWF 692 CDR-H3, DLLNRQGWGTRP 432Chothia Chothia NDYDYCDR-H1, SINAIG 693 CDR-H1, S SYGMA433Contact ContactCDR-H2, MVAGFTGDGVTT 694 CDR-H2, FVAAISWSGPSTY 434Contact ContactCDR-H3, AADVKIGGDYEW 695 CDR-H3, AADLLNRQGWGT 435Contact Contact RPNDYDCDR-H1, GSIFSINA 701 CDR-H1, GRTFSSYG 441IMGT IMGT CDR-H2, FTGDGMT 702 CDR-H2, ISWSGPST 442IMGT IMGT CDR-H3, AADVFTDRDHVD 703 CDR-H3, AADLLQRQGWGT 443IMGT WY IMGT RPNDYDYCDR-H1, INAMG 704 CDR-H1, SYGMA444Kabat KabatCDR-H2, GFTGDGMTKYAE 705 CDR-H2, AISWSGPSTYYAD 445Kabat SVKG Kabat SVKGCDR-H3, DVFTDRDHVDWY 706 CDR-H3, DLLQRQGWGTRP 446Kabat Kabat NDYDYCDR-H1, GSIFSINAMG 707 CDR-H1, GRTFSSYGMA 447AbM AbMCDR-H2, GFTGDGMTK 708 CDR-H2, AISWSGPSTY 448AbM AbMCDR-H3, DVFTDRDHVDWY 709 CDR-H3, DLLQRQGWGTRP 449AbM AbM NDYDYWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, GSIFSIN 710 CDR-H1, GRTFSSY 450Chothia ChothiaCDR-H2, TGDGM 711 CDR-H2, SWSGPS 451Chothia ChothiaCDR-H3, DVFTDRDHVDWY 712 CDR-H3, DLLQRQGWGTRP 452Chothia Chothia NDYDYCDR-H1, SINAMG 713 CDR-H1, S SYGMA 453Contact ContactCDR-H2, LVAGFTGDGMTK 714 CDR-H2, FVAAISWSGPSTY 454Contact ContactCDR-H3, AADVFTDRDHVD 715 CDR-H3, AADLLQRQGWGT 455Contact W Contact RPNDYDCDR-H1, GSIFSINA461IMGT CDR-H2, FTGDGST462IMGT CDR-H3, AADVQLLQSDYE463IMGT FY CDR-H1, INAMG464KabatCDR-H2, GFTGDGSTKYAES465Kabat VKGCDR-H3, DVQLLQSDYEFY466KabatCDR-H1, GSIF SINAMG467AbMCDR-H2, GFTGDGSTK468AbMCDR-H3, DVQLLQSDYEFY469AbMWSGRRefNo. 65457-709.601SEQ Description Sequence SEQ Description SequenceID ID NO: NO:CDR-H1, GSIFSIN470ChothiaCDR-H2, TGDGS471ChothiaCDR-H3, DVQLLQSDYEFY472ChothiaCDR-H1, SINAMG473ContactCDR-H2, LVAGFTGDGSTK474ContactCDR-H3, AADVQLLQSDYE475Contact F
[0276] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.
[0277] All publications, patent applications, issued patents, and other documents referred to in this specification are herein incorporated by reference as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions that are contained in text incorporated by reference are excluded to the extent that they contradict definitions in this disclosure.
Claims
WSGRRefNo. 65457-709.601CLAIMS1. A DLL3-binding molecule, comprising at least one heavy chain only variable domain, or antigen binding fragment thereof, that binds DLL3 (DLL3 VHH), wherein the DLL3 VHH comprises a complementarity determining region 1 (CDR-H1), a complementarity determining region 2 (CDR-H2), and a complementarity determining region 3 (CDR-H3) of any one of clonotypes A to Y, as set forth in Table 2.
2. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype A, as set forth in Table 2.
3. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype B, as set forth in Table 2.
4. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype C, as set forth in Table 2.
5. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype D, as set forth in Table 2.
6. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype E, as set forth in Table 2.
7. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype F, as set forth in Table 2.
8. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype G, as set forth in Table 2.
9. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype H, as set forth in Table 2.
10. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype I, as set forth in Table 2.
11. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype J, as set forth in Table 2.
12. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype K, as set forth in Table 2.
13. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype L, as set forth in Table 2.
14. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype M, as set forth in Table 2.
15. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype N, as set forth in Table 2.WSGRRefNo. 65457-709.60116. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype O, as set forth in Table 2.
17. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype P, as set forth in Table 2.
18. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype Q, as set forth in Table 2.
19. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype R, as set forth in Table 2.
20. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype S, as set forth in Table 2.
21. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype T, as set forth in Table 2.
22. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype U, as set forth in Table 2.
23. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype V, as set forth in Table 2.
24. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype W, as set forth in Table 2.
25. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype X, as set forth in Table 2.
26. The DLL3-binding molecule of claim 1, wherein the DLL3 VHH comprises the CDR-H1, CDR-H2, and CDR-H3 of clonotype Y, as set forth in Table 2.
27. The DLL3-binding molecule of any one of claims 1-26 wherein the CDRs are determined by IMGT, Kabat, AbM, Chotia, or Contact numbering systems.
28. The DLL3-binding molecule of any one of claims 1-27 wherein the CDRs are determined by the IMGT numbering systems.
29. The DLL3-binding molecule of any one of claims 1-27 wherein the CDRs are determined by the Kabat numbering systems.
30. The DLL3-binding molecule of any one of claims 1-27 wherein the CDRs are determined by the AbM numbering systems.
31. The DLL3-binding molecule of any one of claims 1-27 wherein the CDRs are determined by the Chothia numbering systems.
32. The DLL3-binding molecule of any one of claims 1-27 wherein the CDRs are determined by the Contact numbering systems.WSGRRefNo. 65457-709.60133. The DLL3-binding molecule of any one of claims 1 to 32, wherein the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 1-12.
34. The DLL3-binding molecule of any one of claims 1 to 32, wherein the at least one DLL3 VHH comprises an amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 351-373.
35. The DDL3-binding molecule of any one of claim 1 to 33, wherein the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-12.
36. The DDL3-binding molecule of any one of claim 1 to 32 or claim 34, wherein the at least one DLL3 VHH comprises an amino acid sequence set forth in any one of SEQ ID NOs: 351-373.
37. The DLL3-binding molecule of any one of claims 1 to 36, wherein the DLL3 is a human DLL3.
38. The DLL3-binding molecule of any one of claims 1 to 37, comprising two DLL3 VHHs.
39. The DLL3-binding molecule of any one of claims 1 to 38, comprising three DLL3 VHHs.
40. The DLL3-binding molecule of any one of claims 1 to 39, wherein the DLL3-binding molecule comprises one or more additional binding domains that bind to a target other than DLL3.
41. The DLL3-binding molecule of claim 40, wherein the one or more additional binding domains is a domain that binds to an antigen selected from the group consisting of: 1-92-LFA-3, 5T4, Alpha-4 integrin, Alpha-V integrin, alpha4betal integrin, alpha4beta7 integrin, AGR2, Anti-Lewis-Y, Apelin J receptor, APRIL, B7-H3, B7-H4, BAFF, BTLA, C5 complement, C-242, CA9, CA19-9, (Lewis a), Carbonic anhydrase 9, CD2, CD3, CD6, CD9, CDlla, CD16, CD19, CD20, CD22, CD24, CD25, CD27, CD28, CD30, CD33, CD38, CD40, CD40L, CD41, CD44, CD44v6, CD47, CD51, CD52, CD56, CD64, CD70, CD71, CD74, CD80, CD81, CD86, CD95, CD117, CD123, CD125, CD132, (IL-2RG), CD133, CD138, CD166, CD172A, CD248, CDH6, CEACAM5 (CEA), CEACAM6 (NCA-90), CLAUDIN-3, CLAUDIN-4, cMet, Collagen, Cripto, CSFR, CSFR-1, CTLA-4, CTGF, CXCL10, CXCL13, CXCR1, CXCR2, CXCR4, CYR61, DL44, DLK1, DLL4, DPP-4, DSG1, EDA, EDB, EGFR, EGFRviii, Endothelin B receptor (ETBR), ENPP3, EpCAM, EPHA2, EPHB2, ERBB3, F protein of RSV, FAP, FGF-2, FGF8, FGFR1, FGFR2, FGFR3, FGFR4, FLT-3, Folate receptor alpha (FRa), GAL3ST1, G-CSF, G-CSFR, GD2, GITR, GLUT1, GLUT4, GM-CSF, GM-CSFR, GP Ilb / IIIa receptors, Gpl30, GPIIB / IIIA, GPNMB, GRP78, HER2 / neu, HER3, HER4, HGF, hGH, HVEM, Hyaluronidase, ICOS, IFNalpha, IFNbeta, IFNgamma, IgE, IgE Receptor (FceRI), IGF, IGF1R, IL1B, IL1R, IL2, IL11, IL12, IL12p40, IL-12R, IL-12Rbetal, IL13, IL13R, IL15, IL17,WSGRRefNo. 65457-709.601IL18, IL21, IL23, IL23R, IL27 / IL27R (wsxl), IL29, IL-31R, IL31 / IL31R, IL2R, IL4, IL4R, IL6, IL6R, Insulin Receptor, Jagged Ligands, Jagged 1, Jagged 2, KISS1-R, LAG-3, LIF-R, Lewis X, LIGHT, LRP4, LRRC26, Ly6G6D, LyPDl, MCSP, Mesothelin, MRP4, MUC1, Mucin-16 (MUC16, CA-125), Na / K ATPase, NGF, NKp46, Nicastrin, Notch Receptors, Notch 1, Notch 2, Notch 3, Notch 4, NOV, OSM-R, 0X40, PAR2, PDGF-AA, PDGF-BB, PDGFRalpha, PDGFRbeta, PD-1, PD-L1, PD-L2, Phosphatidyl-serine, Pl GF, PSCA, PSMA, PSGR, RAAG12, RAGE, SLC44A4, Sphingosine 1 Phosphate, STEAP1, STEAP2, TAG-72, TAPA1, TEM-8, TGFbeta, TIGIT, TIM-3, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, TMEM31, TNF alpha, TNFR, TNFR2, NFRS12A, TRAIL-R1, TRAIL-R2, Transferrin, Transferrin receptor, TRK-A, TRK-B, uPAR, VAP1, VCAM-1, VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR1, VEGFR2, VEGFR3, VISTA, WISP-1, WISP-2, and WISP-3.
42. The DLL3-binding molecule of claim 40 or 41, wherein at least one of the additional binding domains comprises an antibody or antigen-binding fragment thereof.
43. The DLL3-binding molecule of claim 40 to 42, wherein each of the additional binding domains comprises an antibody or antigen-binding fragment thereof.
44. The DLL3-binding molecule of claim 42 or 43, wherein the antibody or antigen-binding fragment thereof is an Fv, a disulfide-stabilized Fv (dsFv), scFv, a Fab, a single domain antibody (sdAb).
45. The DLL3-binding molecule of any one of claims 1 to 44, wherein the DLL3-binding molecule comprises an Fc region.
46. The DLL3-binding molecule of any one of claims 40 to 45, wherein the DLL3-binding molecule comprises an immunoglobulin Fc region that links the at least one DLL3 VHH and the one or more additional binding domain.
47. The DLL3-binding molecule of any one of claims 1 to 46, wherein the DLL3-binding molecule comprises at least two polypeptide chains each comprising an Fc region polypeptide.
48. The DLL3-binding molecule of any one of claims 45 to 47, wherein the Fc region is a homodimeric Fc region.
49. The DLL3-binding molecule of any one of claims 45 to 48, wherein the Fc region comprises the sequence of any of SEQ ID NO: 301-304, 312-317, or 330-332, or an amino acid that exhibits at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any of SEQ IDNOs: 301-304, 312-317, or 330-332.
50. The DLL3-binding molecule of any one of claims 45 to 47, wherein the Fc region is a heterodimeric Fc region.
51. The DLL3-binding molecule of claim 50, where the heterodimeric Fc region comprises paired or complementary amino acid modifications.WSGRRefNo. 65457-709.60152. The DLL3-binding molecule of claim 50 or 51 wherein the heterodimeric Fc region comprises “knob” and “hole” modifications.
53. The DLL3-binding molecule of any one of claims 50 to 52, wherein the heterodimeric Fc region comprises a first Fc polypeptide and a second Fc polypeptide, wherein the first Fc polypeptide comprises any of SEQ ID NOs: 318-323, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 318-323, and the second Fc polypeptide comprises any one of SEQ ID NOs: 324-329 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 324-329.
54. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises the sequence of SEQ ID NO: 1.
55. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 2.
56. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 3.
57. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 4.
58. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 5.
59. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 6.
60. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 7.
61. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 8.
62. The DLL3-binding molecule of any one of claims 1 to 53, wherein at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 9.
63. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 10.
64. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 11.
65. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 12.
66. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 351.WSGRRefNo. 65457-709.60167. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 352.
68. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 353.
69. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 354.
70. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 355.
71. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 356.
72. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 357.
73. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 358.
74. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 359.
75. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 360.
76. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 361.
77. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 362.
78. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 363.
79. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 364.
80. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 365.
81. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 366.
82. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 367.
83. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 368.WSGRRefNo. 65457-709.60184. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 369.
85. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 370.
86. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 371.
87. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 372.
88. The DLL3-binding molecule of any one of claims 1 to 53, wherein the at least one DLL3 VHH comprises an amino acid sequence of SEQ ID NO: 373.
89. A polynucleotide encoding the DLL3-binding molecule of any one of claims 1-88.
90. A vector comprising the polynucleotide of claim 89.
91. A cell or host cell comprising the polynucleotide of claim 89 or the vector of claim 90.
92. A method of producing a DLL3-binding molecule, the method comprising introducing into a cell the polynucleotide of claim 89 or the vector of claim 90, and culturing the cell under conditions to produce the DLL3 -binding molecule.
93. The method of claim 92, further comprising isolating or purifying the DLL3 -binding molecule from the cell.
94. A DLL3-binding molecule produced by the method of claim 92 or 93.
95. A pharmaceutical composition comprising the DLL3-binding molecule of any of claims 1 to 88 or claim 94.
96. The pharmaceutical composition of claim 95, comprising a pharmaceutically acceptable carrier.
97. A method of treating a disease or condition comprising administering to a subject a pharmaceutically effective amount of the DLL3 -binding molecule of any one of claims 1 to 88 or claim 94, or the pharmaceutical composition of claim 96.
98. The method of claim 97, wherein the disease or condition is a tumor or a cancer, an immune disorder, or an inflammatory disorder.
99. The method of claim 98, wherein the disease or condition is a cancer.
100. The method of claim 99, wherein the cancer is a solid tumor.
101. The method of any one of claims 97 to 100, wherein the disease or condition is a cancer selected from basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastricWSGRRefNo. 65457-709.601cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intraepithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia.
102. The method of any one of claims 97 to 101, further comprising administering an additional therapeutic agent.
103. The method of claim 102, wherein the additional therapeutic agent is an anti -cancer agent.
104. The method of claim 103, wherein the anti-cancer agent is selected from a chemotherapeutic agent, an anti -cancer biologic, radiation therapy, CAR-T therapy, and an oncolytic virus.
105. The method of claim 104, wherein the additional therapeutic agent is an anti -cancer biologic.
106. The method of claim 105, wherein the anti-cancer biologic is an antibody.
107. The method of claim 105, wherein the anti-cancer biologic is a cytokine.
108. The method of claim 105, wherein the anti-cancer biologic is a CAR-T therapy.
109. The method of claim 105, wherein the anti-cancer biologic is an oncolytic virus.
110. The method of any one of claims 97 to 109, further comprising tumor resection and / or radiation therapy.
111. The method of any one of claims 97 to 110, wherein the subject is a human.
